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ABSTRACT 
 Alpha/beta hydrolases (ABHs) are a superfamily of hydrolytic enzymes that process a wide 
variety of substrates. A subfamily of ABHs called carboxylesterases (CEs) are important 
enzymes that catalyze biological detoxification, hydrolysis of certain pesticides, and metabolism 
of many esterified drugs. The chemotherapy drug irinotecan used for treatment of colorectal 
cancer is metabolized to SN-38, the active drug metabolite, by two CE isozymes CES1 (localized 
in the liver) and CES2 (localized in the small intestines).  CES2’s ability to activate irinotecan at 
a faster rate than CES1 creates a localization of activated SN-38 in the gut epithelium, resulting 
in the dose limiting side effect of delayed diarrhea. Development of inhibitors for the CE 
subfamily of ABHs could assist in ameliorating the toxic side effects associated with some 
esterified prodrugs such as irinotecan, and enhance the distribution of prodrugs in vivo. Hence, 
our research targets CES2 for inhibitor design with the goal of amelioration of intestinal 
cytotoxicity associated with irinotecan chemotherapy.  In this work we (i) utilized QSAR 
technology to design and optimize novel sulfonamide CES2 inhibitors; (ii) combined QSAR with 
in silico design to generate new CE inhibitor scaffolds that maintained the potency of previous 
CE inhibitor generations, yet had improved water solubility; and (iii) investigated the 
contribution of the loop 7 in CEs to sensitizing the enzyme to inhibition by sulfonamides through 
docking analysis.  Our QSAR model, developed using 57 sulfonamide analogs, identified several 
features of this class of CE inhibitor that confer their potency. Using a QSAR model, constructed 
using 4 classes of CE inhibitors (benzils, benzoins, isatins, and sulfonamides), as a pocket site to  
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perform in silico design we generated several new scaffolds predicted to have good solubility 
and potency.  This work suggests that the inner loop 7 on CE plays a role in inhibitor selectivity, 
and interactions with this loop should be considered in the development of selective CE 
inhibitors.  The contributions from this work will be applicable to the design of novel ABH 
inhibitors, help to increase the likelihood of these drugs entering in clinical use, and ameliorate 
the dose-limiting side effect associated with irinotecan. 
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CHAPTER 1 INTRODUCTION 
  
1.1 ALPHA/BETA HYDROLASES 
 Alpha/Beta hydrolases (ABHs) are a superfamily of proteins that share a similar 
canonical structure but vary in function.  In 1992, the α/β hydrolase fold was identified from the 
five proteins acetylcholinesterase (Torpedo), carboxylpeptidase II (Latin), dienelactone 
hydrolase (Pseuodomonas), dehydrogenase (Xanthobacter), and lipase (Geotrichum) [1].  Since 
then, this family of proteins has grown from 5 to over 600 proteins, comprising 89 subgroups, 
and containing proteins with a wide range of amino acids. As examples, the 194 residue human 
retinoblastoma binding protein 9 [2] and the dipeptidyl aminopeptidase X [3] which has 723 
residues are both ABHs [4]. In addition to varying sizes, these proteins process a wide variety of 
substrates [4].  Some examples of the hydrolytic variety of these enzymes can be found in these 
examples: acetylcholinesterase, which degrades the neurotransmitter acetylcholine; [4] 
carboxylesterases (CE), which hydrolyze xenobiotics such as organophosphate and carbamate 
pesticides [5] and also illicit drugs such as heroin [6]  and cocaine [7]; thioesterases, which 
degrades thioester bonds [4]; halokane dehydrogenase, which hydrolyzes alkyl chlorides [4]; 
cutinase, which degrades, cutin, a triacylglycerol [4, 8]; and epoxide hydrolases, which 
hydrolyze epoxides [4].  These enzymes possess very little sequence similarity; however they do 
have several conserved features [9, 10] and the same overall fold. 
	  2	  
 The first characteristic feature of this family is an alpha/beta fold; a string of β sheets 
sandwiched in between 2 sets of α helices.  The canonical fold contains 8 mostly parallel β 
sheets (β2 is antiparallel) and 6 α helices.   Strand order is 12435678, and has a connection of 
+1, +2, -1x, +2x, +1x, +1x, +1x.  The beta sheets twist in a left-handed superhelical twist 
fashion, such that first and last strand are at 90º to one another.  The helices αA and αF are 
found on the convex side of the enzyme while the helices αB through αE are located on the 
concave side of the fold [1, 4, 9, 10].  Figure 1-1 shows a schematic of the canonical fold of 
ABHs, using human carboxylesterase 1 (CES1). 
The second feature of this fold is a histidine residue in the catalytic triad consisting of a 
nucleophile, acid, and histidine.  The only residue of the triad that is identical in all ABHs is the 
histidine [10].  Serine, cysteine and aspartate can be nucleophiles, while the acid residue can be 
either glutamate or aspartate [1, 9]. The use of the glutamate as an acid in the triad is novel to the 
ABH family [9].  The histidine residue is positioned after the last beta sheet, [10] nucleophiles 
are located after β5, and the acid residue is typically positioned after β7 on a loop having one or 
two reverse turns [1, 4, 10].   
 A third feature of this fold is a sharp γ turn that houses the nucleophile at its apex, and is 
called a “nucleophilic elbow,” which maintains the hydrolytic function.  The “nucleophilic 
elbow” can be identified by the consensus sequence as S-X-N-X-S, where S is any small residue 
like a glycine, X is any residue, and N is the nucleophile. This “nucleophilic elbow” is positioned 
in such a way to allow easy access of substrate and water molecules to the nucleophile [10]. 
 The presence of an “oxy-anion hole,” which stabilizes the negatively charged 
intermediate generated during catalysis, is the last feature of this fold.  A minimum of two  
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Figure 1-1. The canonical fold of alpha/beta hydrolases using human liver carboxylesterase 
1 (hCE1).  Depicted in blue are the 8 mostly parallel beta sheets.  The helices highlighted in 
green represent the 6 helices common to this fold.  
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backbone nitrogen atoms create the “oxy-anion hole.”  The first is located on a residue 
immediately following the nucleophile and the second nitrogen atom is typically located on a 
residue between the β3 sheet and the αA helix.  With the exception of a few members of the 
ABH family, like the lipases, the “oxy-anion hole” is present in the substrate-free enzyme.  In 
lipases, one residue creating the “oxy-anion” hole resides on a mobile loop, preventing the “oxy-
anion hole” from forming until substrate binds and the loop becomes orientated in the active 
conformation.  
 
1.2 CARBOXYLESTERASE SUBFAMILY 
 Carboxylesterases are one of the subfamilies of ABH enzymes. These enzymes are 
ubiquitous, and found in all kingdoms of life.  This family of enzymes hydrolyzes carboxylate 
esters into their corresponding alcohol and carboxylic acid derivatives. The residues in the 
catalytic triad responsible for metabolism are serine, histidine, and glutamate. The mechanism 
begins when glutamic acid is ionized and then removes a proton from histidine.  The lone pair on 
the histidine then abstracts a proton from serine resulting in the nucleophilic species serine Oγ.  
Initiation of substrate hydrolysis is then performed by nucleophilic attack of the serine Oγ 
residue [5].  The serine Oγ attacks the carbonyl carbon of the carboxylate ester substrate, creating 
a tetrahedral intermediate.  The reformation of the carbonyl moiety causes the release of the OR 
group, which receives a proton from glutamate.  A H2O molecule then attacks the carbonyl 
carbon, generating another tetrahedral intermediate.  Finally, the release of the carboxylic acid is 
performed when the carbonyl bond reforms and releases the serine residue.  This mechanism, 
“ester hydrolysis,” is the primary mechanism, which is employed in most CE inhibition reactions 
(Figure 1-2). 
	  5	  
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1-2. The catalytic mechanism of carboxylesterases 
 The cytotoxicity to the intestinal epithelium by SN-38 is the dose-limiting toxicity.  
Development of selective CE inhibitors has been pursued to ameliorate this mechanism of dose-
limiting toxicity of irinotecan.  Carboxylesterase inhibitors could be given as adjuvunct therapy 
for toxicity modulation of irinotecan, allowing for higher dosing and hence more effective 
treatment of colorectal cancer. 
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 In mammals, CEs can be found in numerous tissues types [11].  The hydrolytic activity is 
based on tissue type; however, the liver isozyme is known to be the most active of all isozymes 
studied.  The hydrolytic abilities of these enzymes are employed in the roles of drug metabolism, 
protection against xenobiotics, and pesticide detoxification.  They are responsible for, 
hydrolyzing clinically useful drugs such as capecitabine [12] and irinotecan [13], [12] illicit 
drugs such as heroin [6];  and detoxifying pesticides such as pyrethoids [14]. 
Therapeutically, CEs have many uses due to their broad substrate specificity.  For 
example, CEs have the potential to be used for protein-based therapies for pesticide 
detoxification.  Organophosphates and carbamates, when used as insecticides, have the potential 
to cause poisoning to humans since they also act on acetylcholinesterase.  However, the 
reversible or irreversible binding of organophosphate and carbamate insecticides to CEs can 
reduce toxicity to humans.  Two reaction pathways are involved in this successful alleviation of 
pesticide poisoning: metabolism of the insecticide by CEs or irreversible inhibition of CEs by the 
insecticides [15], [16].   
      Carboxylesterases are also important to the use of pro-drugs.  Irinotecan is an anticancer 
pro-drug currently used to treat colorectal cancer.  In humans several carboxylesterases exist in 
different tissues, namely liver carboxylesterase 1 (hCE1; CES1), and liver carboxylesterase 2 
(hCE2) both localized in the liver, and human intestinal carboxylesterase (hiCE; CES2) localized 
primarily in the small intestinal epithelial.  Irinotecan is a substrate for hCE1, hCE2, and hiCE.  
Human liver carboxylesterase is the desired enzyme for irinotecan activation.  The enzyme hiCE 
is present in greater concentrations in the small intestine, thus hiCE is much more efficient at 
hydrolyzing irinotecan to the active metabolite SN-38 [12], [17].  The resulting over-production 
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of SN-38 results in damage to the lining of the small intestine, causing delayed diarrhea and 
often requiring hospitalization [12]. 
 
1.3 BACTERIAL CARBOXYLESTERASE 
One CE receptor, bacterial p-nitrobenzyl carboxylesterase (pnbCE), is approximately 489 
amino acids, contains 13 β-sheets and 15 α-helices, and is structurally homologous to the 
mammalian CEs. The catalytic residues are Ser-189, His-399 and Glu-310 [18].  It can hydrolyze 
irinotecan and is simple to express and purify.  The crystal structure of pnbCE, like CES1, has 
been solved.  For these reasons it has been used as a model system to study the mammalian 
carboxylesterases by the Potter and Wadkins labs [19].  
 Several loops on pnbCE have been shown to be important.  In 2011, using molecular 
dynamics and normal mode analysis, it was calculated that the active site loops, loop 5 and loop 
21, had an anticorrelated motion [20].  This motion was found to hold the substrate into place 
during the catalytic reaction.  Gwaltney’s lab performed a molecular dynamics simulation on 
pnbCE to determine which loop the substrate interacted with.  The substrate was found to 
actually interact with loop 7.  Loop 7 is an internal loop surrounding the active site, which 
contains the oxyanion hole.   
 
1.4 CHALLENGES IN INHIBITOR DESIGN FOR CARBXOYLETERASES  
The Potter and Wadkins labs have collaborated for several years, with the goal of 
developing CES2 specific inhibitors to ameliorate the dose limiting side-effect.  Currently, five 
major classes of selective CE inhibitors have been developed, the 1,2 diones (subclasses:  isatins, 
benzils, 1-phenyl-2-pyridyl-ethane-1,2-dione, and indole alkaloid marine natural products), 
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fluorobenzoins, sulfonamides (benzene- and fluorenesulfonamide subclasses), triflouroketones, 
and other miscellaneous inhibitors (loperamide, cholesterol analogs, bis(4-
nitrophenyl)phosphate, benzodioxaphosphorines), all of which show no inhibition of 
acetylcholinesterase [21].  In this work we will focus on the isatins, sulfonamides, benzils, and 
fluorobenzoins (Figure 1-3).  We will not explore the trifluoroketones since they do not have a 
similar mechanism of inhibition compared to the rest of the CE inhibitors, the miscellaneous 
inhibitors since they are not candidates for drug design, or the 1-phenyl-2-pyridyl-ethane-1,2-
diones and indole alkaloid marine natural products, since they were discovered after 
development of our QSAR models.  Most of the CE inhibitors developed have Ki values in the 
nanomolar range.  Two issues, however, plague these compounds: isotyope selectivity and low 
aqueous solubility.  
 Of the classes of CE inhibitors developed, three classes are water insoluble (benzils, 
fluorobenzoins, and sulfonamides), and three classes are generally not isozyme specific (benzils, 
fluorobenzoins and isatins).  The benzils are selective inhibitors for human carboxylesterases, 
discovered in 2005 [22]. The isatins, which are water-soluble, do not show great potency against 
hiCE or specificity between hCE1 and hiCE. The sulfonamides, which show isozyme specificity, 
have great potency against hiCE but suffer from very poor water solubility.  Evaluation of over 
50 sulfonamides [23] revealed an inverse correlation of clog P (calculated Log P value) and log 
Ki.  Hence, the least soluble compounds were the best inhibitors of the enzyme.  These 
characteristics made these  families of inhibitors poor candidates for clinical therapies.    In order 
for hiCE inhibitors to be more effective, new scaffolds, which have more favorable chemical 
properties, must be developed. 
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Figure 1-3. Major scaffolds of mammalian selective carboxylesterase inhibitors used in this 
work 
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1.5 DISSERTATION FOCUS 
      The big idea of my dissertation work is controlling the dose limiting side-effect of 
irinotecan.  This would decrease the toxicity of irinotecan, allow clinicians to give higher doses 
of irinotecan, and in turn provide a more effective, and less taxing therapy for patients.  Our 
approach to preventing the dose limiting side-effect is through development of CES2-selective 
inhibitiors.  Although we have made some progress in developing selective inhibitors for this 
family of enzymes, a more rational way of developing drugs is needed.  What we need to 
understand to design effective CES2 selective inhibitors is three things.  Firstly, we need to 
understand how to make CES2 inhibitors potent, a more potent drug means less needs to be 
administered to achieve the desired medicinal effect.  Secondly, we must understand how to 
make a CES2 inhibitor soluble, an insoluble drug is not typically feasible for clinical use.  Lastly, 
we should understand how to make a CES2 inhibitor selective.  A CES2 inhibitor shouldn’t 
prevent CES1 and other critical ABH enzymes such as AChE from functioning.  Therefore the 
emphasis of my project is defining contributions that control these features: potency, solubility, 
and selectivity.  
  We have used computational work and kinetics to probe specificity.  Our computational 
analysis has helped us understand the requirements for inhibitor potency and generate new 
inhibitor scaffolds with enhanced drug-like properties.  Docking and kinetic analysis was used to 
explain the molecular interactions that control isozyme specificity. By studying both the 
inhibitors, through ligand-based methods such as quantitative structure activity relationships, in 
silico design and kinetics, ways to develop potent, water soluble and selective inhibitors have 
been delineated.   
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CHAPTER 2 BACKGROUND OF METHODS 
 
2.1 QUANTITATIVE STRUCTURE ACTIVITY RELATIONSHIP (QSAR) 
      Quantitative structure activity relationship (QSAR) is a mathematical and statistical model 
where the structures of a series of compounds are correlated to their biological activities. The 
development of the QSAR modeling technique is credited to Hansch, who used a series of 
descriptors to correlate a series of steroids to their biological activity [24-26].  QSAR models can 
be used for a number of applications.  One such use is determination of structural properties that 
increase the potency of a series of inhibitors.  An example of this application can be seen in the 
2009 study performed by Hicks et al., wherein they developed a series of 57 sulfonamide 
inhibitors based on their prior three dimensional quantitative structure activity relationship (3D-
QSAR) results indicating that halogenation of the phenyl ring would increase the potency of the 
sulfonamide inhibitors [27, 28]. A second applicaton of QSAR modeling is predicting the 
activities of a series of compounds that have not been experimentally tested.   Numerous research 
groups have successfully used QSAR to predict activities of potential drug compounds [19, 29-
34].  QSAR may tell the researcher what properties are important for increasing potency against 
a target, but it does not tell specific moieties that should be introduced, although this can 
sometimes be inferred from the experiment.   
 The advantage of QSAR is that it can speed up the identification of lead drug targets by 
successfully weeding out inactives (compounds not having the desired biological activity).  This 
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technique is also ligand-based, thus, unlike docking, is not limited to targets that have an 
experimentally derived 3D structure.  Because of these qualities, QSAR is well suited for drug 
design and optimization.  In our study, we used it to optimize existing sulfonamide CE inhibitors, 
and as a hypothetical pocket site for in silico design (will be discussed in later chapters).   
     A typical QSAR experiment has three main components: (1) a dataset of compounds, (2) a 
set of descriptors, (3) and an algorithm to correlate the descriptors to the compound’s activity. 
The QSAR dataset usually consists of a least 10 compounds usually having a common scaffold, 
with only variances in substituents and/or substitution pattern.  The dataset should have a broad 
range of activities, typically at least 3 orders of magnitude. Descriptors are properties that are 
derived from the structure of a compound, and can be expressed in a numerical form.  There are 
several types of descriptors varying from zero dimensional to six dimensional.  With increasing 
dimensionality comes a more complex description of a series of compounds (atom count, 1D 
descriptor; versus HOMO, 3D descriptor).    All descriptors 3 dimensional (3D) and higher are 
dependent on the 3D structure of the compound.  The descriptors used are correlated to the 
structures in the compound series by some algorithm. Examples of algorithms that can be 
used are simple linear regression analysis, multiple linear regression, principle components 
regression (PCR), partial least squares (PLS), principle component analysis (PCA), comparative 
molecular field analysis (CoMFA), neural networks, or genetic algorithms (GA).   
 We used a GA for all modeling experiments.  A genetic algorithm functions by initially 
developing a population of models.  Subsequently, crossing-over events and random mutations 
of properties describing the model are performed to develop a new population of models.  The 
number of generations can be designated by the user.  Typically, this iterative processs is 
continued until a certain q2 valued is reached.  Q2 is the cross-validated correlation coefficient.  
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This value represents the goodness of predictability for the generated model.  In a biological 
system anything abouve 0.4 is considered statistically significant. Many programs have been 
developed to generate QSAR models, such as SYBYL, CoMFA, and Quasar.  In this work, 
multidimensional QSAR was used employing the program Quasar to develop our 
multidimensional QSAR models.   
 The QSAR model is developed and validated using a training set and a test set. A training 
set consists of a series of compounds with experimentally derived properties.  These compounds 
are used develop the QSAR equation.  Typically a range of three orders of magnitude, in the 
biological property being studied, is needed to develop a decent model.  The model can be 
validated using two types of test sets to determine the robustness of the model.  The first, is 
called an internal test set, and is a group of compounds that have known experimental values, 
while the second, is an external test set, and does not have experimentally derived values for the 
property you are developing your model for.  The more accurately your model is at correctly 
predicting the values of these compounds in the internal or external test set the higher the q2 
value.   
 
2.2 AMSOL 7 
 The AMSOL program calculates solvation energies and class IV partial atomic charges 
[35].  It is an SCF program that uses solvation models based on the NDDO semi-empirical 
molecular orbital theory. The SM5.42R model within the AMSOL program was used to calculate 
both the free energy of solvation and the partial atomic charges.  This model used the CM2 
charges and calculates the partial atomic charges in both the gas phase and solution phase.  The 
NDDO, AM1, or PM3 semi-empirical Hamiltonians may be used with this solvation model.  The 
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parameter we used was the PM3 to match the charge models of molecular mechanics used in 
Chem3D software. 
 The SM5.42R is a rigid gas phase model; thus, it does not take into account the geometry 
relaxation in solution [36].  The compounds are, however, optimized in the gas phase and these 
parameters are used for the solvent phase as well.  For this experiment the gas phase CM2 
charges were used.  Therefore, a solvent phase optimization was unnecessary and the SM5.42R 
proved sufficient. 
 
2.3 LIGBUILDER 
 In silico drug design is a structure based drug design technique that relies on the 3-
dimensional structure of a target to develop a novel drug candidate.  This technique has been 
used to develop several drugs that are currently in clinical trials [37].  Several programs exist to 
perform in silico design such as Concerts [38], Grid [39], LeapFrog [40], LigBuilder [37], Ludi, 
SPROUT [41, 42], and Synopsis [43].  In general these types of program build a drug candidate 
inside the crystal structure of a target receptor by adding either atoms or molecular fragments 
such as benzene or sulfonamide groups.  
 The active site of a target receptor is termed a “pocket” in this in silico process. 
Identification of a pocket site for an enzyme is simple when a 3D structure is available.  This 
however is not the case for enzymes that have no experimentally solved structure.  One option to 
getting around this is quantitative structure activity relationships (QSAR).  QSAR can be used to 
develop a pseudo-receptor site, in which known ligands are used to develop a model that 
represents features of the active site.  These pseudo-receptor sites can be 3-dimensionally 
represented and used as a hypothetical pocket site for an enzyme target when there is no 
	  15	  
experimentally solved structure. In using these models in in silico design processes, new lead 
compounds for various drug targets can be generated.  
 In this work we used LigBuilder 1.2v [37] for all of our in silico design.  LigBuilder uses 
a genetic algorithm to develop the best candidates. A total 20 generations of models are created.  
LigBuilder has two options for building structures, GROW and LINK.  The link method allows 
the user to position several moieties in the receptor site; then subsequently LigBuilder builds 
linkages to connect these groups.  The GROW module requires positioning a seed structure in 
the receptor site.  Then, fragments and atoms are incrementally added to the structure to develop 
an initial population of candidates.  We used the GROW module for all design performed here.   
 LigBuilder uses a series of three input files to dictate the parameters of the run; the first is 
pocket.index that contains parameters to generate the pocket site key interactions map. The 
second is grow.index that contains files to generate populations of compounds.  The third is 
process.index, which contains filters to pool the best 200 compounds in a final dataset.  Default 
parameters were used for both pocket.index and process.index.  During the GROW process 
several parameters can be modified.  Our modifications to the GROW input files are described in 
the appropriate chapters where they were used.  Examples of some typical pocket.index, 
grow.index, and process.index input file are contained in the appendix. 
 
2.4 ALOGPS 
 Solubility of compounds is an important variable that affects the efficacy, potency, and 
clinical usefulness of drugs in vivo.  Because humans are 70 to 80% water, a water-insoluble 
drug will never be active in patients, due to the drug’s inability to dissolve.  To assist in the 
development of water-soluble drugs, their solubilities can be tested (for synthesized compounds) 
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or predicted to rule out unfavorable candidates that have yet to be synthesized. The Online 
Lipophilicity/Aqueous Solubility Calculation software, ALOGPS 2.1, is an online lipophilicity 
server that can predict LogS (Log of solubility) of compounds using their structures [44, 45].  
The url for this program is http://www.vcclab.org/lab/alogps/. This program was developed using 
a neural network algorithm and a data set of 1400+ compounds.  We used ALOGPS to predict 
the solubilities of all compounds generated.  Compounds were converted to SMILES string then 
appended into one file.  The libraries were uploaded to the ALOGPS website; then the output file 
was saved.  For all calculations, the ALOGpS (calculated solubility) value was used.  To 
calculate the actual solubility in grams per liter the following equation was used. 
 
Solubility = (antilog(LogS))*MW  (Equation 2-1) 
Solubility = S * MW  (Equation 2-2) 
 
where, LogS is ALOGpS value, and MW is the molecular weight of the compound. 
 
2.5 MOLECULAR DOCKING 
  Molecular docking is the process of predicting the binding orientation of a ligand in its 
target receptor.  This computational method is used heavily in virtual screening to determine 
interactions that are present between a receptor and ligand [46-49].  Typically, a target receptor 
is a macromolecule like RNA, DNA or a protein. Identification of molecular interactions to 
binding of the ligand to the receptor can contribute the development of novel drugs, and help to 
define molecular pathway analysis.  Docking works by first searching for ligand poses (possible 
receptor-ligand conformation), and then scoring of poses to determine the most likely bioactive 
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conformation.   
 Several methods exist to explore active site space, and to score poses in docking. In rigid 
docking, the simplest algorithms treat both the receptor and the ligand as rigid bodies.  Thus, in 
these cases, only translational and rotational degrees of freedom are considered.  Examples of 
algorithms that allow for a researcher to consider the conformational degrees of freedom of the 
ligand are Monte Carlo [50], incremental construction [50-52], and genetic algorithms[53]. 
Monte Carlo methods change the ligand conformation either randomly or through bond rotation 
after each iteration.  Incremental construction builds a ligand up in the active site of the receptor 
step-wise.  Genetic algorithms evolve a population of ligand conformations and orientations in 
the receptor.  After ligand conformations are generated the poses are scored or ranked using a 
scoring algorithm. 
 Several docking programs exist today: DOCK [54], FRED [55], Autodock [56], Glide 
[57], GOLD [58], Surflex [59].  In this work we used DOCK program which was developed by 
Kuntz et al., which uses the incremental construction method to explore the active site space, and 
find a receptor-ligand conformation with a high degree of shape compementarity [60]. 
 
2.6 MODELLER 
 Protein homology modeling is a process that generates the most probable 3-dimensional 
structure of a protein using its amino acid sequence and a template protein structure.  A template 
protein is any structure that is highly homologous in sequence to the input sequence and has a 
solved 3-dimensional structure.  The protein input is then structurally aligned to the template.  
This process is valuable due to the large number of unsolved protein sequences.  A homology 
model can allow a researcher to evaluate structural features even in the absence of a crystal 
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structure 
 MODELLER is a homology-modeling program that we used to generate a 3D structure 
of our mutant proteins. The MODELLER BLAST analysis is used to find protein sequences that 
are highly homologous to the input protein sequence.  The wild-type pnbCE structure was used 
as our template structure.  The modeling process produced five candidates for each mutant.  We 
performed further analysis on the model that had the lowest ZDOPE score (a measure of the 
quality of the model).  The lower the ZDOPE score, the better the model.  Models with positive 
scores are not likely to be native-like, while models with scores less than -1 are strongly 
suggestive of the native protein structure.  
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CHAPTER 3 IMPROVED, SELECTIVE, HUMAN INTESTINAL 
CARBOXYLESTERASE (CES2) INHIBITORS DESIGNED TO 
MODULATE 7-ETHYL-10-[4-(1-PIPERIDINO)-1-
PIPERIDINO]CARBONYLOXYCAMPTOTHECIN 
(IRINOTECAN; CPT-11) TOXICITY 
 
3.1 ABSTRACT 
CPT-11 is an antitumor prodrug that is hydrolyzed by carboxylesterases (CE) to SN-38, a 
potent topoisomerase I poison. However, the dose limiting toxicity, delayed diarrhea, is thought 
to arise, in part, from activation of the prodrug by a human intestinal CE (hiCE). Therefore, we 
have sought to identify selective inhibitors of hiCE that may have utility in modulating drug 
toxicity. We have evaluated one such class of molecules (benzene sulfonamides) and developed 
QSAR models for the inhibition of this protein. Using these predictive models, we have 
synthesized a panel of fluorene analogues that are selective for hiCE, demonstrating no cross 
reactivity to the human liver CE, hCE1, or toward human cholinesterases, and have Ki values as 
low as 14 nM. These compounds prevented hiCE-mediated hydrolysis of the drug and the 
potency of enzyme inhibition correlated with the clogP of the molecules. These studies will 
allow the development and application of hiCE-specific inhibitors designed to selectively 
modulate drug hydrolysis in vivo.  
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3.2 INTRODUCTION  
Carboxylesterases (CEs) are ubiquitously expressed enzymes that are thought to be 
responsible for the hydrolysis of xenobiotics [61]. They catalyze the conversion of esters to their 
corresponding alcohols and carboxylic acids. Because numerous clinically used compounds are 
esterified, an approach used by the pharmaceutical industry to improve the water solubility of 
molecules, they are substrates for these enzymes. Hence, drugs such as heroin, cocaine, 1 
(irinotecan; CPT-11; [62] Figure 3-1), capecitabine, oseltamivir, lidocaine, and meperidine are 
all hydrolyzed by CEs [12, 13, 17, 63-73]. Therefore, identifying compounds that modulate the 
hydrolysis of these agents may be useful in either altering the half-life and/or toxicities 
associated with these drugs. For example, the β-blocker flestolol, is rapidly hydrolyzed by CEs to 
an inactive metabolite and hence its biological activity is rapidly lost [74]. Inhibition of the 
enzyme responsible for this hydrolysis would increase the in vivo stability of the molecule and 
likely improve its therapeutic utility. In contrast, the delayed diarrhea that is associated with 1 
treatment is thought to arise, in part, from hydrolysis of the drug in the intestine by the human 
intestinal CE (hiCE, CES2) [12, 17, 75] to yield 2 (7-ethyl-10-hydroxycamptothecin SN-38; 
Figure 3-1). Because this is the dose limiting toxicity for this highly effective anticancer agent, 
approaches that ameliorate this side effect would improve patient quality of care and potentially 
allow drug dose intensification. This could potentially be achieved by an inhibitor that targets 
hiCE within the gut.  
 In 2004 the Potter lab discovered the sulfonamide class of CES2 inhibitors using Telik’s 
target related affinity profiling  [76, 27].  The sulfonamide compounds are very potent CES2 
specific inhibitors, having no cross reactivity to the cholinesterases human acetyl- or butyrylcho-
linesterase (hAChE and hBChE, respectively).  The Wadkins lab developed a QSAR model for 
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these sulfonamides to determine what features of these compounds contributed towards thier 
potency.  This study indicated that halogenation of the benzene rings would increase potency of 
sulfonamide inhibitors.  We also demonstrated the usefulness of computational research in the 
design of CES2 inhibitors. However, these studies were based on a series of 9 compounds (4-12 
in Table 3-1) with a disparate set of different chemotypes. Here we have considerably expanded 
these analyses and have now assayed and analyzed 57 benzene sulfonamides for their ability to 
inhibit hiCE, hCE1, hAChE, or hBChE.  We developed a new QSAR model with this expanded 
dataset of sulfonamides to further delineate any relevant features important for CES2 inhibition 
of the sulfonamides. Using detailed QSAR models, we have designed a series of novel fluorene 
analogues that are highly potent hiCE inhibitors and can modulate 1 metabolism. Potentially, 
these molecules would be lead compounds for subsequent drug design.  
 
Figure 3-1 Flow chart of QSAR inhibitor design process 
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Figure 3-2 Hydrolysis of CPT-11 By Carboxylesterases 
 
 
	  23	  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sulfonamide 
Scaffold 
	  24	  
 
	  25	  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	  26	  
Table 3-1 Compound database for sulfonamide inhibitors and Ki values 
  a C6H4 represents benzene ring. b Data taken from Wadkins et al.[27] c Data taken from 
Hatfield et al. (manuscript submitted). d For the CEs, 3 was used as a substrate and the respective 
thiocholines were used for hAChE and hBChE. The general structure of the sulfonamides is 
indicated. The X in the subfragment represents the point of attachment to the sulfonamide 
moiety.  
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3.3 RESULTS  
3.3.1 SELECTIVE INHIBITION OF CES2 BY BENZENE SULFONAMIDES  
Based on our previous work, the Potter lab identified benzene sulfonamides as selective 
inhibitors of hiCE [27]. The 3D-QSAR analysis presented in this chapter indicated that (i) 
halogenation of the phenyl rings resulted in more potent compounds, and (ii) the central region 
of the inhibitor-enzyme complex was hydrophobic and could accommodate a large aromatic 
structure. Therefore, the Potter lab synthesized or acquired a total of 57 sulfonamide analogues, 
mostly containing halogen atoms appended to the benzene rings, and assessed their inhibitory 
potency toward the CEs hiCE and hCE1, as well as hAChE and hBChE. These assays used o-
nitrophenyl acetate (oNPA) as a substrate for CEs and acetylthiocholine and butyrylthiocholine 
for the respective cholinesterases.  
The majority of the compounds were shown to be excellent inhibitors having Ki values 
ranging from 41 to 3240 nM. The vast majority of the sulfonamides were selective for hiCE, 
with only one molecule showing weak activity toward hCE1 (compound 11). Compound, 11 was 
still over 250-fold more potent against hiCE (Ki values were 53 vs 13700 nM for hiCE and 
hCE1, respectively). None of the sulfonamides inhibited either hAChE or hBChE (data not 
shown), consistent with Wadkins et al. previous reports of these types of compounds [27].  The 
specificity of the sulfonamides for hiCE is though to be due to unique interactions with amino 
acids within the active site of this protein since, both CEs and cholinesterases demonstrate very 
similar crystal structures, [63, 77].   
Six compounds were inactive toward all enzymes (28, 39, 41, and 44-46). The majority 
of these compounds contained large bulky atoms or moieties present within either the terminal 
benzene rings (28, 39, 41) or the central domain of the molecule (44-46). These groups would 
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likely impede access of the inhibitor to that active site gorge, thereby mitigating their biological 
activity.  
The mode of enzyme inhibition by the sulfonamide inhibitors was partially competitive, 
indicating that while their structure resembled the substrate molecule, they were unable to com-
pletely inhibit substrate hydrolysis [78]. For this series of compounds, therefore, the inhibitory 
potency will be partially dependent upon the structure of the substrate. To confirm that these 
molecules could indeed inhibit the hydrolysis of other substrates, the Potter lab also assessed 
their effect on the metabolism of irinotecan.  
 
3.3.2 3D-QSAR ANALYSES 
We undertook detailed 3D-QSAR analyses with the goal of identifying specific domains 
within the molecules that might improve (or ablate) inhibitory potency. We have previously 
performed similar studies, and the pseudoreceptor site models that have been generated have 
significantly enhanced subsequent inhibitor design. Therefore, compounds 5, 8, 8-11, 14-31, 35-
37, 47-56, and 60 were used as a training set for the development of the QSAR model. This was 
then validated using molecules (the test set).  As can be seen from Table 3-2 and Figure 3-2, the 
linear correlation coefficients (r2) for the observed versus predicted Ki values for the training set 
were ~0.9, with similar values for the cross correlation coefficients (q2).  Because q2 values 
greater than 0.4 are considered statistically significant for biological systems [79], these models 
are likely to have excellent predictive value in the design of novel sulfonamide-based hiCE 
inhibitors. In addition, the q2/r2 values were close to unity, confirming the validity of the models.  
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Table 3-2. QSAR validation parameters obtained from Quasar software when using the Ki values 
for hiCE inhibition with either irinotecan or oNPA as a substrate  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Substrate r2 q2 q2/r2 
Irinotecan 0.89 0.83 0.93 
oNPA 0.91 0.88 0.96 
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Figure 3-3.Graphs demonstrating the correlation between the predicted and the observed Ki 
values obtained from the QSAR models. (A) Graph when using oNPA as a substrate, and (B) 
when using irinotecan. Linear correlation coefficients for the line fits (r2) are indicated on the 
graphs.  
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The QSAR models were reasonable at predicting the Ki values for the fluorene analogues 
56-60, with all compounds except 58 being considered excellent inhibitors of hiCE (<100 nM) 
when using oNPA as a substrate. Interestingly, the latter molecule had the highest clogP value 
(5.69), suggesting that for these models, this parameter is not a major determinant of biological 
potency. Significantly, while the fluorene moiety increased the length of the molecule by 4-5 Å 
as compared to the benzene derivative, this did not significantly impact enzyme inhibition. Also 
it should be noted (see Figure 3-2) that the model was very poor at predicting the efficacy of 7. 
This is potentially due to the fact that this compound contains a  
disulfide chemotype (unlike all of the other molecules that were assayed) and can potentially 
adopt alternate conformations that would not be accurately predicted by the model.  
The QSAR predicted Ki values for the inhibition of hiCE mediated irinotecan metabolism 
were not as good as though seen for oNPA. Indeed, while the fluorene compounds were 
considered good inhibitors of hiCE (Ki values in the low µM range), only 58 was predicted with 
any great accuracy (Figure 3-2b). This is likely due to the fact that only 12 compounds were used 
as the training set for this model, and this did not include any of the fluorene analogues. 
However, these QSAR models will allow for rapid screening of analogues for inhibitor potency 
prior to the initiation of chemical synthesis.  
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Table 3-3: Predicted and observed Ki Values for hiCE with five fluorene analogues (Compounds 
56-60) that were postulated from the QSAR analyses to be excellent CE inhibitors 
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3.3.3 PSEUDORECEPTOR SITE QSAR MODELS 
To provide a graphical representation of the QSAR results, we developed a pseudoreceptor 
model for hiCE with data sets derived from the inhibition of hydrolysis of oNPA (Figure 3-3A). 
This figure outlines the interactions that describe receptor-ligand binding in the enzyme. The 
model has primarily anionic (red areas) regions of charge located in a cluster at the base of the 
model and a weakly cationic (blue spheres) domain located at the top. This is consistent with all 
our previous analysis of hiCE inhibitors, where charge asymmetry was observed both in the 
QSAR models 20, 21, 24, 27-29 and in the enzyme structure determined from homology 
modeling [27]. We also present an electrostatic potential map of the model (Figure 3-3B) 
oriented to emphasize the charge asymmetry. While the origin of this charge distribution is not 
completely understood, at least for homology structures of hiCE, it maps well onto the position 
of charged amino acids present within the active site [27]. It should be remembered that these 
figures represent a description of the interior surface of the active site and not the combined 
surfaces of the inhibitor molecules. However, in general, the electrostatic potential inside the 
active site was negative [80] and hence it is not clear whether the positive areas required to fit the 
inhibition data reflect interactions within the active site alone, or represent potential interactions 
with positively charged residues near the active site opening. The interpretation of these models 
will be greatly enhanced if a crystal structure of hiCE becomes available.  
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Figure 3-4. 3D-QSAR pseudoreceptor site models generated from the enzyme inhibition data for 
hiCE using the benzene sulfonamides with 3 as a substrate. These models were generated using 
results obtained from all 57 sulfonamides and include compound 8 for reference. Both figures 
were generated using Raster3D4 [81] and Molscript 44. (A) The model is depicted as colored 
spheres on a hydrophobic gray grid. Areas that are hydrophobic are indicated in gray, where 
dark-blue spheres represent regions that are positively charged (+0.25e) and light-blue spheres 
correspond to reduced charge (+0.1e). Dark-red spheres indicate domains that are negatively 
charged (-0.25e), and light-red spheres represent areas of reduced negative charge (-0.1e). In all 
cases, e is the charge of the proton. (B) Stereo view of a 3D-QSAR pseudoreceptor site model 
that describes sulfonamide binding as a molecular surface upon which the electrostatic potential 
is mapped. The electrostatic potential is calculated from the Quasar software partial charges, 
which were defined as -0.25e, -0.1e, +0.1e, and +0.25e for negative salt bridge, hydrophobic 
negative, hydrophobic positive, and positive salt bridge characteristics, respectively. As above, e 
is the charge of the proton. The figure is oriented to emphasize the charge asymmetry that 
appears in all QSAR models that we have observed in previous analyses [27, 82-86]. 
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3.4 DISCUSSION 
In this chapter, we have demonstrated that potent, selective inhibitors of hiCE based upon 
the benzene sulfonamide scaffold can be developed. This has resulted in the development of a 
series of fluorene analogues that have Ki values in the low nM range for both the inhibition of 
hydrolysis of irinotecan and oNPA. These compounds (56-60) were designed and synthesized 
based upon prior 3D-QSAR pseudoreceptor site models that indicated that a bulky, hydrophobic 
central domain within the inhibitors improved their potency.  
The benzene sulfonamide analogues that we assayed fell into four broad classes. 
Compounds 4-13 were originally identified in a small scale library screen, [27] and they 
essentially contained three domains. This included terminal and central phenyl rings bonded via 
sulfonamide chemotypes and substitutions within the rings that altered the chemical properties of 
the compounds. Because compound 13 demonstrated the lowest Ki for hiCE inhibition, this 
molecule was used as a scaffold for the design and synthesis of analogues 14-55. Due to the fact 
that the most potent compounds tended to be halogen substituted, [27] we concentrated our 
efforts on the generation of inhibitors containing these atoms, principally in the terminal benzene 
rings (molecules 14-41). Among this latter series of compounds, we noted that substitution in 
either the 3-(meta-) or 4-(para-) position with chlorine or bromine (compounds 17-19; Ki values 
ranging from 67-85 nM) resulted in significantly lower inhibition constants as compared to that 
of the unsubstituted molecule (8; Ki) 1060 nM). Indeed, 17-19 were the most potent of the 
molecules containing substitutions within the terminal benzene rings. These halogens increase 
the hydrophobicity of the molecules (clog P for 17-19 range from 4.3-4.7, ∼1 log greater than 
compound 8), and therefore these analogues would be more likely to localize within the 
hydrophobic active site gorge of the protein.  
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In contrast, substitution with multiple larger atoms (e.g., compound 28) resulted in loss of 
biological activity and is likely due to the fact that this molecule is too large to fit within the 
active site of hiCE. Furthermore, molecules containing a carboxylic acid or amide group at the 4-
position (39 and 41) were inactive. Whether this loss of enzyme inhibition is due to electronic 
effects on the other atoms within the sulfonamide, or a steric interaction that forces the inhibitor 
into a conformation such that it can no longer interact with amino acids that line the active site, 
or a combination of both, is unclear. However, it is apparent that introducing substitutions that 
increase the clogP without dramatically increasing the size of the molecules can improve the 
potency of these analogues.  
Compounds 42-54 contained substitutions within the central benzene ring coupled with 
halogens appended in the terminal phenyl groups. In general, these modifications resulted in 
reduced potency toward hiCE inhibition. This is exemplified by compounds 44-46, which are 
inactive in this assay. However, 54, which contains the 2,3,5,6-tetrafluoro substitution, resulted 
in increased activity as compared to the unsubstituted molecule (19). Because these compounds 
demonstrate very similar clogP values, the increase in biological activity is likely due to a change 
in the electron distribution afforded by the very electronegative fluorine atoms. As we have not 
yet obtained the X-ray structure of hiCE, it has not been possible to identify the specific amino 
acids with which these sulfonamides interact. Hence, it is unclear how these small molecules 
demonstrate specificity for hiCE. However, based on previous observations that sulfonamides 
can inhibit thrombin, we presume that a similar mechanism of enzyme inhibition occurs [87-89].  
These studies demonstrated that the oxygen atoms within the sulfonamide group can hydrogen 
bond with amino acids present within the active site of this protein. Therefore, we believe that 
the unique arrangement of residues present within the hiCE catalytic gorge and their ability to 
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form hydrogen bonds with the sulfonamides, represent the key interactions responsible for 
selective CE inhibition.  
Consistent with our previous reports describing CE inhibitors, [82, 83, 86] molecules that 
contained substitutions that increased the bulkiness or width of the compound were generally 
poor inhibitors. This was exemplified in this series of analogues by 28, 39, 41, and 44-46. All of 
these sulfonamides contained groups or atoms that significantly increased either the width or 
length of the molecule that would preclude facile access of the inhibitor to the CE active site. 
Because the hydrolysis of compounds by CEs is dramatically influenced by their ability to 
interact with the catalytic amino acids, [72, 80] it is highly likely that the same holds true for 
inhibitor molecules. Therefore, compounds that exceed the dimensions of the active site gorge in 
these proteins would not be inhibitors of these proteins. Molecules 28, 39, 41, and 44-46 are 
much larger and bulkier than the other compounds described here and therefore do not inhibit 
hiCE.  
 On the basis of the results of the QSAR analyses, we hypothesized that introducing a 
larger, planar, aromatic core domain within the center of the molecule should increase its 
potency. This was due to the fact that this moiety would increase the clogP (hydrophobicity) of 
the compound, without impeding the ability of the sulfonyl groups to interact with the amino 
acids present within the active site. This is consistent with the 3D-QSAR model depicted in 
Figure 3-3. This data set was generated using both compounds 56 and 60 in the training set. 
Excluding these compounds resulted in QSAR relationships that predicted 56-60 to be good 
inhibitors, but the experimental data revealed them to be excellent inhibitors: much better than 
predicted and some of the most potent compounds we have examined to date. One difficulty with 
any QSAR analysis is that the fewer members of a class of molecules in the training set, the less 
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likelihood of correct prediction of that series of compounds. Hence, we rebuilt the models, 
including 56 and 60, to determine whether this would result in improved prediction of the Ki 
values for 57-59. As expected, the predictive properties of the data were improved by at least 1 
order of magnitude by including 56 and 60, suggesting that as we synthesize and test more 
fluorene-containing molecules, we should be able to produce a more accurate QSAR relationship 
for other classes of molecules beyond those used in this study.  
  In general, halogen substitution of the distal phenyl rings slightly decreased the Ki value 
as compared to that of the unsubstituted analogue 11, whereas methyl groups added to the central 
phenyl ring did not much affect the binding of the analogues. This was somewhat surprising, as 
the 3D-QSAR pseudoreceptor model (Figure 3-3) is highly hydrophobic in the central ring area, 
as indicated by gray lines. However, replacement of the central phenyl ring with a naphthyl or 
fluorene chemotype greatly reduced the inhibition constants of the compounds, i.e., making them 
more potent hiCE inhibitors. We attribute this to π-π interactions of the small molecules with the 
tryptophan and phenylalanine rings that are known to line the active site gorge of hiCE [5]. 
Similarly, this would explain the potent inhibitory power of the indole-containing isatins that we 
have previously characterized [83].  
 
3.5 CONCLUSIONS 
 In summary, the active site contains a large area of hydrophobicity in the central ring 
area, and the active site has a charge separation.  Our QSAR model suggests that potency of the 
sulfonamide inhibitors can be increased by (i.) the addition of a larger hydrophobic core region 
of the sulfonamides, (ii.) substitution of the distal benzene rings with halogens and placing those 
electronegative groups in the para or meta position, (iii.) removal of moderately EWG groups 
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from the para position, (iv.) removal of bulky groups from the core region of the sulfonamides.  
Dr. Potter’s Lab is currently determining the ability of these compounds to inhibit hiCE 
intracellularly and evaluating whether any of these molecules represent valid lead compounds for 
in vivo use. If so, they may allow the design of clinical candidates, suitable for the modulation of 
irinotecan induced toxicity, in patients treated with this drug.  
 
3.6 EXPERIMENTAL  
3.6.1 THREE DIMENSIONAL QSAR MODELING OF INHIBITORS   
Multidimensional-QSAR modeling of carboxylesterase inhibitors was performed using 
Quasar 5 software [90-92] running on a Macintosh G5. The structure for each compound was 
built using Chem 3D, and each structure was minimized with MM2 and PM3 formalisms. The 
solvation energies and charges were calculated using the AMSOL 7.1 program [35] using the 
SM5.42R solvation method. The gas phase charges obtained were used for all QSAR analyses. A 
resulting receptor surface was then generated using Quasar 5.0 and analyzed to yield over 200 
independent models and subsequently refined to generate ~ 7000 pseudoreceptor site models. 
Repeated analyses of the data sets were then performed until the cross correlation coefficients 
(q2) were greater than 0.7 for the experimentally determined versus the predicted Ki values. 
Routinely, this yielded correlation coefficients (r2) of > 0.8.  
Two independent QSAR models were constructed using two different training sets. The 
first was constructed using 37 sulfonamides as inhibitors of hiCE using oNPA as a substrate. The 
second was obtained using the Ki values of 12 inhibitors of irinotecan hydrolysis. In all cases, a 
range of Ki values spanning 3 orders of magnitude were used to ensure a reasonable model. We 
then included the structures of a number of potential inhibitors of hiCE in the test set to identify 
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novel chemical scaffolds that might be potential selective inhibitors of hiCE. These included the 
fluorene-containing compounds 56-60.  
 
PUBLICATION NOTICE 
This work was published in the Journal of Medicinal Chemistry in 2009. 
Improved, Selective, Human Intestinal Carboxylesterase Inhibitors Designed to Modulate CPT-
11 Toxicity, Latorya D. Hicks, Janice L. Hyatt, Shana Stoddard, Lyudmila Tsurkan, Carol C. 
Edward, Monika Wierdl, Randy M. Wadkins, Philip M. Potter. Journal of Medicinal Chemistry 
52 (2009) 3742-3752 
 
 
 
 
 
 
 
 
 
 
 
	  43	  
 
 
CHAPTER 4 IN SILICO DESIGN AND EVALUATION OF 
CARBOXYLESTERASE INHIBITORS 
 
4.1 ABSTRACT 
Carboxylesterases (CEs) are important enzymes that catalyze biological detoxification, 
hydrolysis of certain pesticides, and metabolism of many esterified drugs. The development of 
inhibitors for CE has many potential uses, including increasing drug lifetime and altering 
biodistrubution; reducing or abrogating toxicity of metabolized drugs; and reducing pest 
resistance to insecticides. In this chapter, we discuss the major classes of known mammalian CE 
inhibitors and describe our computational efforts to design new scaffolds for development of 
novel, selective inhibitors. We discuss several strategies for in silico inhibitor development, 
including structure docking, database searching, multidimensional quantitative structure activity 
analysis (QSAR), and a newly-used approach that uses QSAR combined with de novo drug 
design. While our research is focused on design of specific inhibitors for human intestinal 
carboxylesterase (hiCE), the methods described are generally applicable to inhibitors of other 
enzymes, including CE from other tissues and organisms.    
 
4.2 INTRODUCTION  
Carboxylesterases are enzymes that convert esters into the corresponding alcohol and 
carboxylic acid. Carboxylesterases are members of the larger α/β-hydrolase fold family that 
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includes a wide variety of enzymes such as lipases, cholinesterases, haloalkane dehydrogenases, 
and epoxide hydrolases [9, 93, 94]. The catalytic machinery of the CE is an amino acid triad 
consisting of the residues serine, histidine, and glutamate that sit in a nucleophilic elbow, making 
these enzymes members of the even larger family of serine hydrolases.  
Carboxylesterases are ubiquitous in nature. In mammals, they are expressed in numerous 
tissues [11, 95]. The hydrolytic activity will vary based on tissue type, with the liver isozyme 
being one of the most active of all isozymes studied. The hydrolytic activity of these enzymes 
are important in drug metabolism, protection against xenobiotics, and detoxifying pesticides such 
as pyrethoids [14]. CE's are also responsible for hydrolyzing clinically useful drug such as 
capecitabine and irinotecan [12, 13], as well as illicit drugs such as heroin [6].  
CEs have potential as therapy for pesticide overexposure. Organophosphate and 
carbamate insecticides have the potential to poison humans by acting on acetylcholinesterase 
(AChE). CEs can bind organophosphate and carbamate insecticides and reduce toxicity by two 
pathways: metabolism of the insecticide by CEs and irreversible binding by the insecticides [15, 
16].  
 Carboxylesterases are also important in the activation of prodrugs. One such clinically 
important prodrug is irinotecan (7-ethyl-10-[4-(1-piperidino)-1-
piperidino]carbonyloxycamptothecin), an anticancer agent used as front-line therapy for 
colorectal cancer (Figure 3-1). In humans, several CEs have been well characterized, particularly 
liver carboxylesterase 1 (hCE1) and human intestinal carboxylesterase (hiCE), the latter of which 
is localized to the small intestinal epithelia. Both hCE1 and hiCE are known to convert irinotecan 
into its active form, SN-38 (7-ethyl-10-hydroxycamptothecin; Figure. 3-1). However, hiCE is 
expressed at high levels in the small intestine and is much more efficient at converting irinotecan 
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than hCE1 [12, 17]. Thus, overproduction of SN-38 occurs in the small intestine during 
irinotecan therapy, and tissue damage to this organ contributes to delayed diarrhea in patients, a 
side-effect that often requires hospitalization [96]. This is the dose-limiting toxicity of irinotecan. 
Development of hiCE-selective CE inhibitors to reduce or eliminate unwanted toxicity of 
irinotecan has been the recent goal of our laboratories. Selective hiCE inhibitors are envisioned 
as adjuvant therapy for the modulation of diarrhea, potentially allowing for higher dosing of the 
drug and more effective treatment of colorectal cancer.  
Several molecular structural scaffolds of CE inhibitors exist (Figure 1-3), which include, 
sulfonamides, benzils, benzoins, carbamates, isatins, organophosphates, oxysterols, pyrethoids, 
acridines, trazines, trifluromethylketones, piperidines, serine specific agents, and inorganic 
compounds. In general, most of these inhibitors show limited selectivity or specificity among 
isozymes or across species.  
Over the last several years, we have developed a number of specific or semi-specific 
hiCE inhibitors. However, one difficulty that has persisted among these inhibitors is poor water 
solubility. This chapter gives a brief overview of previously described molecular scaffolds of CE 
inhibitors, followed by a description of recent developments in the in silico methodologies we 
are using to design new selective and specific inhibitors with greater water solubility and overall 
"drugability" of their chemical properties. Detailed reviews of CE inhibitors have appeared 
recently [5, 97]. Here, our focus is on computer-based development of selective inhibitors of 
hiCE with the specific purpose of modulating irinotecan activation in the small intestine. 
However, the methodology used is general enough that it could be applied to the development of 
inhibitors of any enzyme 
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In the last chapter we developed a QSAR model using an expanded dataset of 
sulfonamide inhibitors.  This was performed to further dileneate features, which contributed 
toward this class of CE inhibitors potency.  Understanding the details that confer potency to 
these inhibitors is important, however, we also have a need to develop soluble compounds.  In 
this chapter we demonstrate that we can generate soluble CE inhibitor compounds using a dual 
QSAR, de novo design method approach. 
 
4.3 CARBOXYLESTERASE INHIBITORS: SCAFFOLDS, SELECTIVITY, 
SPECIFICITY AND MECHANISM OF INHIBITION  
4.3.1 ACETYLCHOLINESTERASE INHIBITORS AND THEIR CE INHIBITION  
We begin this chapter by looking at selectivity for CEs by several known groups of 
AChE inhibitors, starting with the alkylphosphonic esters, also known as organophosphate 
(OPs), which may be the most well known class of CE inhibitors. OPs are commonly used as 
insecticides (e.g., malathion (diethyl dimethoxythiophosphorylthiosuccinate) and paraxon 
(diethyl 4-nitrophenyl phosphate). Organophosphates are toxic due to their inhibition of AChE 
activity, which allows the muscarinic receptors to be continually activated by acetylcholine. The 
result of this AChE inhibition is the cholinergic effect, with symptoms of salivation, lacrimation, 
urination, defecation, gastrointestinal distress, vomiting, muscle spasms and ultimately death if 
the reaction is severe enough. Hence, sarin (O-isopropylmethylphosphonofluoridate), soman (O-
pinacolylmethylphosphonofluoridate) and tabun (ethyl dimethylamidocyanophosphate), which 
demonstrate high affinity for human AChE, have been used as chemical warfare agents.  
Carboxylesterases can also be irreversibly inhibited by organophosphates. The 
mechanism of inhibition involves the attack from the enzyme's serine Oγ on the phosphate atom 
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of the organophosphate. This creates a covalent bond ending the mechanism at an acyl–enzyme 
intermediate. Strategies to develop CEs to combat chemical warfare compounds have been 
pursued by the military. Essentially, CEs could be used as “bioscavengers”, which work by 
sequestering or hydrolyzing a toxic substrate [98]. Recent work shows that hCE1 shows a  
preference for binding the PR enatiomers of soman and cyclosarin analogues (1700-, 2900-fold  
respectively) and a slight preference for the PS enantiomer of sarin analogues (5-fold) [99]. 
However, only one group of OPs has been found to be semi-selective for CEs: the 
benzodioxaphosphorines (Bomins; attributed to Patent USSR 06.22.1985. No. 1187444). Their 
selectivity however is only about 10-fold greater than for AChE, and hence the problematic 
toxicity of OPs make them an unlikely scaffold for development of clinically useful compounds. 
The carbamates (CBs) contain a central amide ester group and two alkyl or aryl substituents 
located on the nitrogen atom. CBs are not as toxic as the OPs but they still induce the same 
cholinergic effect. The CBs are reversible inhibitors of AChE and, like the OPs, have been used 
as insecticides (e.g., Carbaryl (1-naphthyl methylcarbamate)). The carbamates are also used in 
many clinical applications. For example rivastigmine (S)-N-ethyl-N-methyl-3-[1-
(dimethylamino)ethyl]-phenyl carbamate is used to treat Alzheimer’s disease. Rivastigmine is a 
selective, reversible brain AChE inhibitor [100].  
Irinotecan also contains a carbamate moiety, which is primarily responsible for its initial 
cholinergic activity [80, 101]. Carbamates for CE inhibition have been explored by the Potter 
and Danks groups, who showed that four nitrophenyl derivatives with carbamate-linked side 
chains could selectively inhibit hiCE and rCE [102]. These derivatives were the first attempt at 
developing specific hiCE inhibitors. However, inhibition by these compounds is also confounded 
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by their AChE inhibition, and hence has the potential problems associated with all cholinergic 
drugs.   
Trifluoromethylketones (TFKs), like the OPs and CBs, will also inhibit AChE; the 
carbonyl carbon of the TFK can form a covalent bond to the serine residue of the catalytic triad. 
Thus they are non-specific inhibitors of CEs. Although these CE inhibitors are some of the most  
potent known, they exhibit both partially competitive and partially noncompetitive modes of 
inhibition. Their mode of binding is somewhat unique compared to the rest of the CE inhibitors, 
in that they take time to reach equilibrium before maximum inhibitor potency can be reached 
[85]. TFKs inhibit a range of mammalian CEs. Hence, selectivity toward hiCE is problematic.   
Acridine inhibitors of AChE include tacrine, which is used to treat Alzheimer’s disease. Tacrine 
itself is not an inhibitor of hCE1, but 6,9-diamino-2-ethoxyacridine and 9-amino-6-chloro-2-
methoxyacridine does inhibit hCE1 selectively over hiCE. These derivatives are low µM 
inhibitors of hCE1 [77].  
 
4.3.2 MORE SPECIFIC CE INHIBITORS  
The AChE/CE cross inhibitors listed above came primarily from studies that emphasized 
the similar catalytic activity of the members of the α/β-hydrolase fold family. Indeed, the very 
first collaboration between the Potter and Wadkins laboratories was on molecular modeling of 
the interaction of irinotecan with AChE and the related butyrylcholinesterase[103]. In the 
subsequent decade, the quest for isozyme-specific CE inhibitors has produced several molecular 
scaffolds that do not possess anti-AChE activity. The design of many of the analogs was a 
combination of chemical library screens to isolate reasonably selective CE inhibitors, followed 
by chemical intuition and plausible synthetic schemes.  
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Telik’s Target Related Affinity Profiling (TRAP) method was originally employed in the 
search for novel CE inhibitors. In this method, compounds were screened for their binding 
affinities toward a panel of protein targets. The binding affinities were subsequently used to 
create an “affinity fingerprint", which was subsequently used to identify novel inhibitors. Telik’s 
methodology has the advantage of needing few initial compounds to generate several new 
scaffolds of inhibitors. The TRAP analysis had been utilized in the identification of novel 
inhibitors for cyclooxygenase-1 (COX-1) [104]. Hsu and coworkers used 19 known COX-1 
inhibitors, all reversible competitive inhibitors of COX-1, comprising 8 structurally dissimilar 
classes, to create an affinity fingerprint for COX-1 inhibition. Using TRAP analysis, they derived 
3 new COX-1 inhibitors. We used this method to identify novel CE inhibitors. The sulfonamides 
and benzils were both discovered through this methodology [27, 86].  
 
4.3.3 SULFONAMIDES  
The initial screening of a library of compounds isolated 9 sulfonamide derivatives as 
specific hiCE inhibitors vs. other human hydrolases [27]. Using a limited QSAR analysis of 
these 9 compounds, a number of other sulfonamides were synthesized or obtained from 
commercial sources. Examination of this larger group of sulfonamides determined that the ring at 
the central core moiety could accommodate either benzene or fluorene [27, 28]. The fluorene 
sulfonamides, in general, are more potent than the benzene sulfonamides with inhibition 
constants ranging from 41 nM to 3240 nM for benzene sulfonamides and from 14 nM to 91 nM 
for the fluorene sulfonamides. The majority of sulfonamides do not inhibit AChE or 
butyrylcholinesterase (BChE), and hence are highly selective CE inhibitors.  
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The mechanism of inhibition for the sulfonamides is partially competitive. However, 
unlike the majority of the CE inhibitors, there is no carbonyl carbon atom or electron deficient 
atom that would be susceptible to attack from the serine Oγ residue. Attack on the sulfur atom of 
the sulfonamide is an energetically disfavored process due to the stability of the sulfonamide. 
The sulfonamides could potentially hydrogen bond to the enzyme and lock it into a stable 
complex, or they may bind to the opening of the active site, blocking the entrance to the gorge.  
The extended conformation of the sulfonamides matches the shape of the active site 
gorge of a homology model of hiCE, so it is entirely possible that they occupy the binding site of 
the enzyme, giving rise to isoform specificity. However, the sulfonamides as a whole suffer from 
very poor water solubility. Evaluation of over 50 sulfonamides [28] revealed an inverse 
correlation of clogP and log Ki. Hence, the least soluble compounds were the best inhibitors of 
the enzyme. This is the major difficulty with using sulfonamides as scaffolds for a potential drug 
application.  
 
4.3.4 BENZILS  
The diphenylethane-1,2-dione (benzil; Figure 1-3) analogues are another class of isotype-
selective mammalian CE inhibitors that we have examined after the initial drug screening. Benzil 
itself is not a new compound (discovered in the late 1800s). However, it was not until 2005 that 
it was discovered to be a selective inhibitor for human carboxylesterases [86]. Inhibition 
constants (Ki) ranged from 4 nM to 18 µM for 31 benzil analogues that were evaluated, with no 
inhibition of AChE. The analogs were found to be competitive reversible inhibitors of the CEs 
The proposed mechanism of inhibition involves the inability of the enzyme to release the 
aldehyde as a leaving group. With no appropriate leaving group after the formation of the 
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tetrahedral intermediate, the initial carbonyl is reformed. The crystal structure of hCE1 has been 
solved with benzil in the active site, suggesting that cleavage of the dione moiety could occur, 
consequently generating a benzoic acid or benzaldehyde [105]. In contrast to the sulfonamides, 
there is no correlation between clogP values for these compounds and their Ki values, making 
them a much more interesting platform for drug development. Their selectivity appears to arise 
from the dihedral angle of the dione moiety. When the carbonyl oxygen atoms are cis-coplanar, 
greater selectivity for hCE1 occurs, while non-planarity results in selectivity for hiCE [106].  
 
4.3.5 BENZOINS AND FLUOROBENZOINS  
During the exploration of the benzil scaffold, compounds of similar structure were also 
tested for activity against the mammalian CEs.  The compound 1,2-diphenyl-2-hydroxy ethanone 
(benzoin; Figure. 1-3) was found to be a weak but selective inhibitor of CEs, having a Ki of 2.7 
µM for hiCE and 7.2 µM for hCE1. Subsequent addition of electron withdrawing groups to the 
benzene rings in both benzils and benzoins produced more potent, highly selective inhibitors. In 
particular, addition of fluorine significantly increased their ability to inhibit mammalian CEs 
without resulting in inhibition of AChE or BChE. The inhibition constants for the fluorinated 
analogues ranged from 8 nM to 1.3 µM [82].  
 
4.4 IN SILICO METHODS AND DEVELOPMENT OF ISATINS  
4.4.1 COMPUTATIONAL APPROACHES  
One conceivable method of computationally deriving selective inhibitors for CEs might 
be to dock small molecule libraries into the active site of CEs in order to predict new inhibitors. 
However, in practice there are complications with that strategy that limit its effectiveness. The 
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substrate specificity of CEs is dependent on two structural features: the dimensions of their 
active site gorge and the external opening to the gorge. We have examined these important 
parameters using molecular dynamics calculations of CEs from rabbit, human liver, human 
intestine, and a bacterial CE (rCE, hCE1, hiCE, and pNB, respectively) [Shawn’s-REF]. In 
addition, we have used normal mode calculations to examine low-frequency motions of the CEs 
(large conformational changes). Both the active site gorge diameter and the opening to the active 
site fluctuate significantly with time (Figure 4-1), so determining which structure the known 
inhibitors are binding to is complicated. The basic rationale for the need to include molecular 
dynamics in the development of enzyme inhibitors for the related AChE has been recently 
reviewed [107]. This rationale also applies to CEs. Briefly, enzymes are in constant motion at 
temperatures near 37°C and the understanding of the fluctuation is crucial for in silico docking or 
assembly of inhibitors. In the case of the α/β hydrolase fold family, the active site residues are at 
the bottom of a ~22 Å gorge, the walls of which are also fluctuating. The crystal structure of 
hiCE has not been determined, and so by necessity a homology model would need to be used for 
this enzyme (although it should be noted that earlier homology models of rCE [80] based on the 
folding of AChE were remarkably similar to the subsequently-determined crystal structure [108]; 
α carbon RMSD ~ 2Å). The crystal structures for the other 3 enzymes (rCE, hCE1, pNB) have 
been determined and hence MD calculations are easily accomplished. Even though the crystal 
structures exist, there is an additional reason MD is an important tool for docking ligands into 
these molecules. As with other enzymes, the crystal structures containing known substrates or 
inhibitors in the active site have an active site that is too small to accommodate other known, 
larger substrates. For example, the structure of hCE1 containing a product of benzil hydrolysis 
would be too close-packed to allow placement of CPT-11 in the same locale [105]. This can be 
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resolved by allowing the enzyme structure to fluctuate. An example of this is shown in Figure. 4-
1, where the active site gorge diameter size of the pNB CE is calculated throughout a lengthy 10 
ns MD simulation. Note that access to the active site can fluctuate from as little as 3.0 Å to as 
wide as 7.5 Å over a relatively short period of 1 ns.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-1. Fluctuation in the diameter of the active site gorge of a carboxylesterase from B. 
subtilis. The analysis was performed with a procedure modified from the work of McCammon 
and colleagues [109]. The solvent-accessible surface was calculated with an increasing probe 
radius until it no longer made contact with the active site Ser and His residues. The structure was 
taken from PDB code 1QE3 [18].  
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Other regions of structural fluctuation in CEs are the loops that form a putative lid over 
the entrance to the active site gorge. Normal mode analysis (NMA) of hCE1 and a homology 
model of hiCE (modeled using hCE1 as a template) was performed with the ElNémo web server 
[110], which is a web interface to the Elastic Network Model that implements the ‘rotation-
translation-block’ (RTB) approximation. The lowest non-zero frequency mode for the enzymes 
having a high degree-of-collectivity (mode 7) are shown in Figure 4-2. It is this fluctuation that 
makes MD a critical component of inhibitor design by computer for the family of α/β hydrolases. 
However, these fluctuations are also a drawback to this type of computational design since 
computer docking to multiple enzyme structures must be performed.  
 The combination of MD and docking has been used for development of specific 
inhibitors of AChE vs. other serine hydrolase enzymes, and hence we expect this approach has 
the potential to work for CEs as well. Generic docking of known AChE inhibitors to a static 
AChE are generally not predictive for the relative magnitudes of the inhibition constants [107]. 
This has been attributed to the inability of static models to correctly calculate the entropy change 
upon inhibitor binding. A more successful approach taken by the McCammon laboratory 
involves using not just one static structure of CE for docking potential inhibitors, but rather 
numerous CE structures taken from a molecular dynamics simulation [111]. However, given the 
complications inherent in this approach, we developed a computationally-simpler multi-
dimensional QSAR model as a reduced representation of the inhibitor binding site. This has the 
advantage over crystal structure docking approaches in that it does not require us to know the 
molecular details of the inhibitor binding site, just the chemical properties and Ki values for the 
inhibitors.  
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Figure 4-2. Fluctuation of the loop forming part of the "lid" over the active site in 
carboxylesterases (yellow residues) determined from normal mode calculations for (A) hCE1 
and (B) hiCE homology model. The "lid" is oriented toward the bottom of each molecule. 
Arrows indicate the extent of motion for the entire enzyme for the lowest frequency mode (mode 
7). The view is into the active site gorge. The active site residues Ser, Glu and His are shown in 
green. While the effect on catalysis of these loops is unknown, they may serve to bind substrate 
and guide it toward the active site gorge or to cover the active site to prevent diffusion of 
substrate out of the gorge before hydrolysis.  
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The idea for the indole-2,3-diones (isatin compounds; Figure. 1-3) was developed from 
this QSAR approach using biochemical data on the sulfonamide and benzil inhibitors. Our data 
suggested the presence of aromatic moieties were important for inhibition [86, 106]. Other 
earlier work found that there was a size constraint on the entrance to the active site gorge [80]. 
Using these two considerations as a parameter guide, a database search of commercially 
available compounds related to benzil was initiated, resulting in isatins as potential inhibitors of 
CEs. Simultaneously, a combination of QSAR and computerized model building using the 
sulfonamide data led to the prediction that indole-containing compounds would be CE inhibitors, 
and would also lead to selectivity for hiCE (Figure 4-3). This was ultimately borne out by 
analysis of 74 compounds related to isatin, and the discovery of several that were selective for 
hiCE [83], with inhibition constants as low as 6 nM. Below, we describe in detail the 
computational analysis that led to the predicted structures containing indole. Further, we describe 
the QSAR "grand model" that combines all compounds that we have evaluated for inhibition of 
CEs.  
 
4.4.2 QUANTITATIVE STRUCTURE ACTIVITY RELATIONSHIPS (QSAR) 
QSAR correlates the molecular structure and properties of a set of compounds with their 
activity. The parameters used for QSAR are molecular descriptors that can range from a simple 
count of atoms to HOMO and LUMO calculations; electronegativity; and other quantum 
molecular features. A QSAR model can also be modeled as a three-dimensional structure, which 
will show visually the nature of the relationship between the inhibitors and the receptor. QSAR 
has long been popular in assisting in the determination of essential interactions between the 
receptor and inhibitor. In our previous studies, almost all of the CE inhibitors have been 
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investigated through QSAR. These studies generated suggestions for improving the activities of 
inhibitor compounds (e.g., the addition of halogens, and inclusion of a larger aromatic moiety in 
the core of the inhibitor structure [27, 28, 112]).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-3. Selected indole-containing compounds originally predicted by the de novo design 
software LigBuilder to be good inhibitors of hiCE using a QSAR model based entirely on 
sulfonamides.  The prediction led to discovery and evaluation of isatins [83]. 
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QSAR reveals the important interactions between the ligands and the receptor site by 
using ligands that are known to be active inhibitors of the receptor of interest. The de novo 
design is an approach to structure-based drug discovery that utilizes a binding site pocket to 
build ligands specifically for the receptor [37, 113]. Common de novo design programs that are 
used today are GRID [39], SPROUT [41, 42], CONCERTS [38], SYNOPSIS [43], LeapFrog 
[40], and LigBuilder [37].  
Using QSAR models as pocket sites for de novo design is an approach that can be utilized 
when no experimental receptor structure is available. Combining QSAR and de novo design has 
been used by several investigators [114-118]. For example, Gueto and coworkers [114] 
developed a CoMFA (Comparative Molecular Fields Analysis) model for aromatase inhibitors 
with 45 training set compounds and used a test set of 10 sulfonanilide compounds. This CoMFA 
model was used to generate new inhibitors in silico with the NEW module of LeapFrog, 
followed by calculation of their predicted activity. As another example, Kapou and coworkers 
[115] combined CoMFA and CoMSIA with LeapFrog to study and design steroidal mustard 
esters using a training set of 26 compounds and test set of 12 compounds. This model was then 
subsequently used to design new inhibitors using the OPTIMIZE module of LeapFrog.   
CoMFA uses a grid-based approximation to develop 3D-QSAR models, and includes 
parameters such as steric and electrostatic effects by using both a Lennard-Jones and Coulombic 
potential. CoMSIA and LeapFrog also use a grid-based approximations to develop new 
compounds with good binding energies. In our laboratory, we have used the Quasar program [91, 
92] to develop a 6D-QSAR model for hiCE inhibitors, and the de novo design program 
LigBuilder to generate new scaffolds of hiCE inhibitors (Table 4-1). The Quasar program is a 
grid-based technique as  
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Table 4-1. Potential selective hiCE inhibitors output by LigBuilder using the QSAR structure 
shown in Figure 4-6.  While many of these compounds are synthetically unfeasible, they do 
present a series of scaffolds that, combined with chemical intuition, may produce selective 
inhibitors in much the same way the isatins were discovered. 
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well, and it employs a genetic algorithm for model generation and induced fit. In addition of the 
3 spatial dimensions of Quasar, the 4th dimension allows for analysis of different conformations 
of ligands (4D-QSAR), while the 5th dimension takes into account the potential for induced fit 
(5D-QSAR) [91]. The 6th dimension of Quasar added the ability to investigate different 
solvation effects (6D-QSAR) [119]. The following equation is used for calculation of binding 
affinity in Quasar.  
Ebinding = Eligand–receptor - Eligand desolvation + Eligand strain - T∆S + Einduced fit 
The term Eligand–receptor is calculated by the following equation, 
Eelectrostatic + Evan der Waals + Ehydrogen bonding + Epolarization. 
Spreafico and coworkers have successfully used Quasar to develop models that include 
several classes of compounds [119]. Their data indicate that Quasar is effective when combining 
steroids, quinoline derivatives, fluorophenylindazole derivatives, and spirocyclic derivatives as 
inhibitors of glucocorticoid receptor.  
The QSAR model developed in our study included sulfonamide, benzil, fluorobenzoin, 
and isatin inhibitors (Figure. 1-3). The TFKs were omitted because their mechanism of binding is 
different from the rest of these inhibitors, and requires a pre-incubation time to be most effective 
[85]. A more thorough investigation of TFK inhibition has recently appeared [112]. Our previous 
studies have used QSAR for development of pseudo-receptor site models in an effort to delineate 
pertinent information about the active site that could be useful in the design of new inhibitors 
[27, 28, 82, 83, 85, 86, 106]. However, these studies only somewhat used the pseudo-receptor 
site models for de novo design of potential inhibitors and were derived from limited data sets. 
Here we report our results on predicted structures using a "grand model" of CE inhibition based 
on data from 210 CE inhibitors comprising four inhibitor families.  Our expectations were that 
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using this pseudo-receptor site as a hypothetical binding site might yield inhibitors other than 
indoles with improved drug-like properties (e.g., better water solubility).  
The 6D-QSAR modeling of hiCE inhibitors was performed using Quasar 6.2 software 
running under Mac OS X. The 210 structures used included 4 diverse scaffolds; benzils, 
fluorobenzoins, isatins, and sulfonamides. Each analog had been previously drawn using 
Chemdraw, imported into Chem3D, and minimized first by using the MM2 molecular mechanics  
force field, followed by the PM3 semi-empirical method within MOPAC [90]. The solvation 
energies and charges were calculated using AMSOL and the SM5.42R solvation method [36]. 
SM5.42R is a rigid solvation model, which optimizes a compound's structure in the gas phase but 
optimizes only its electronic structure in the solvent phase. Gas phase charges were used for all 
QSAR analysis.  
A training set of 133 compounds and a test set of 77 compounds were used to build the 
QSAR model. The Ki values that were used for these computations were those derived from the 
inhibition of o-nitrophenylacetate (oNPA) hydrolysis. As with any QSAR model that uses 
structurally divergent ligands, the complication in this process is the choice of how to align the 
structures with one another. We chose the central benzene ring of the sulfonamide inhibitors as 
the template to which all the other compounds would be aligned. The resulting 3D-pseudo-
receptor site model describing the interactions between the active site and the ligands is shown in 
Figure 4-4, and is referred to as the “grand model” for hiCE inhibitors. The r2 (squared 
correlation coefficient of model) and q2 (predicted squared correlation coefficient, which 
describes the predictive quality of the model) generated were both 0.835, and the predicted vs. 
experimental ∆G° for inhibition constant values are shown in Figure 4-5. This QSAR model was 
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fairly robust in prediction of inhibitor binding, and therefore we used it as a template upon which 
to build new molecules.  
 
 
 
Figure 4-4. Stereo view of the 3-dimensional "grand model" for hiCE inhibitors is depicted as 
colored spheres on a hydrophobic gray grid. Areas that are hydrophobic are indicated in gray, 
whereas dark blue spheres represent areas that are positively charged (+0.25e) and light blue 
spheres correspond to lesser charge (+0.1e). Dark red spheres represent areas that are negatively 
charged (-0.25e), light red spheres indicate less negative charge (-0.1e). In all cases, e is the 
charge of the proton. The structure of representative sulfonamides (black), isatins (blue), benzils 
(green), and benzoins (pink) are shown. The Figure was generated using Molscript[120] and 
Raster3D [81] . 
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Figure 4-5. Predicted vs. experimental ∆G° values (in kcal/mol) for inhibition constants of 4 
classes of molecules that inhibit the hiCE hydrolysis of o-nitrophenylacetate. Ki values were 
determined using a partially-competitive inhibitor model. The training set is indicated by the 
filled ovals, while the test set is represented by open boxes. The compound labeled "a" is a 
disulfide and is the lone member having this moiety. The compound labeled "b" is a 2,5-
bis(trifluoromethyl) benzil analog. Its surprising lack of activity is under investigation. For 
clarity, compounds with Ki values > 100 µM are not included on this plot.  
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4.4.3 DE NOVO LIGAND DESIGN  
The next step in the process was to have LigBuilder synthesize potential inhibitors based 
on the 3D-QSAR structure. LigBuilder begins with a user-defined seed structure that is the 
starting point for building new ligands by adding molecular fragments to the seed until the 
binding site is fully occupied. Each compound derived in this manner is evaluated via the 
Lipinski “rules” [121], and compounds violating these rules are rejected. LigBuilder uses an 
empirical scoring function to evaluate binding affinity, which is much different than that used by 
Quasar. LigBuilder alone has been combined with docking and pharmacophore modeling to 
design inhibitors for tyrosine kinase 2 [122], but to our knowledge has not been combined with 
QSAR models for lead compound development. To account for the other 3-dimensions of 6-D 
QSAR, the vertices of the model shown in Figure 4-4 were assigned pseudo-atomic properties 
within LigBuilder based on the corresponding property indicated in the legend of Figure 4-4. 
With this model as a hypothetical active site, potential inhibitors for hiCE were constructed from 
the seed structures 1,2-dione, p-aminoaniline, and benzene. For benzene, growth was allowed 
from all carbons in the ring. For p-aminoaniline, two seeds were used. The first allowed growth 
only from the amino group nitrogens, while the second allowed growth from both the amino 
groups and all unsubstituted ring carbons.   
The results of this process are shown in Table 4-1 for the different starting seeds. Once 
the structures were generated, they were evaluated in the 6D-QSAR shown in Figure 4-4, and the 
top 5 ranked structures (lowest predicted Ki values) are shown. All of these computationally-
derived structures were predicted to have good activities against hiCE, with free energy scores in 
the range of -10 to -13 kcal/mol (Ki from 46.7 nM to 0.3 nM). While only a select few 
compounds are shown in Table 4-1, over 40 new structural classes of inhibitors emerged from 
	  65	  
this in silico process. These classes show new features such as large aromatic or planar groups 
attached to a long alkyl chain, the inclusion of a large part of the polar groups within cyclic ring 
systems, two aromatic groups joined together by a central alkyl group, and hybrid compounds 
that are a cross between two or more groups of inhibitors.   
Table 1 also illustrates a problem with computer-generated ligands. Clearly, some of the 
predicted compounds are not feasible as biochemically active molecules, particularly the 
anhydrides that would be highly reactive with water. However, ignoring such unfeasible 
compounds, water solubility of most of the predicted structures using ALOGPS 2.1 indicated 
they have greater solubility than the sulfonamides, and many have solubility comparable to the 
anticancer drug irinotecan. This suggests that the solubility can be enhanced while maintaining 
or even improving the activity when a combined approach is used. Synthesis of a subset of these 
new classes of inhibitors is underway to verify the predicted results.  
 
4.5 CONCLUSIONS 
Over the last decade, QSAR has allowed a detailed analysis of known CE inhibitors and 
helped to generate CE inhibitors with greater specificity. As an example, tetrafluorine substituted 
sulfonamide analogs were synthesized when QSAR analysis of nine sulfonamides suggested the 
addition of halogens would increase potency [27]. The observed results concluded that this new 
inhibitor had greater selectivity for hiCE versus hCE1 than the previous nine. Another example 
is the fluorene sulfonamides [28], which were pursued because results from pseudo-receptor sites 
suggested that the active site of hiCE could accommodate a larger aromatic moiety. The fluorene 
sulfonamides proved to be much more potent than the structurally-similar benzene sulfonamide. 
The specificity was also not affected by inclusion of the fluorene moiety in the core. Hence, 
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QSAR (particularly, the 6D-QSAR methodology used by Quasar) is an invaluable tool for 
developing specific hiCE inhibitors.  
While QSAR analysis has aided in the design to-date of more potent and specific 
inhibitors, it has not effectively addressed the issue that plagues most of the CE inhibitors 
designed theoretically: low aqueous solubility. The analysis and design described in this article 
suggest features of potential inhibitors that will increase their water solubility and yet retain or 
enhance potency. Further, our QSAR models are beneficial in understanding how the inhibitors 
are interacting within their binding site, which is presumed to be the enzyme active site. Such 
studies are useful in pointing toward optimization of lead compounds for structural scaffolds that 
may be discovered through means other than computer-generated structures.  
 
PUBLICATION NOTICE 
This work was published in the Journal of Pesticide Science in 2010 
In Silico Design and Evaluation of Carboxylesterase Inhibitors, Shana V. Stoddard, Xiaozhen 
Yu, Philip M. Potter, Randy M. Wadkins. Journal of Pesticide Science 35 (2010) 240-249 – 
invited review 
 
 
 
 
 
 
 
	  67	  
 
 
 
CHAPTER 5 COMBINING QUANTITATIVE STRUCTURE 
ACTIVITY ANALYSIS WITH IN SILICO DESIGN AND 
DOCKING TO DEVELOP NOVEL, SOLUBLE, SELECTIVE, 
AND SYNTHETICALLY ACCESSIBLE CARBOXYLESTERASE 
INHIBITOR SCAFFOLDS 
 
5.1 ABSTRACT 
 Carboxylesterases (CEs) perform hydrolysis reactions, breaking down xenobiotics and 
metabolizing drugs.  For example, the anticancer drug irinotecan is converted to its active form 
by the isozymes human carboxylesterase one (CES1, enriched in the liver) and human intestinal 
carboxylesterase (CES2, primarily enriched in the small intestine). CES2 converts CPT-11 to 
product 200 times faster than CES1, resulting in toxicity to the small intestinal epithelial.  This 
cytotoxicity produces the dose-limiting side effect of delayed diarrhea.  Selective inhibition of 
CES2 would promote better irinotecan distribution, increase irinotecan lifetime, and decrease its 
toxic side-effects.  While in recent decades CES2 inhibitors have been developed, low water 
solubility has been an issue that prevents these potent inhibitors from use in the clinic.  Many of 
these CEs also lack the appropriate selectivity.  Therefore, we have used a triune approach to 
generate novel, potent, water-soluble, and selective CES2 inhibitors.  We combined quantitative 
structure activity relationships with in silico design to generate new soluble inhibitors candidates 
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for CES2.  Two of our previous QSAR models were used as hypothetical pocket sites for de 
novo design.  Using the program LigBuilder1.2v, a library of 3100+ new compounds were 
generated in silico from 4 initial seed structures.  The Ki score for each compound was predicted 
using the original multi-class QSAR model and the solubility predicted using the ALOGPS 2.1 
program. We also developed a selectivity model to screen for selective CES2 inhibitors. In this 
chapter we present our experimental results for our top in silico generated scaffolds.  Our results 
suggest that (i.) solubility can be increased while maintaining inhibitor potency, (ii.) inclusion of 
several classes of inhibitors aids in development of new drugable features, and (iii.) loop 7 plays 
a role in inhibitor selectivity. 
 
5.2 INTRODUCTION 
 Carboxylesterases (CEs) are ubiquitous enzymes that carry out hydrolysis reactions of 
carboxylate ester functional groups.  CEs play an important role in drug biodistribution of 
esterified drugs.  In some cases they deactivate drugs, and subsequently decrease the amount of 
active metabolite in vivo; hydrolysis of flestolol is an example of this [74].  In other cases these 
enzymes activate pro-drugs in vivo; such as is the case with irinotecan, a front line chemotherapy 
drug for colorectal cancer [12, 17].  In the last decade, researchers have tried to develop selective 
CE inhibitors to abrogate the activity of the intestinal CE isozyme (CES2), which has been 
shown to produce the dose limiting side effect associated with irinotecan therapy [12, 17, 123].  
Selective CES2 inhibitors would result in a myriad of benefits, namely, improving patient care 
through the reduction of intestinal cytotoxicity, reducing the dosage levels required to achieve 
the desired medicinal effect, increasing the lifetime of drugs deactivated by CES2, and 
improving biodistribution of drugs activated by CEs.  
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      A variety of in silico methods have been shown to be useful in developing potent 
inhibitors for numerous biological targets, including CEs.  Recently, Topai et al. used a 
pharmacophore model to screen the MoDa database for new gelatinase inhibitors [124].  In 2012 
Qu et al. used docking to help create improved compstatin inhibitors and to explain experimental 
results [46].  Tanabe et al. also used docking to effectively design inhibitors for the α-
glucosidase receptor [47].  From their docking insights, they generated novel compounds that 
introduced new interactions within α-glucosidase [47].  In 2004, Wadkins et al. reported the first 
class of CE isozyme specific compounds (the sulfonamides), and in 2005 reported the benzil 
scaffolds as mammalian specific CE inhibitors [27, 86].  Both the sulfonamides and benzils were 
originally identified using Telik’s target related affinity profiling technique, then optimized using 
quantitative structure activity relationships (QSAR) studies.  In 2007 Hyatt et al. identified a 
series of isatin compounds through database searching [83].  The sulfonamides and benzils were 
discovered to be potent CE inhibitors yet water insoluble (Table 5-1).  The isatins possessed 
water solubility, but in general, had moderate potency and lacked appropriate CE selectivity 
(Table 5-1).  We can see that there is a broad range of the average CES2 inFhibitor activity 
(range 34 nM to 15665 nM) 
 
  
 
 
 
 
Table 5-1: CE Inhibitor Solubility and Ki  
CE inhibitor class Average Solubility 
(mg/L) 
Average Ki (nM) 
Sulfonamides 7  (Benzene Sulfonamides)    746  
(Fluorene Sulfonamides)      34  
Benzils 15  209 
Isatins 1000  15665 
Fluorobenzoins 9000  457 
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 Poor water solubility is a persistent problem in drug development altogether [125, 126], 
resulting in many drug candidates not reaching the market. One problem that plagues selective 
CES2 inhibitor development is the fact that there is an inverse correlation of LogP with potency, 
rendering most selective potent compounds insoluble [28].  The solubility problem is often 
overcome by chemical intuition on the part of the researcher [127-130].  Guantai et al. used 
chemical intuition to develop enone- and chalcone-chloroquinoline hybrid analogs having 
antiplasmodial activity [129].   By replacing the triazole linker with an aminoalkyl- or 
piperazinyl-based linker, they improved the solubility by increasing the polarity of the 
compound.  In 2009, Emmitte et al. designed thiophene inhibitors for polo-like kinase 1 with 
improved solubilities by introducing an amine polar group on the compound [130]. In 2010 
Young et al. also used the addition of a polar functional group to enhance solubilities of a series 
of CE inhibitor compounds.  They replaced one of the phenyl rings of benzil with a pyridine 
group enhancing the solubility relative to benzil [131].  Yoshizawa et al. improved the solubility 
of an angiogenesis inhibitor SU5416 by formulating the inhibitor in a pegylated O/W emulsion 
[132].  Ohashi et al. reduced the planarity of a pyrrolo[3,2-c]pyridine derivative (a hedghog 
signaling inhibitor) to improve the solubility compared with the parent compound [128]. While 
many individuals have successfully enhanced the solubility of a series of compounds, in silico 
methods are not typically employed to addresses this problem.  Visentin et al. have attempted to 
use QSAR and chemical intuition to enhance solubility of existing 1,4-dihydropuridine scaffolds 
[127]; however, this model was not extremely successful.  A computational method that could be 
employed to enhance solubility would greatly benefit the drug design society.  
 In the last chapter we hypothesized that the water insolubility of the CE inhibitors could 
be addressed by using a dual method approach of QSAR coupled with in silico design.  We also 
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hypothesized that the inclusion of multiple classes of CE inhibitors in the development of the 
QSAR model would aid in the generation of scaffolds that had more drugable features.  We were 
successful in proposing compounds that maintained predicted potency yet enhanced predicted 
solubility; however many compounds were synthetically inaccessible and experimental 
validation of the method was not performed.  In this chapter we have generated several new CE 
scaffold candidates and experimentally tested 1 scaffold and 4 scaffold precursors.  We have also 
compared the results of this approach using our multi-scaffold QSAR model against the results 
gathered using the singular class sulfonamide scaffold QSAR model.  
 In addition to developing soluble scaffolds, understanding the molecular details 
contributing to inhibitor specificity between CEs would also significantly improve our ability to 
rationally develop inhibitors and/or drug candidates.  Computational modeling had been 
performed on many classes of CE inhibitors to describe their potency as inhibitors, but never to 
predict which isozyme receptor they would favor.  The development of a predictive model for 
inhibitor selectivity would also aid in teasing out compounds with inappropriate selectivity.  The 
residue composition of loop 7 varies between CES1 and CES2 (Table 5-2). We hypothesized that 
the structural variances of loop 7 between the CES1 and CES2 played a role in selection of 
inhibitors. In this chapter, we investigated the contribution of the loop 7 in CEs to sensitizing the 
enzyme to inhibition by sulfonamide inhibitors through a combination of homology modeling, 
docking and kinetics.  Our results suggest that the inner loop 7 on CE plays a role in inhibitor 
selectivity, and interactions with this loop should be considered in the development of selective 
CE inhibitors. 
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Table 5-2: Loop 7 rsesidue variations between pnbCE, CES1, and CES2.  Loop 7 residues are 
numbers 104 to 116. 
 
5.3 RESULTS 
5.3.1 SCAFFOLDS GENERATED FROM LIGBUILDER 1.2v DE NOVO GENERATION 
PROGRAM 
  We used both our 2009 sulfonamide QSAR model (SM) [28] and our 2010 grand model 
(GM) [133] developed from multiple classes of CE inhibitors as hypothetical pocket sites, to test 
our hypothesis that the predicted water insolubility of the CE inhibitors could be overcome by 
using a dual method approach of QSAR coupled with in silico design.  The development and 
evaluation of these models can be found in chapters 3 (SM) and 4 (GM).   
 Scaffolds generated from the SM were compared to scaffolds generated from the GM, to 
test the hypothesis that the inclusion of multiple classes of CE inhibitors, in developing the 
QSAR model, aided in generation of more drugable features in silico.  Compound generation 
was restricted to Lipinski rules (MW < 500; LogP < 5, Number of hydrogen donors < 5, and 
number of hydrogen acceptors < 10), a parameter not used in our previous 2010 study, to aid in 
solubility enhancement.  A total of 3167 compounds were generated using LigBuilder 1.2v, 
consisting of 196 distinct scaffolds.  We used the following criteria to narrow down our dataset. 
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Compounds with a solubility of  > 50 mg/L, and having an activity (CES2 inhibitory potency) of 
less than -7.0 kcal/mol, were pooled into our hit database.  Fifty milligrams per liter was chosen 
as the solubility cutoff because it is an improvement relative to the sulfonamide scaffold 
solubility of 7 mg/L.  The activity score cutoff was chosen to generate compounds that also 
maintained CES2 potency.  Figure 5-1 shows examples of the types of scaffolds generated.  Of 
the 196 scaffolds outputted, scaffolds 112, and 126 were selected for further investigation.  
 
5.3.2 COMPARISON OF COMPOUNDS GENERATED WITH THE SULFONAMIDE 
MODEL VERSUS COMPOUNDS GENERATED WITH THE GRAND MODEL 
 The solubility of each compound was calculated first using the ALOGPS program.  We 
found that 136 compounds showed improved solubility compared to that of the sulfonamide 
inhibitors.  The GM generated 66 compounds encompassing 13 different scaffold classes.  The 
SM generated 70 compounds having 18 different scaffold classes.   
 The activity of each compound was predicted by using the initial QSAR “grand” model 
[133].  The grand model has a q2 of 0.835; thus this model has goodness of predictability.  Fifty-
nine compounds either maintained activity or showed improved activity compared to the 
previous generations of CE inhibitors (determined by ∆Gº score  < -7.00).  From the grand model 
we generated 29 compounds consisting of 7 scaffolds having improved solubility and potency.  
The sulfonamide model outputted 30 compounds having improved solubility and potency 
consisting of 13 scaffolds of molecules. 
 Our goal was to identify scaffolds, which could be substituted easily, that already had 
inherent solubility themselves.  We did not want to pursue compounds whose solubility was a 
property conferred to them by the addition of substituents.  Thus the solubility of the remaining  
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Figure 5-1: Examples of compounds generated from grand model using LigBuilder 1.2v 
program.  Corresponding solubility (given in mg/L) and ∆Gº score (given in kJ/mol) for each 
compound are listed below the structure. 
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20 scaffolds was assessed to identify soluble scaffolds (Table 5-2 and Figures 5-2 and 5-3).  Nine 
scaffolds produced had improved solubility (≥ 50 mg/L).  Eight of these scaffolds had 
solubilities greater than 150 mg/L. Of these nine the SM produced 2 scaffolds having decent 
solubility, while all seven of the remaining scaffolds generated from the GM had improved 
solubility Table 5-2.  Of the remaining 9 scaffolds, those having solubility < 490 mg/L and 
scaffolds not easily synthetically accessible were eliminated. This resulted in a final dataset of 
two scaffolds, 112 and 126, both generated from the GM.  The rest of this chapter will discuss 
these scaffolds. 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
Table 5-2: Comparison of Scaffolds Solubilities from SM and GM  
Table 5-2: Comparison of Scaffolds 
Solubilities from SM and GM 
Model 
Used 
Scaffold ID Predicted 
Solubility (mg/L) 
GM 101 910  
GM 102 1460 
GM 103 220 
GM 112 490 
GM 126 1720 
GM 106 190 
GM 107 62 
SM B –series 7.39 
SM C –series 7.87 
SM D –series 6.67 
SM E –series 200 
SM F –series 24.94 
SM G –series 7.35 
SM H –series 1.04 
SM I –series 150 
SM J –series 1.27 
SM K –series 0.83 
SM L –series 2.07 
SM M –series 1.22 
SM N –series 1.36 
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Figure 5-2 Scaffolds generated from the GM 
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Figure 5-3 Scaffolds generated form the SM 
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5.3.3 SCAFFOLD 126; 1-(BENZYLSULFINYL)-2-(FURAN-3-YL)ETHANOL 
 Scaffold 126 contains both a furan ring and a phenyl ring, which are connected by an 
ethane sulfinyl linker.  The ethane portion of the compound is located toward the furan ring and 
the sulfinyl moiety is benzylic to the phenyl ring.   Our QSAR model predicts that scaffold 126 
has an inhibition activity of 1131 nM.  The solubility for 126 is predicted to be 1720 mg/L 
respectively.  Fourteen analogs were generated having the 126 scaffold. We designed simple 
analogs of these compounds, A13, A14, A15, and A16. 
 We were unable to find a synthetic scheme for our 126 scaffold; however, we did find a 
synthesis for the 126 scaffold precursor ((ABUS) alpha/beta unsaturated sulfoxides) in the patent 
US 7,744,889 B2 (Scheme 5-1). Briefly, this synthesis is performed by first executing a 
Williamson ether synthesis to generate a thiolether, followed by a sulfoxidation reaction to form 
sulfinyl acetic acid on a benzylic chloride analogs.  Lastly, a Knoevenagel condensation reaction 
with aldehyde analogs will generate the alpha/beta unsaturated sulfoxide (126 precursor 
compound).  
 
 
 
 
Scheme 5-1. Synthetic scheme for alpha/beta unsaturated sulfoxide (126 precursor) scaffold 
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 Our goal was to use our models to identify scaffolds or point us to scaffolds that had 
drugable features. While the 126 scaffold was not easily accessible, the ABUS were.  Thus, we 
predicted the activities and solubilities of these scaffold precursors to test our models.  It can be 
seen that the scaffold precursor does not have as significant potency or solubility as the 126 
analog; however, there is still marked improvement by 2 orders of magnitude in the solubility of 
these compounds relative to the sulfonamides  (7 mg/L) and in some of the overall CES2 potency 
considering the broad range of average CES2 inhibitory potency (34 nM to 15665 nM).  
 
126 Scaffold Analog nM Solubility (mg/L) 
A13 1550 1720 
A14 2280 1700 
A15 1130 630 
A16 1340 830 
Corresponding Scaffold 
Precoursor   
ABUS-13 8730 940 
ABUS-14 5310 150 
ABUS-15 6350 160 
ABUS-16 10900 320 
 
Table 5-3: Predicted solubility and Ki of 126 analogs and ABUS analogs  
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5.3.4 SCAFFOLD 112 (BENZYLSULFINYL)BENZENE  
 Scaffold 112 is (benzylsulfinyl)benzene.  LigBuilder designed 114 analogs of scaffold 
112. Our previous attempt at producing compounds with enhanced water solubility generated 
several compounds that were synthetically unfeasible.  Thus, this attempt was performed in an 
effort to overcome this issue.  Scaffold 112 was found to be commercially available.  Analogs of 
the 112 scaffold have substituted phenyl and or benzyl rings.  The synthetic Scheme shown in 
scheme 5-2 can be used to develop 112 analogs.  The thiolether will be created in step one, using 
a Williamson ether type synthesis, followed by a sulfoxidation reaction, using MCPBA, to yield 
the final analog structure.  Benzenethiol, benzyl bromide and several analogs of these 
compounds can be purchased from Sigma Aldrich.   
  We could find no reported activity of this specific scaffold in carboxylesterases for 
inhibition, or details of them as substrates.  For CES, similar compounds have been reported to 
be substrates for a modified thermolysin, a bacterial zinc dependent protease, which performs 
hydrolysis reaction of peptide bonds with hydrophobic amino acids [134]. A sulfonamide 
scaffold (Figure 5-2) similar in structure to 112 was found to be an inhibitor for the matrix 
metalloproteinases, another member of the protease family [135].  Finally, this scaffold is similar 
to the benzil analogs (Figure 5-2), which are used as mammalian carboxylesterase inhibitors [84, 
86].    
 The 112 scaffold had a predicted inhibition of 40 µM, and a solubility of 490 mg/L. Dr. 
Potter’s lab his found this scaffold experimentally to have an activity of < 4% at 100 µM.  The 
112 scaffold analogs developed by LigBuilder possessed much stronger inhibition values, in the 
subnanomolar range.  
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Figure 5-4. Scaffolds similar to 112 that have biological activity against proteins in the 
alpha/beta hydrolase family  
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Scheme 5-2. Synthetic scheme for scaffold 112 
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5.3.5 DOCKING OF SULFONAMIDE CES2 INHIBITORS INTO PNBCE, PNBCE-CES1-
LOOP7-MUTANT AND PNBCE-CES2-LOOP7-MUTANTS RECEPTORS 
 To test our hypothesis that loop 7 contributes to CE inhibitor selectivity, we developed 
pnbCE mutant homology models, where the loop 7 of pnbCE was substituted with either the loop 
7 of CES1 or CES2.  The homology models were developed using the MODELLER program. 
Forty-two sulfonamides were docked into the homology models to determine whether the model 
could accurately predict their selectivity.  In our internal test set, thirty-seven sulfonamides were 
experimentally found to be selective CES2 inhibitors.  Five sulfonamides in the dataset were 
experimentally shown to have no selectivity between CES1 and CES2.  The average difference 
between receptors was 2.46 kJ/mol in favor of the CES2 mutant receptor (Table 5-4). 
 
 
 
 
Table 5-4: Average docking score of sulfonamide inhibitors  
 
5.4 DISCUSSION 
5.4.1 EFFECT OF INCLUDING SEVERAL INHIBITOR SCAFFOLDS INTO QSAR 
MODEL DEVELOPMENT 
 We originally hypothesized that including multiple CE inhibitor classes in the 
development of the QSAR model used for in silico design would significantly aid in generating 
scaffolds with more drugable features, namely enhanced solubility.  The SM produced more 
compounds than the GM. However, after filtering through the compounds produced, the GM 
Molecule 
 
CES1 
Average 
Dock Score 
CES2 
Average 
Dock Score Difference Preference 
Sulfonamides -46.55 -49.01 2.46 CES2 
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generated more soluble scaffolds.  In fact all the scaffolds generated from the GM had improved 
solubility.  Six of the seven scaffolds showed solubility improvement of two to three orders of 
magnitude compared to that of the sulfonamide scaffold (7 mg/L).  In contrast, 10 of the 13 
scaffolds outputted from the SM failed to have any solubility enhancement.  Six scaffolds 
actually showed decreased solubility compared to the sulfonamide scaffold. The GM was the 
only model that generated scaffolds having gram level solubility.  This result shows that a multi-
class QSAR model as a template for in silico generation can produce highly water-soluble 
scaffold leads.   
 A combination of factors allows our method to produce novel and soluble inhibitors. We 
use the program Quasar to develop our QSAR models.  Quasar has multiple dimensions most 
notably the 6th dimension, which factors in solubility. The GM, which was developed using four 
CE inhibitors classes, was able to capitalize on the best features of each class of inhibitors.  The 
sulfonamides, fluorobenzoins, and benzils have high potency toward CES2, enabling the model 
to produce compounds having comparable potency against CES2.  The isatins and 
fluorobenzoins, which in general are less specific for CES2, have high solubilities of 1000 mg/L 
and 9000 mg/L respectively.  Thus, including them in the model allowed us to draw from the 
solubility of these less specific CE inhibitors.  The SM generated scaffolds with solubility 
equivalent to that of the sulfonamides.  Since the sulfonamides were the only class included in 
developing this QSAR model the SM was unable to take advantage of the solubility properties of 
the other CE inhibitors.  Therefore, when generating compounds using the SM, we generated 
compounds that had features similar to the sulfonamides.   
 Our 112 scaffold was synthetically accessible and commercially available, illustrating 
this dual method approach’s ability to design compounds that are accessible.  We did find that 
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obtaining the original 126 scaffold was more difficult, as it could not be purchased; however, this 
scaffold did lead us to the alpha/beta unsaturated sulfoxide scaffold that had reasonable 
properties (decent potency, solubility, and selectivity) which can be optimized.  Therefore we 
believe that this process was a success overall. 
 The sulfonamide compounds were shown to favor the pnbCE-CES2-loop7 receptor, 
supporting the hypothesis that loop 7 plays a role in inhibitor selection.  By expanding this model 
further, to include other regions of importance, we may be able to use this as a predictive model 
to determine selectivity. 
 
5.5 CONCLUSION 
Including several classes of inhibitors is shown to significantly aid in developing 
scaffolds with enhanced water solubility.  While the model is capable of producing promising 
compounds that have the potency and solubility we desire, the inclusion of the less specific 
inhibitors could potentially mean that the scaffolds we generate are not specific for the isozyme 
we desire.  However we believe that the inhibitors will have CES2 inhibitory potency.  Thus an 
external model capable of predicting the selectivity of our compounds generated from this dual 
method would be ideal.   
 We have shown in this work that loop 7 is another important factor in determining 
inhibitor selectivity.  Our first generation model for selectivity determination of CE inhibitors 
can be used to help predict the selectivity of untested CE inhibitors compounds.  This model 
however could be improved by further expanding it to entail the other important regions 
necessary for inhibitor selectivity. 
 
	  86	  
5.6 EXPERIMENTAL 
5.6.1 MULTI-DIMENSIONAL QSAR MODELING OF THE SULFONAMIDE MODEL 
AND THE GRAND MODEL 
 The SM and the GM QSAR models were developed as previously described in Chapters 
3 and 4.  
 
 5.6.2 IN SILICO DESIGN OF NEW CARBOXYLESTERASE INHIBITORS USING 
LIGBUILDER 
 We used our QSAR model as a hypothetical pocket site for in silico generation of novel 
hiCE inhibitors using the GROW module in LigBuilder 1.2v[37].  The atomistic properties of the 
model were assigned pseudoatomic properties within LigBuilder based on the corresponding 
property. With this model as a hypothetical pocket site, potential inhibitors for hiCE were 
constructed from the seed structures 1,2-dione, p-aminoaniline, and benzene. For benzene, 
growth was allowed from all carbons in the ring. For p-aminoaniline, two seeds were used. The 
first allowed growth off only the amino group nitrogens, while the second allowed growth off 
both the amino groups and all unsubstituted ring carbons.  The 1,2-dione seed was allowed to 
grow off both terminal hydrogens. Seeds 1 through 3 were chosen because of their similarity to 
the core of the sulfonamide analogs.  Seed 4 was chosen because the dicarbonyl moiety was 
found to be important in inhibition of hiCE.  The GROW module of the LigBuilder program 
takes a seed structure, with designated growth points, and attaches new structural fragments onto 
those growth points. The growth is dictated by identifying fragments that will have the strongest 
interaction (binding affinity) possible to the receptor at the attachment site. In LigBuilder the 
binding affinity is calculated by SCORE an empirical scoring function. An example GROW 
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GROW command file is included in the Appendix.  As indicated before, Lipinski’s rules were 
accounted for in this process. Typically, two hundred new compounds are produced per seed, 
and then ranked.  Scaffolds were selected by defining the largest core structure within a family of 
analogs. 
 
5.6.3 PREDICTION OF INHIBITION SCORES USING GRAND MODEL, AND 
SOLUBILITIES USING ALOGPS 
     The previous QSAR model developed was used to predict the activities of the generated 
compounds.  The charges and solvation energies of the generated compounds were calculated 
using AMSOL 7.1 as previously described.  Minimizations and alignment of generated 
compounds was unnecessary since compounds were generated from pre-aligned seed structures, 
thus not performed.  To predict the aqueous solubility the 3D structures in the MOL2 files were 
converted into SMILES strings to be read into the online server at VCCLAB.  The aqueous 
solubility of all compounds was predicted using the online server ALOGPS program 
(http://www.vcclab.org) [44, 45]. 
 
5.6.4 CE INHIBITION ASSAY OF INHIBITOR CANDIDATES 
 CE inhibition assays were performed as previously done in [28]. 
 
5.6.5 ALIGNMENT OF ALPHA BETA HYDROLASES BY PROTEIN SEQUENCE 
 Using the DALI pairwise comparison program [136], hCE1 and hiCE were aligned to 
pnbCE to deteremine corresponding residues for loop 7. 
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5.6.6 HOMOLOGY MODELING OF PNBCE-CES1-LOOP7 AND PNBCE-CES2-LOOP7 
MUTANTS 
 Homology models of the pnbCE-CES1-loop7 mutant and the pnbCE-CES2-loop7 mutant 
were generated using MODELLER.  Protein fasta sequence were modified then imported into 
Chimera, after which a BLAST search was performed.  The pnbCE wild type structure was 
chosen as the template structure (pdb: 1QE3). MODELLER was the used to develop 5 homology 
models.  The model with the lowest ZDOPE score was chosen as the docking receptor.  
 
5.6.7 DOCKING ANALYSIS OF SULFONAMIDE INHIBITORS 
 Computational evaluation can delineate important interactions between the inhibitors and 
receptors, where mechanisms of inhibition and sites of interactions are unknown. Docking is a 
technique that has been performed for many biologically-important receptors [137], [54].    It is 
used here to predict the interactions between pnbCE-wild type, pnbCE-hiCE-loop7-mutants, 
pnbCE-hCE1-loop7-mutant, hCE1-wild-type and the ten most selective sulfonamide inhibitors, 
suggesting the inhibitor’s binding mode(s).  
     Using the Marvin Sketch program (Chem Axon), compounds were converted from 2D to 3D 
structures, after which an initial structural energy minimization was performed using the energy 
gradient optimization method.  Chimera (UCSF [138]) was then used to perform a full structural 
minimization (using steepest decent followed by conjugate gradient), to calculate total charges 
on the molecules, and to add all remaining hydrogens not explicitly defined in the 2D structure.  
DOCK 6.3 was then used for all docking analyses. The success rate, which the percentage of 
generated conformations that have a heavy atom RMSD equal to or less than 2 Å of the crystal 
structure pose, for DOCK (70%) is comparable to FlexX (61%), Glide (82%), and GOLD (77%) 
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[139, 140]. Default parameters were used throughout the flexible docking analysis, with the 
exception of number of orientations, which was varied through the course of several docking 
simulations (500 orientations evaluated).  The pnbCE-wild type, pnbCE-CES1-loop7-mutants, 
pnbCE-CES2-loop7-mutant, hCE1-wild-type receptors were used. The active site was identified 
by aligning each receptor to pnbCE receptor used or MD simulation that included the pNV 
molecule in the active site.  The protein chain from the MD simulation was then deleted leaving 
the pNV molecule in the active site of the docking receptor. We generated all molecular graphics 
images using the UCSF Chimera package. 
 
PUBLICATION NOTICE 
This work was submitted to Journal of Medicinal Chemistry in 2013 
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CHAPTER 6 INSIGHTS AND IDEAS GARNERED FROM 
MARINE METABOLITES FOR DEVELOPMENT OF 
ACETYLCHOLINESTERSE AND AMYLOID-β  
AGGREGATION INHIBITORS 
6.1 ABSTRACT 
Due to the diversity of biological activities that can be found in aquatic ecosystems, marine 
metabolites have been an active area of drug discovery for the last 30 years.  Marine metabolites 
have been found to inhibit a number of enzymes important in the treatment of human disease. 
Here, we focus on marine metabolites that inhibit the enzyme acetylcholinesterase, which is the 
cellular target for treatment of early-stage Alzheimer’s disease. Currently, development of 
anticholinesterase drugs with improved potency, and drugs that act as dual acetylcholinesterase 
and amyloid-β aggregation inhibitors, are being sought to treat Alzheimer’s disease.  Seven 
classes of marine metabolites are reported to possess anti-cholinesterase activity. We compared 
these metabolites to clinically-used acetylcholinesterase inhibitors having known mechanisms of 
inhibition. We performed a docking simulation and compared them to published experimental 
data for each metabolite to determine the most likely mechanism of inhibition for each class of 
marine inhibitor.  Our results indicate that several metabolites use mechanisms of inhibition not 
currently employed in the clinically-used drugs rivastigmine, galanthamine, donepezil, or tacrine.  
These new mechanisms may be useful in rational drug design of tighter binding 
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anticholinesterase drugs, or even development of inhibitors with both acetylcholinesterase and 
amyloid-β aggregation inhibition properties.                                       
 
6.2 INTRODUCTION 
6.2.1 INTRODUCTION TO ACETYLCHOLINESTERASE STRUCTURE AND 
FUNCTION 
     Acetylcholinesterase (AChE) is a member of the α/β hydrolase fold family of enzymes [94].  
This enzyme degrades the excitatory neurotransmitter acetylcholine (ACh) in the synaptic 
junction at an extraordinarily fast catalytic rate, with a 2nd order rate constant almost as fast as a 
diffusion-controlled reaction [141, 142]. ACh is degraded to choline and acetate through a 
hydrolysis mechanism, resulting in decreased signal transmission in nerve synapses.  
     In 1991, using X-ray crystallography, Sussman’s lab elucidated a 2.8 Å resolution structure of 
AChE, from the Torpedo californica electric ray [143]. Two sites participate in the hydrolysis 
reaction of ACh: an anionic site and an esteratic site.  The anionic site draws ACh into the active 
site, followed by hydrolysis in the esteratic site.  The catalytic triad (Ser-200, Glu-327 and, His-
440) resides at the bottom of a 20 Å gorge.  This long, narrow gorge contains 14 conserved 
aromatic residues (e.g., Tyr-70, Trp-84, Tyr-121, Trp-279, Phe-288, Phe-290, Phe-330, and Tyr-
334) leading to the active site [144]. Residues Phe-288 and Phe-290 and the catalytic triad create 
the esteratic site.  Residues Trp-84 and Phe-330 are located in the anionic site [144]. 
Approximately 14 Å away from the anionic site is another negatively charged site called the 
peripheral anionic binding site (PAS), composed of residues Tyr-70, Asp-72, Tyr-121, Trp-279, 
and Tyr-334.  Binding of substrates and inhibitors to the PAS causes a conformational change to 
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AChE, reducing ACh’s ability to enter the active site [144, 145]. A schematic of AChE is shown 
in Figure 6-1. 
     Acetylcholinesterase is the drug target for treating the neural degenerative disorder 
Alzheimer’s disease (AD). AD in elderly individuals is characterized by memory loss, difficulty 
in storing new information, and behavioral and cognitive difficulties [146, 147].  The progressive 
nature of AD can require a high level of care since patients lose the ability to perform simple 
daily functions.   
     There are two hypotheses to explain the pathology of AD.  One suggests that the decrease in 
ACh production within the synaptic junction contributes to the onset of AD (cholinergic 
hypothesis) [148-150]. The other suggests that the development of toxic amyloid-β peptide 
aggregates in the brain contributes to the progression of AD a (Amyloid hypothesis) [148, 151]. 
The cholinergic hypothesis suggests that inhibition of AChE can result in improved cognition by 
increasing ACh activity.  The amyloid hypothesis suggests that drugs that inhibit amyloid plaque 
formation will slow the progression of AD.  Inestrosa demonstrated that AChE promotes the 
formation of amyloid-β peptide aggregates, and that compounds that bind to the PAS of AChE 
can act as amyloid-β aggregation inhibitors [152]. Therefore, some AChE inhibitors (AChE-I) 
can effectively prevent both ACh hydrolysis and plaque aggregation in AD.  These dual-function 
inhibitors (DFI) have the potential to be more effective than single-function inhibitors. 
     Current clinical AD therapies use the anticholinesterase drugs rivastigmine, tacrine, 
galanthamine, and donepezil [150], [153]. (Figure 6-2)  Binding modes of these drugs are 
depicted in Figure 6-1. The inhibition of AChE increases the amount, and prolongs the duration, 
of ACh present in the synaptic junction. More ACh is then allowed to enter the nicotinic 
receptors due to increased ACh levels. The current chemotherapeutic options have low 
	  93	  
specificity toward AChE and are poorly tolerated in some patients [149]. Patients receiving 
donepezil show only moderate improvement of symptoms of AD [148, 153]. Thus development 
of higher affinity inhibitors may also help to alleviate the mental impairment associated with 
AD. Recently, inhibitors that inhibit both AChE and prevent amyloid-β aggregation have been 
suggested as a new therapeutic route [154, 155], although there are none currently in use. 
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Figure 6-1 Binding modes for tacrine, donepezil, galanthamine and rivastigmine AChE 
inhibitors.  
 Modes of binding to acetylcholinesterase of current anticholinesterase drugs.  A. 
Acetylcholinesterase structure, B. Tacrine, C. Donepezil, D, Galanthamine, E. Rivastigmine. 
Residues highlighted are known to interact with inhibitors. Residues with purple ribbon are 
catalytic triad (Ser-200, Glu-327, and His-440).  Cyan residues with labels represent residues 
having interactions to inhibitor.  We generated all molecular graphics images using the UCSF 
Chimera package (a resource for biocomputing, visualization, and informatics at the University 
of California, San Francisco; supported by NIH P41 RR001081). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	  96	  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6-2: Current clinically-used acetylcholinesterase inhibitors 
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6.2.2 MARINE METABOLITES AS ACETYLCHOLINESTERASE INHIBITORS   
     Presently, there are no marine natural products in clinical use as AChE-I.  Given the past 
success of drugs derived from marine organisms [156], exploring marine metabolites (MM) for 
novel lead anticholinesterase compounds may identify new compounds with novel interactions 
with AChE that garner selectivity and gain potency in treating AD. The purpose of this chapter, 
then, is the comparison of known marine-derived compounds having anticholinesterase activity 
to compounds whose mechanism of action are well understood to identify both similarities as 
well as novel properties of the marine compounds. 
     Marine metabolites vary greatly in structure, mass, and chemical composition [157]. Only 7 
different classes of MM are reported to have anticholinesterase activity: a sesquiterpene acetate 
[158, 159], (2) a pyrrole derivative [160, 161], (4) a tetrazacyclopentazulene [162],  (1) a 
bromotyrosine derivative [163, 164], (6, 7) plastoquinones [165], (3, 5) farnesylacetones [165, 
166], and poly-alkylpyridinium polymers (Poly-APS) [167-169]. Overall, these metabolites have 
been found to have moderate levels of anticholinesterase activity and generate inhibition through 
several different mechanisms. A review by Hostettmann was published in 2006 on all 
acetylcholinesterase inhibitors known up to that point, including those of marine origin [170]. 
Our paper includes new inhibitors discovered from marine species since 2006. Hostettmann’s 
review detailed the structural information but not the enzyme-inhibitor interactions. Our focus is 
illustrating the inhibitor interactions within the AChE receptor and comparing them to 
compounds with known inhibition mechanisms. We have incorporated both experimental studies 
from the literature and our molecular ensemble docking studies of MM into the AChE receptor 
to better understand the molecular interactions of each inhibitor class.  Four acetylcholinesterase 
structures (pdb codes 1ACL, 1DX6, 1EVE and 1ACJ) were used for all docking analysis. The 
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marine products aplysamine and Poly-APS were excluded from the docking analysis since 
aplysamine is an allosteric site inhibitor [163], and the Poly-APS are large molecular weight 
polymers; these compounds are not discussed in this paper.  All other compounds were docked in 
their neutral state.   
 
6.3 RESULTS AND DISCUSSION 
6.3.1 THE OPISTOBRANCH MOLLUSK AND ITS METABOLITE, ONCHIDAL: A 
SESQUITERPENE ACETATE  
     In 1978, the compound onchidal (Figure 6-3), a sesquiterpene acetate containing an α/β-
unsaturated aldehyde and an acetate ester, was isolated from the mucous secretion of the O. 
binneyi mollusk species by Ireland and Faulkner [158]. Onchidal was shown to interact with the 
acetylcholine recognition site, specifically the esteratic site, and found to have a Kd of 300 µM. 
 Docking of Onchidal into AChE 
     Onchidal was shown to interact with the esteratic site in our simulation, which is consistent 
with Abramson’s work [159]. Three poses were generated for onchidal Figure 6-4.  In all three 
poses the cyclohexane ring is positioned in the bottleneck.  In two of the three poses the acetate 
ester is in the oxyanion hole. The lowest energy pose (scores listed in Table 6-1) for onchidal 
(Figure 6-5a) was generated using the 1DX6 receptor and places the acetate ester in the oxyanion 
hole, the aldehyde in the acyl pocket and onchidal’s cyclohexane ring in the bottleneck created 
by Phe-330 and Tyr-121.  The major interactions were potential hydrogen bonding (H-bonding) 
interactions with Gly-118 and Gly-119 of the oxyanion hole, hydrophobic contacts with the 
bottleneck, and a H-bond with His-440 of the catalytic triad (Figure 6-5a).  It should be noted 
that potential H-bonds meet the distance requirements for H-bonds, but were not selected by the  
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Figure 6-3: Marine metabolites with anticholinesterase activity: 1. Onchidal,20,21 2. 
Marinoquinoline,22,23 3. Dihydromonooxofarnesylacetone,27,28 4. Pseudozoanthoxanthin-like 
compound,24 5. Monooxofarnesylacetone,27,28 6. Sargachromenol.27 7. Sargaquinoic acid,27  
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Figure 6-4:  Three docking pose generated for onchidal in various AChE receptors. 
A. Onchidal poses docked in 1ACL receptor. B. Onchidal pose docked in 1DX6 receptor C. 
Onchidal pose docked in 1EVE receptor. 
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Table 6-1.  Docking scores of current anticholinesterase drugs and marine metabolites into 
acetylcholinesterase receptors 
 
Receptor 
 1ACL  1ACJ  1DX6  
1DX6 
w/H20 1EVE 
Ligand all scores in kJ/mol 
  
Donepezil -59.79 -10.86 -53.65 -61.18 -56.74 
Tacrine -35.28 -33.83 -33.91 -34.09 -34.36 
Galanthamine -35.28 -35.77 -36.47 -38.76 -36.38 
Acetylcholine -31.78 -34.06 -31.99 -31.25 -31.61 
Onchidal -47.51 -44.28 -48.55 -47.37 -46.14 
Marinoquinoline -30.77 -34.27 -31.09 -30.50 -31.05 
Tetracyclopentazulene -42.341 -44.031 -41.772 -42.031 -42.512 
Sargaquinoic acid -67.92 ND -63.14 -69.81 -67.15 
Sargachromenol -62.98 -61.45 -62.82 -67.67 -65.16 
Monooxofarnesylactone -59.00 -55.34 -57.81 -50.22 -57.36 
Dihydromonooxofarnesylactone -56.00 -55.38 -55.94 -52.83 -55.51 
Docking galanthamine into its own receptor with and without this conserved water molecule both resulted in 
the crystallographic pose being selected.    
All inhibitors generated similar scores and poses in each receptor with the exception of donepezil in the 1ACJ 
receptor and onchidal. The best pose for onchidal was chosen. 
1,2 - Tetrazacyclopentazulene has two main poses (pose 1 scores are denoted by (1), pose 2 scores are denoted 
by (2). 
ND - Sargaquinoic acid would not dock into the 1ACJ receptor due to the Phe-330 ring position occluding the 
active site gorge (see supplementary Figure 4) 
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Figure 6-5. Binding modes and molecular interactions of onchidal, marinoquinoline and PZT 
compound metabolites to AChE 
 Docking poses of A. Onchidal, B. Marinoquinoline, and C. PZT compound in the 
acetylcholinesterase receptor. Left panel orientation: looking into the active site. Right panel 
orientation: 90º upward rotation from left panel. Purple, orange, and cyan residues are catalytic 
triad, oxyanion hole, and aromatic gorge residues respectively. Figures were generated using 
molecular graphics images using the UCSF Chimera package (a resource for biocomputing, 
visualization, and informatics at the University of California, San Francisco; supported by NIH 
P41 RR001081).  
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automated search criteria due to angle constraints. Due to the flexibility of the enzyme, the 
proposed H-bonds are plausible.   
     During catalysis by AChE, H-bonding to the backbone residues Gly-118, Gly-119, and Ala-
201 stabilizes the tetrahedral intermediate formed in the substrate. This suggests compounds 
capable of H-bonding with the oxyanion hole could inhibit AChE in a novel manner.  Some 
aldehyde protease inhibitors have been shown to interact with the oxyanion hole and provide 
strong inhibition [171, 172]. The H-bonding interaction with oxyanion hole residues in AChE is 
unique to marine metabolites. Interactions with the oxyanion hole and His-440 are not present 
when donepezil, galanthamine, tacrine and rivastigmine are bound to AChE.  The hydroxyl 
group of galanthamine does interact with a water molecule that is located in the oxyanion hole, 
but not the residues of the oxyanion hole itself [173].  When onchidal is docked in the 1DX6 
receptor with this conserved water molecule present, it resulted in onchidal performing a 
clockwise rotation, to prevent steric clashes with the water molecule Figure 6-6.  The ester group 
shifts backwards 2.96 Å away from the catalytic serine; the aldehyde group moves 6.34 Å 
downward.  This may be the initial binding mode onchidal undergoes, after which onchidal may 
rotate, displacing the water in oxyanion hole; then the catalytic reaction can occur.  
     Because onchidal is an irreversible inhibitor, a covalent bond should be formed between it 
and the AChE receptor. Several reaction mechanisms for onchidal inhibition were suggested by 
Abramson: (i) Schiff base formation with a lysine; (ii) attack on the β-unsaturated carbon in 
conjugation with the aldehydes by a Cys, Lys, His, or Tyr; and (iii) the formation of 1,4-
dialdehyde, which reacts with a Lys to form a pyrrole covalent adduct. Abramson did not have 
the benefit of the crystal structure of AChE solved by Sussman in 1991, limiting their 
mechanistic analysis. All lysines in AChE are located on the outside and not buried inside.  
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Figure 6-6.  Docking pose of onchidal with water molecule present in 1DX6 receptor 
A. Overlay of onchidal poses docked with (blue) and without (green) oxyanion hole water 
molecule. B. Onchidal pose without oxyanion water C. Onchidal with oxyanion water. 
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There are 7 Cys in AChE, six of which are paired and involved in intrachain di-sulfide bonds, 
and the last is not near the active site or in the gorge. Only one His, the active site His-440, is 
located in the gorge. Several tyrosines are located in the gorge; Tyr 442, 334, 130, 121, and 70. 
Based on the crystal structure and Abramsons’ findings, the most probable mechanism is attack 
on the β-unsaturated carbon in conjugation with the aldehyde by a Tyr; however, attack on this 
particular moiety or by a Tyr was not supported by our docking analysis. It is also plausible that 
a direct acylation reaction between Ser-200 and the vinyl ester of onchidal could occur, after 
which a Lys or Arg residue could react with the aldehyde product.  There are however no Lys or 
Arg residues that are present in the active site. 
Here, we consider other possible chemical mechanisms of irreversible inhibition based on 
our docking analysis. Ser-200 is closest to the α-unsaturated carbon in conjugation with the 
acetate (3.538 Å).  The carbonyl carbon on the aldehyde is 3.736 Å away, and the β-unsaturated 
carbon in conjugation with the aldehyde is 4.989 Å away from the Ser-200. Nucleophilic attack 
on the α-unsaturated carbon in conjugation with the acetate could result in the formation of a 
covalent adduct and acetate production (Scheme 6-1A). This mechanism would be achieved by 
(i) nucleophilic attack on the α-unsaturated carbon in conjugation with the acetate, followed by 
(ii) reformation of the double bond releasing acetate (pathway A).  We also considered the 
pathways B and C shown in Scheme 1B and 1C respectively. In pathway B, Ser-200 would 
attack the β-unsaturated carbon in conjugation with the aldehyde, pushing the electrons onto the 
aldehyde oxygen.  The electronegative oxygen would then attack the α-unsaturated carbon in 
conjugation with the acetate, forming a five-member ring.  Finally, reformation of the double 
bond would release acetate and then form an aromatic furan ring structure.  In pathway C, Ser-
200 attacks the aldehyde carbon, pushing the electrons onto the aldehyde oxygen.  
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Scheme 6-1. Potential pathways for irreversible inhibition by onchidal. Pathway A is the 
suggested pathway for irreversible inhibition of AChE. 
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Like pathway B, the electronegative oxygen would then attack the α-unsaturated carbon in 
conjugation with the acetate, forming a five-member ring.  Reformation of the olefin would 
release acetate and generate a 2,3-dihydrofuran ring (2-oxolene ring).  Pathways B and C employ 
a disfavored 5-endo-trig pathway, suggesting that they are less probable than pathway A.  It 
should be noted that a disfavored pathway is only disfavored, not impossible [174]. Both the 
distance and feasibility of pathway A suggest it is most likely the pathway that generates 
irreversible inhibition of AChE. 
     Onchidal’s irreversible inhibition of AChE makes it unsuitable for direct use as an 
anticholinesterase inhibitor for human diseases, but it could have potential for use in insecticides 
or pesticides.   However, onchidal’s interaction with the oxyanion hole is a new mechanistic area 
that  AChE-I’s rivastigmine, tacrine, galanthamine, and donepezil do not use.  Onchidal’s 
structure could therefore be used for rational drug design in developing novel inhibitors for use 
in clinical treatment.   
 
6.3.2 THE GLIDING BACTERIA RAPIDITHRIX THAILANDICA AND ITS PYRROLE 
METABOLITES 
     Rapidithrix thailandica is a gliding bacterium that was discovered in seaweed extracted from 
the Andaman Sea off the coast of Thailand by Srisukchayakul [175, 176].  Kanjana-opas and co-
workers isolated pyrrole derivatives marinoquinoline (Figure 6-3), 3-(2-aminophenyl)-pyrrole, 
and 2,2-dimethyl pyrrolo-1,2-dihydroquinoline from R. thailandica in 2006 [160]. 
Marinoquinoline, which has an extended aromatic system, inhibited AChE with an IC50 value of 
4.9 µM. The other isolated metabolites did not possess anticholinesterase activity. The inactive 
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pyrrole derivatives isolated lacked an extensive aromatic ring system.  This structural difference 
suggested that inhibition produced by marinoquinoline was due to π-π stacking interactions.   
Docking of Marinoquinoline to AChE  
     No prior work has elucidated which are the specific residue or residues in the aromatic gorge 
marinoquinoline is potentially stacking against.  We hypothesized that marinoquinoline interacts 
with AChE by participating in π-π stacking with Trp-84, similar to tacrine’s mode of binding 
[144].  We observed marinoquinoline docked against the Trp-84 (Figure 6-5b) in all structures of 
AChE and having a binding score of -31.09 kJ/mol (1EVE receptor), supporting this hypothesis 
of π-π stacking to an aromatic residue.  In the 1ACJ structure that was crystallized with tacrine 
as a ligand, Phe-330 is oriented approximately 90º upward compared to its position in the 1ACL, 
1DX6 and 1EVE structures (Figure 6-7). Upon binding of tacrine, Phe-330 forms a π-stacking 
interaction with the inhibitor.  It is likely that marinoquinoline would cause Phe-330 to move into 
a similar position to that observed for tacrine. The rotation of Phe-330 would decrease the 5 Å 
bottleneck in the gorge, making it more difficult for acetylcholine to reach the active site. 
Docking marinoquinoline into the 1ACJ structure generated an improved score of -34.27 kJ/mol. 
Our data suggest that binding of marinoquinoline to AChE results in the compound inhibiting the 
enzyme in an manner analogous to tacrine (Figure 6-8a).        
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Figure 6-7 Alignment of 1ACJ, 1ACL, 1DX6 and 1EVE receptors 
Alignment of tacrine receptor (1ACJ) places the F330 and W279 in a different conformational 
location than the galanthamine (1DX6) or donepezil (1EVE) or 1ACL receptors. Residues 
labeled in purple, orange, and cyan represent the catalytic triad, oxyanion hole, and aromatic 
residues of the gorge. 
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Figure 6-8: Molecular interactions of marinoquinoline and PZT-compound with AChE 
Expanded views of molecular interactions for A. Marinoquinoline, B. PZT compound, in the 
acetylcholinesterase receptor.  
 
 
 
6.3.3 THE PARAZOANTHUS AXINELLAE (O. SCHMIDT), ZOANTHID CORALS, AND 
TETRAZACYCLOPENTAZULENE NATURAL PRODUCTS. 
     The pigmentation of Zoanthid corals is vast, and produced by tetrazacyclopentazulene 
compounds (TCP; Figure 6-3).  One yellow TCP, called a pseudozoanthoxanthin-like compound 
(PZT compound), was isolated by Turk and co-workers in 1994 [162]. Like onchidal, this 
compound was shown to be a competitive acetylcholinesterase inhibitor (Ki of 4 µM).  Unlike 
onchidal, which interacts with the esteratic site of acetylcholinesterase, the PZT compound was 
found to interact with the aromatic residues lining the active site gorge as determined by 
fluorescence emission spectroscopy.  Turk and co-workers found that the signal from the 
intrinsic tryptophan located in the gorge of acetylcholinesterase was quenched in the presence of 
the inhibitor. These results suggested that an interaction between a Trp residue and the inhibitor 
was the mechanism of inhibition.  
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Binding of a Tetrazacyclopentazulene (PZT) compound to AChE  
      Using the 1EVE receptor, the pose for the PZT compound scored at -42.51 kJ/mol and 
showed a T-stacking interaction with Trp-84, and three H-bonding interactions.  H-bonding 
interactions occur between the triad residues Ser-200 and His-440, and the oxyanion hole residue 
Gly-118 (Figure 6-9).  The docking of the PZT compound into the 1ACL receptor resulted in a 
score of -42.34 kJ/mol, which positioned the PZT compound stacked against Trp-84 (Figure 6-
5c).  Both poses are in agreement with published experimental data that suggest interaction with 
a Trp residue. While the authors Turk and coworkers could not determine which Trp residue was 
interacting with PZT compound, our docking analysis suggest that it interacts with Trp-84 in 
some way.  There are several conserved Trp residues in the gorge, Trp-84, Trp-233, and Trp-279.  
Trp-279 is located at the entrance, Trp-233 is in the acyl pocket and Trp-84 is in the anionic 
binding site. Because the PZT compound is a competitive inhibitor, the Trp-279 is unlikely to be 
a binding partner.  Our docking analysis does not support an interaction between Trp-233 and the 
PZT compound.    
A PZT-compound-Trp-84 interaction could share the same binding mode as tacrine [144] 
and marinoquinoline. Based on the conformational changes that occur when tacrine binds AChE, 
when PZT compound binds the receptor Phe-330 would rotate to a position to allow for the 
double π-π stacking interactions (Figure 6-8b).  Like marinoquinoline, the binding score 
improved when docked into the 1ACJ receptor (-44.04 kJ/mol). Thus we believe, upon binding, 
PZT most likely forms π-π interactions with both Trp-84 and Phe-330, which in turn closes off 
the bottleneck, disallowing ACh to enter the acyl pocket.  
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Figure 6-9. Poses generated for PZT-compound.   Poses generated from docking PZT-compound 
in the AChE.  A. shows the lowest binding energy pose, B. shows pose consistent with 
experimental data 
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 Both marinoquinoline and PZT-compound share the same binding mode as tacrine; 
however the PZT-compound binds tightest to AChE.  Tacrine’s best docking score was -35.28 
kJ/mol, which is 9 kJ weaker then PZT-compound’s binding score.  A paper by Muñoz-Ruiz 
[155] used the indole ring of donepezil and the fused ring of tacrine to develop potent dual site 
inhibitors, with the tacrine moiety bound to the anionic site.  Replacement of tacrine by the PZT-
compound has the potential to increase the potency of these DFIs even more.  
 
6.3.4 THE BROWN ALGA SARGASSUM SAGAMIANUM AND THE 
PLASTOQUINONES AND FARNESYLACETONES METABOLITES. 
     Ryu [29] in 2003 and Choi [28] and co-workers in 2007 reported the isolation of a series of 
terpenoid compounds (Figure 6-3) from the brown alga Sargussum sagamianum. Four 
compounds were isolated from the alga: (7) sargaquinoic acid (IC50 23.2 µM), (6) 
sargachromenol (IC50 32.7 µM), (5) monooxofarnesylacetone (IC50 65.0 µM) and (3) 
dihydromonooxofarnesylacetone (IC50 48.0 µM).  All four compounds have moderate levels of 
bovine erythrocyte AChE inhibition, with a specificity for butyrylcholinesterase.   
     Based solely on structural comparisons, we hypothesized these compounds likely inhibit 
AChE in two ways: stacking interactions with aromatic residues, and interactions with the 
esteratic site. No experimental work has been done to probe the mechanism of inhibition of the 
plastoquinones or farnesylacetones thus far.  
Docking of the Plastoquinones and Farnesylacetones into AChE  
     Docking of the two plastoquinones resulted in similar binding modes (Figure 6-10).  Three 
stacking interactions were observed in sargaquinoic acid (7): (i) the quinone moiety of 
sargaquinoic acid positioned next to Trp-84; (ii) the 6-7 olefin stacked with Phe-330; and (iii) the 
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10-11 olefin stacked against Tyr-334. Sargaquinoic acid’s binding score was the best of all 
metabolites considered, being -67.92 kJ/mol in the 1ACL receptor.  Sargachromenol has one less 
stacking interaction than does sargaquinoic acid. We observed the reduced quinone moiety of 
sargachromenol stacking against Trp-84 and the 3-4 double bond of sargachromenol stacked 
against Phe-330 (Figure 6-10).  However, sargachromenol’s α/β unsaturated carboxylic acid 
substituent also H-bonds with the backbone of residue Phe-288 located in the esteratic site. 
Sargachromenol binds slightly weaker to the receptor than sargaquinoic acid, with its best 
binding score being -65.16 kJ/mol in the 1EVE receptor. 
     The farnesylacetones, unlike the plastoquinones, do not share a similar binding mode. 
Dihydromonooxofarnesylacetone (3), which participates in two H-bonding interactions, has a 
binding score of -56.00 kJ/mol in the 1ACL receptor.  At the top of the gorge, in the PAS, its α/β 
unsaturated π bond H-bonds to Tyr-121, at the base of the gorge in the esteratic site (Figure 6-
10).  This compound is unique for this family in that its major source of interaction with the 
receptor is through H-bonding compared to stacking interactions. Monooxofarnesylacetone (5) 
also has a H-bond to AChE, albeit to His-440 instead of Gly-119 or Tyr-121.  Like sargaquinoic 
acid, monooxofarnesylacetone π-stacks against Trp-84, Phe-330 and Tyr-334 (Figure 6-10).  The 
binding score for monooxofarnesylacetone is almost 9 kJs weaker than sargaquinoic acid at 
-59.00 kJ/mol in the 1ACL receptor.  
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Figure 6-10. Binding modes and molecular interactions of farnesylacetones and plastoquinones 
metabolites to AChE.  
     Docking poses of A. monooxofarnesylacetone B. dihydromonooxofarnesylacetone C. 
sargaquinoic acid and D. sargachromenol in the acetylcholinesterase receptor. Left panel 
orientation: looking into the active site. Right panel orientation: 90º upward rotation from left 
panel. Purple, orange, and cyan residues are catalytic triad, oxyanion hole, and aromatic gorge 
residues respectively. 
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Both the plastoquinones and farnesylacetones are competitive inhibitors of AChE, which occlude 
the active site gorge in a manner similar to donepezil. They all protrude somewhat out of the 
gorge, suggesting that they prevent acetylcholine from entering the AChE binding site. 
Donepezil stacks against Phe-330 and Trp-84 and interacts with the Trp-279 located in the PAS. 
The plastoquinones and monooxofarnesylacetone, like donepezil, primarily use stacking 
interactions to stabilize the receptor ligand complex, stacking against Trp-84, Tyr-334, and Phe-
330 within the gorge. The isoprene units of the farnesylacetones and the plastoquinones have the 
right number of linker carbons and degree of flexibility to allow participation in multiple 
aromatic interactions simultaneously.  In general, the plastoquinones and farnesylacetones bind 
to the side opposite the PAS at the entrance of the gorge, with the exception of 
dihydromonooxofarnesylacetone that H-bonds to Tyr-121 of the PAS.  
     In the development of dual binding site inhibitors that bind to the anionic site and to the 
peripheral anionic site, a linker is needed which can span the length of the gorge.  Linkers that 
bind strongly to the gorge would greatly increase the potency of these dual site inhibitors. Many 
linkers used thus far have contained amides [155, 177], aliphatic chains [154, 155], pyrimidine 
rings [178], piperidine rings [154, 177], and other cyclic aromatic structures [154, 177]. In our 
docking studies, the plastoquinones bind tighter to AChE than donepezil (best score -59.79 
kJ/mol), with farnesylacetones coming in close behind donepezil.  The terpene type linker seems 
to bind well in the gorge, capitalizing on multiple stacking interactions.  Thus, it may be a useful 
new linker to consider in creation of dual site inhibitors.  Dihydromonooxofarnesylacetone has 
two ketone residues, one that binds the oxyanion hole and one that binds to the PAS residue Tyr-
121, and therefore suggests a new di-ketone scaffold for amyloid-β aggregation inhibitors.   
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6.3.5 DESIGN OF NEW DUAL ACHE AND AMYLOID BETA AGGREGATION 
INHIBITORS 
 Using the docking scores and poses of marine metabolites investigated, we designed 12 
new AChE inhibitor candidates (Figure 6-11).  We hypothesized that we could both generate 
new compounds using the MM as scaffolds that would have better binding scores and that we 
would be able to predict the pose of these compounds based on the docking data of the MM 
precursors used.  These compounds were then docked into the 1EVE and 1DX6 receptors. Table 
2 shows the docking scores of the designed inhibitor candidates.  Eleven of the twelve 
compounds show improved docking scores compared to donepezil.  Only one compound, MM-
P07 (best dock score -58.26 kJ), showed less favorable binding to the AChE receptor than 
donepezil.  The best compound, MM-P12, had a PZT base, a terpene linker, and the indoline ring 
of donepezil at the top.   
      While using the marine metabolites as starting point to develop new AChE inhibitor 
scaffolds with improved docking scores was successful, it was difficult to accurately predict the 
interactions they would be calucated to have with the receptor. We found that several new 
interactions were employed in our new compounds.  For example, Tyr-130 was not found to 
have any major interactions with the marine metabolites themselves; however, we observed 4 
compounds having H-bonding interactions with Tyr-130.  The best inhibitor candidate, MM-P12 
(shown in Figure 6-11; docking score of -73.43 kJs), has an amino group, from the PZT 
compound scaffold, that hydrogen bonds with Tyr-130.  Compounds MM-P04 (quinone moiety 
from sargaquinoic acid), MM-P05 (quinone moiety from sargachromenol), and MM-P08 also 
were found to H-bond to with Tyr-130.  We will not discus the poses of each new inhibitor in 
detail but will highlight some important features contributing the increased potency of these 
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compounds. We also observed that the orientation of compounds could be exactly opposite what 
we hypothesized. For example, the PZT-compound and marinoquinoline were used in our 
scaffolds in an effort to drive what we considered the base of the compound to the anionic site 
through a stacking interaction with Trp-84 that was observed with each of the precursors.  
However, the addition of the PZT compound to the terpenoid scaffold produced poses where this 
moiety was at both the base, stacking against Trp-84, as expected, and the periphery of the gorge, 
participating in stacking reactions with Trp-279 in the PAS, and with Tyr-334.  The latter 
orientation also allows the carbonyl group of the MM-P01 compound, closest to the PZT ring 
system, to H-bond with Tyr-121.  This produces a slightly more favorable dock score for this 
pose compared to the former pose (-72.93 kJ, versus -71.97 kJ).  Both poses, however, show 
improved binding to the AChE receptor compared to the MM precursors.  This inversion of 
orientation was observed for compounds MM-P08, MM-P07, and MM-P10 (1DX6 receptor 
only).  While some new interactions were shown to occur we were able to develop compounds 
which posed exactly or fairly close to how we expected, such as the compounds MM-P04, MM-
P05, MM-P10), MM-P14, MM-P12, MM-P13, MM-P06, MM-P02, and MM-P01.   
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Figure 6-11: Proposed Dual Function Inhibitors developed using MM Scaffolds: The top 
portion shows the 12 scaffolds, which were successfully docked into the AChE receptor.  Each 
compound was made using portions of MM that had some specific interaction within the AChE 
receptor.  The indoline and piperidino moieties used in some of the compounds are from 
donepezil.  The names for each MM structure can be found in Figure 2. 
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Dual function inhibitors must interact with the PAS of AChE.  Of the 12 compounds we 
designed, eight have the capability of interaction with the PAS in some fashion (MM-P01, MM-
P04, MM-P05, MM-P06, MM-P07, MM-P08, MM-P09, and MM-P10 Table 6-2).  Four of these 
compounds stack with Trp-279 (MM-P06, MM-P07, MM-P09, and MM-P10).  MM-P04 and 
MM-P05 H-bond with Tyr-121. Two compounds interact with both residues (MM-P01, and 
MM-P08). 
 
 
 
 
 
 
 
 
 
 
 
Table 6-2.  Docking scores of proposed dual function inhibitors into acetylcholinesterase 
receptor 
 
 
 
 
Compound Best Score 
(kJ/mol) 
Receptor Interacts 
with PAS 
MM Scaffolds 
used to create 
Compound 
MM-P01 -72.93 1EVE Yes 3, 4, 5 
MM-P02 -63.02 1EVE No 2, 3, 5 
MM-P04 -62.62 1EVE Yes 3, 5, 7 
MM-P05 -71.95 1EVE Yes 3, 5, 6 
MM-P06 -62.00 1DX6 Yes 2, and donepezil 
MM-P07 -58.26 1DX6 Yes 4 and donepezil 
MM-P08 -65.76 1EVE 
Yes 2, 5, and 
donepezil 
MM-P09 -72.19 1EVE 
Yes 4, 5, and 
donepezil 
MM-P10 -64.77 1DX6 Yes 4 and donepezil 
MM-P12 -73.43 1EVE 
No 4, 5, and 
donepezil 
MM-P13 -68.90 1DX6 No 3, 4, 5 
MM-P14 -60.78 1EVE No 2, 3, 5 
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6.4 SUMMARY 
      Exploring marine metabolites (MM) as an option for lead compounds may identify new 
useful interactions and scaffolds that increase potency and garner selectivity.  From these 
compounds, we can identify new target sites within acetylcholinesterase for development of 
AChE-I.  Future generations of AD drugs could utilize H-bonding to the oxyanion hole residues, 
stacking interactions with Tyr-334, and H-bonding to Tyr-121 in the PAS to inhibit AChE.  
Development of novel acetylcholinesterase inhibitors that have characteristics of MM, such as an 
increased number of protonatable nitrogen atoms that stack against Trp-84, and creation of 
terpene linkers for dual site inhibitors, may help to develop compounds with greater potencies 
from optimization of stacking interactions in the gorge. Several of these properties exhibited by 
the MM can also be included in the design of DFI that prevent both ACh degradation and 
amyloid-β aggregation.  Overall these MM bind tighter to AChE than galanthamine, or tacrine, 
and several metabolites bind tighter than donepezil.  Selectively crossing scaffold features of the 
MM successfully produced compounds with even better AChE binding than the precursor 
scaffolds used, yet the overall pose was difficult to predict. Many compounds generated 
interacted with the PAS site, the critical interaction contributing to inhibition of amyloid-β-
aggregation.  Determination of isozyme specificity, and effects on amyloid-β aggregation for the 
sesquiterpene acetate [158, 159], pyrrole derivative, PZT-compound, plastoquinones, and 
farnesylacetones classes of MM described in this article, would provide an additional guide to 
development of novel compounds as therapies for Alzheimer’s disease.   
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6.5 MATERIALS AND METHODS 
     Computational evaluation can delineate important interactions between the inhibitors and 
receptors, where mechanisms of inhibition and sites of interactions are unknown. Docking is a 
technique that has been performed for many biologically-important receptors [137], [54].    It is 
used here to predict the interactions between AChE and an inhibitor, suggesting the inhibitor’s 
binding mode(s).  
     Using the Marvin Sketch program (Chem Axon), compounds were converted from 2D to 3D 
structures, after which an initial structural energy minimization was performed using the energy 
gradient optimization method.  Chimera (UCSF [138]) was then used to perform a full structural 
minimization (using steepest decent followed by conjugate gradient), to calculate total charges 
on the molecules, and to add all remaining hydrogens not explicitly defined in the 2D structure.  
DOCK 6.3 was then used for all docking analyses. The success rate, the percentage of generated 
conformations that have a heavy atom RMSD equal to or less than 2 Å of the crystal structure 
pose, for DOCK (70%) is comparable to FlexX (61%), Glide (82%), and GOLD (77%) [139, 
140]. Default parameters were used throughout the flexible docking analysis, with the exception 
of number of orientations, which was varied through the course of several docking simulations 
(1000 to 30,000 orientations evaluated). When the docking simulation did not locate a minimum 
for a particular compound (incomplete docking) the orientation number was increased for the 
dataset.  Four acetylcholinesterase structures (pdb codes 1ACL, 1DX6, 1EVE and 1ACJ) were 
used for all docking analysis. The active site was identified using the ligands galanthamine, 
donepezil and tacrine located in the crystal structures of 1DX6, 1EVE and 1ACJ, respectively. 
For the 1ACL, to define the active site with a clinically-used inhibitor the decamethonium ion 
was deleted, donepezil was placed in the active site by aligning the 1EVE receptor to 1ACL then 
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deleting the 1EVE receptor.  A 12 Å receptor box was used for docking inhibitors into the 
enzyme crystal structures. We generated all molecular graphics images using the UCSF Chimera 
package.   
     The marine products aplysamine and Poly-APS were excluded from the docking analysis 
since aplysamine is an allosteric site inhibitor [163], and the Poly-APS are large molecular 
weight polymers; these compounds are not discussed in this paper.  All other compounds were 
docked in their neutral state.  The inhibitor from the crystal structure of each AChE was also 
docked into all AChE structures, including its own, to verify that the docking algorithm could 
correctly identify known crystal structure poses.  Galanthamine has a conserved water molecule, 
to which the hydroxyl group H-bonds.  Docking galanthamine into its own receptor with and 
without this conserved water molecule both resulted in the crystallographic pose being selected.   
All inhibitors generated similar scores in each receptor with the exception of donepezil in the 
1ACJ receptor (Table 6-1).  The drastic difference between donepezil in the tacrine receptor 
makes sense, since the Phe-330 residue is in an orientation that cannot interact with the 
piperidine moiety, a critical interaction for this inhibitor. Our docking results are consistent with 
the observed experimental data for onchidal, marinoquinoline, and tetrazacyclozulapentene 
compound interactions with AChE.  Our data also suggest new target regions within the AChE 
receptor, potential structural scaffolds for novel AChE inhibitors, and reasonable binding modes 
for the plastoquinones and farnesylacetones.  The binding scores from the docking analysis could 
not accurately be compared to the literature inhibition values determined experimentally since 
several reported values are given as IC50, a unit that is concentration dependent, and 
concentrations of enzymes used for performing the assay were not always reported in the 
literature.  The docking scores themselves are internally consistent.   
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CHAPTER 7 SUMMARY OF RESEARCH IMPLICATIONS AND 
FUTURE RESEARCH 
 
This goal of this work was to define contributions that contribute to the potency, 
solubility, and selectivity of CE inhibitors.  This would help us to be able to design novel CES2 
specific inhibitors.  This work addressed three major questions to help us better design novel 
CES2 inhibitors.  First, how do make potent CES inhibitors?  Second, how do we design soluble 
CES2 inhibitors?  Last, how do we develop selective CES2 inhibitors? 
In chapter 3 we used an expanded set of sulfonamide inhibitors to develop a new QSAR 
model.  This was performed to further delineate the structural features that made this class of CE 
inhibitors potent.  Our new QSAR model expanded our knowledge on why the sulfonamide 
inhibitors were potent.  It showed that (i. Increasing hydrophobicity of the core sulfonamide 
scaffold, (ii.) halogen substitution at the distal benzyl rings improved potency (iii.) placement of 
those halogens in the meta or para position, (iv.) removal of moderately EWG from the para 
position, and (v.) removal of bulky groups from the core benzene ring would all improve the 
potency of the sulfonamide scaffold.  This information helped us to address the question, “how 
do we make CES2 inhibitor potent?”   
In chapter 4 and 5 a multi-scaffold QSAR model was developed and used as a 
hypothetical pocket site for in silico design to generate soluble new soluble CE inihibtors.  These 
chapters showed us that we could use a dual method approach of generating a QSAR model 
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followed by in silico design to generate novel scaffolds that had improved solubility relative to 
the sulfonamide scaffold.  The biggest aid in generating soluble scaffolds however was the use of 
the four disparate classes of CES2 inhibitor compounds, thus, answering the question of how to 
design soluble CES2 inhibitors.  It was the inclusion of four CE inhibitor classes that allowed us 
to create compounds with the best features of each class.  The novelty of this approach is that it 
was performed for an enzyme target that has no experimentally derived 3D structure.  A process 
like this could be applied to many targets were no structural information of the target 
macromolecule is known.  This would play a significant role in the drug discovery industry.   
In chapter 5, we also developed a docking model that helped us to determine some 
features that confere specificity on the sulfonamide compounds.  Our models showed that 
interactions with the internal loop 7 were important in determining inhibitor selectivity between 
CES1 and CES2.  With further development this model could be used as a predictive model to 
filter out nonspecific inhibitors. 
  Chapter 6 investigated another alpha/beta hydrolase protein acetycholinesterase.  We 
predicted through a docking analysis that the marine metabolite onchidal interacts with the 
oxyaninon hole of Loop 7 in AChE.  We suggested through docking the binding mode of 7 
competive acetylcholinesterase inhibitors derived from marine natural products.  
Using the three models we have developed, we can develop compounds, which will be 
potent, soluble, and selective against CES2.  A system like this is not limited to just alpha/beta 
hydrolases, but could be applied to many protein systems. Fuuture studies should synthesize a 
large pool of the generated compounds and assay them against the CEs and cholinesterases 
enzymes to deteremine their potency, solubility, and specificity. 
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A.1.1 MASTERSCRIPT FOR PREDICTION 
 
# This program prepares files to be read into the Quasar Program 
# Shana Stoddard 
#!/bin/sh 
 
#input file will be the mol2 files from ligbuilder  
#the output files will be the corresponding pdb files 
 
echo "mol2 files are being converted to pdb files" 
cd /Users/shana/Desktop/Tanshionones/ligbuilder/OD_GM_seed-v3mTan.results.mdb  
sudo cp /Users/My_Research/QSAR/Prediction-scripts-1/babel-mol2-pdb 
/Users/shana/Desktop/Tanshionones/ligbuilder/OD_GM_seed-v3mTan.results.mdb  
chmod ugo+x babel-mol2-pdb 
./babel-mol2-pdb 
 
echo "mol2 files are being converted to canonical files" 
 
cp /Users/My_Research/QSAR/Prediction-scripts-1/babel-mol2-pdb 
/Users/shana/Desktop/Tanshionones/ligbuilder/OD_GM_seed-v3mTan.results.mdb  
chmod ugo+x babel-mol2-smi 
./babel-mol2-smi 
 
# 
echo "mol2 files are being converted to mopint files" 
cp /Users/My_Research/QSAR/Prediction-scripts-1/babel-mol2-mopint 
/Users/shana/Desktop/Tanshionones/ligbuilder/OD_GM_seed-v3mTan.results.mdb  
chmod ugo+x babel-mol2-mopint 
./babel-mol2-mopint 
 
#echo "Keywords are being written in mopint files" 
 
cp /Users/My_Research/QSAR/Prediction-scripts-1/Keywords-start 
/Users/shana/Desktop/Tanshionones/ligbuilder/OD_GM_seed-v3mTan.results.mdb  
cp /Users/My_Research/QSAR/Prediction-scripts-1/Keywords-write.py 
/Users/shana/Desktop/Tanshionones/ligbuilder/OD_GM_seed-v3mTan.results.mdb  
chmod ugo+x Keywords-start 
chmod ugo+x Keywords-write.py 
./Keywords-start 
 
echo "AMSOL run file is being written" 
 
cp /Users/My_Research/QSAR/Prediction-scripts-1/AMSOL-Print-part1-start 
/Users/shana/Desktop/Tanshionones/ligbuilder/OD_GM_seed-v3mTan.results.mdb  
cp /Users/My_Research/QSAR/Prediction-scripts-1/Print.part1.AMSOL.py 
/Users/shana/Desktop/Tanshionones/ligbuilder/OD_GM_seed-v3mTan.results.mdb  
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cp /Users/My_Research/QSAR/Prediction-scripts-1/AMSOL-insertion-start 
/Users/shana/Desktop/Tanshionones/ligbuilder/OD_GM_seed-v3mTan.results.mdb  
cp /Users/My_Research/QSAR/Prediction-scripts-1/Amsol-outname.py 
/Users/shana/Desktop/Tanshionones/ligbuilder/OD_GM_seed-v3mTan.results.mdb  
cp /Users/My_Research/QSAR/Prediction-scripts-1/AMSOL-Print-part2-start 
/Users/shana/Desktop/Tanshionones/ligbuilder/OD_GM_seed-v3mTan.results.mdb  
cp /Users/My_Research/QSAR/Prediction-scripts-1/Print.part2.AMSOL.py 
/Users/shana/Desktop/Tanshionones/ligbuilder/OD_GM_seed-v3mTan.results.mdb  
cp /Users/My_Research/QSAR/Prediction-scripts-1/multiplestest.run_all.pl 
/Users/shana/Desktop/Tanshionones/ligbuilder/OD_GM_seed-v3mTan.results.mdb  
 
chmod ugo+x AMSOL-Print-part1-start 
chmod ugo+x Print.part1.AMSOL.py 
chmod ugo+x AMSOL-insertion-start 
chmod ugo+x Amsol-outname.py 
chmod ugo+x AMSOL-Print-part2-start 
chmod ugo+x Print.part2.AMSOL.py 
 
./AMSOL-Print-part1-start 
./AMSOL-insertion-start 
./AMSOL-Print-part2-start 
 
echo "AMSOL is being run" 
chmod ugo+x AMSOL-list.pl 
cp /Applications/amsol7.1/amsol7.1.exe 
/Users/shana/Desktop/Tanshionones/ligbuilder/OD_GM_seed-v3mTan.results.mdb  
perl AMSOL-list.pl 
 
echo "Charges are being extracted from AMSOL output files" 
 
cp /Users/My_Research/QSAR/Prediction-scripts-1/charges 
/Users/shana/Desktop/Tanshionones/ligbuilder/OD_GM_seed-v3mTan.results.mdb  
cp /Users/My_Research/QSAR/Prediction-scripts-1/charge_finder-SVS-FL.py 
/Users/shana/Desktop/Tanshionones/ligbuilder/OD_GM_seed-v3mTan.results.mdb  
chmod ugo+x charges 
chmod ugo+x charge_finder-SVS-FL.py 
./charges 
 
echo "Solvation charges are being extracted from AMSOL output files" 
 
cp /Users/My_Research/QSAR/Prediction-scripts-1/Solv_extraction 
/Users/shana/Desktop/Tanshionones/ligbuilder/OD_GM_seed-v3mTan.results.mdb  
cp /Users/My_Research/QSAR/Prediction-scripts-1/Solvation-finish.py 
/Users/shana/Desktop/Tanshionones/ligbuilder/OD_GM_seed-v3mTan.results.mdb  
cp /Users/My_Research/QSAR/Prediction-scripts-1/Solvator 
/Users/shana/Desktop/Tanshionones/ligbuilder/OD_GM_seed-v3mTan.results.mdb  
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chmod ugo+x Solv_extraction 
chmod ugo+x solvator 
chmod ugo+x Solvation-finish.py 
./Solv_extraction 
./solvator 
python Solvation-finish.py 
 
#echo "QSAR input pdb files are being written" 
 
cp /Users/My_Research/QSAR/Prediction-scripts-1/pdb.Namechange 
/Users/shana/Desktop/Tanshionones/ligbuilder/OD_GM_seed-v3mTan.results.mdb  
cp /Users/My_Research/QSAR/Prediction-scripts-1/svs-pdb-filename-exchange.py 
/Users/shana/Desktop/Tanshionones/ligbuilder/OD_GM_seed-v3mTan.results.mdb  
chmod ugo+x pdb.Namechange 
chmod ugo+x svs-pdb-filename-exchange.py 
./pdb.Namechange 
 
echo "Copying clean up program to folder. Use only if everything is correct!!!" 
echo "Clean up program must be run from directory" 
cp /Users/My_Research/QSAR/Prediction-scripts-1/clean-up 
/Users/shana/Desktop/Tanshionones/ligbuilder/OD_GM_seed-v3mTan.results.mdb  
chmod ugo+x clean-up 
 
echo "at" 
date 
echo "Program is finished" 
 
 
A.1.2 BABEL-MOL2-PDB SCRIPT 
 
babel -imol2 *.mol2 -opdb *.pdb 
 
 
A.1.3 BABEL-MOL2-SMI SCRIPT 
 
babel -imol2 *.mol2 -osmi *.smi 
 
A.1.4 BABEL-MOL2-MOPINT 
 
#!/bin/sh 
 
for file in `ls -1 *.mol2` 
 
do 
 babel -imol2 $file -omopin $file.mopin 
done 
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A.1.5 KEYWORDS-START SCRIPT 
 
#!/bin/sh 
 
for file in `ls -1 *.mol2.mopin` 
do 
 python Keywords-write.py $file 
done 
 
 
A.1.6 KEYWORDS-WRITE.PY SCRIPT 
 
import string  
import os 
import sys 
 
# This will only work for file names ending with .#.mo.out or the like, where 
#the file number is in the 1st from last position in the filename. 
 
inFile = sys.argv[1] 
inParts = string.split(inFile, ".") 
print inParts 
print ("%s is running." %inFile) 
outName = inParts[0] 
outName = outName+".mo.dat" 
  
 
input = open('%s' %inFile,'r') 
 
#input = open(Benz.svs.mo.out, 'r') 
outFile = open('%s' %outName,'a') 
#outFile = open(test.keywords.mo.dat, 'a') 
outFile.write("SM5.42R SOLVNT=WATER 1SCF TRUES PM3 HFCALC=1SCF \n") 
outFile.write("(aqueous) \n") 
 #outFile = open(Benz.chg, 'a') 
 
 
infile = open('%s' %inFile,'r') 
infile.readline() 
infile.readline() 
for i in range (1, 100): 
 line = infile.readline() 
 outFile.write(line) 
   
A.1.7 AMSOL-PRINT-PART1-START 
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#!/bin/sh 
 
for file in `ls -1 multiplestest.run_all.pl` 
do 
 python Print.part1.AMSOL.py $file 
done  
 
 
A.1.8 PRINT.PART1.AMSOL.PY 
 
 
outfile = open("AMSOL-list.pl", 'w') 
infile = open("multiplestest.run_all.pl", 'r') 
 
def main(): 
  
 for i in range (1, 21): 
  line = infile.readline() 
  print line 
  outfile.write(line) 
  
main () 
 
 
A.1.9 AMSOL-INSERTION-START 
 
#!/bin/sh 
 
for file in `ls -1 *.mo.dat` 
do 
 python Amsol-outname.py $file 
done 
 
 
A.1.10 AMSOL-OUTNAME.PY 
 
import string  
import os 
import sys 
 
outfile = open("AMSOL-list.pl", 'a') 
 
inFile = sys.argv[1] 
inParts = string.split(inFile, ".") 
print ("name is being written to AMSOL file") 
#print ("%s is running." %inFile) 
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outName = inParts[0] 
outName = outName+".mo.dat " 
print outName 
outfile.write(outName) 
 
A.1.11 AMSOL-PRINT-PART2-START 
 
#!/bin/sh 
 
for file in `ls -1 multiplestest.run_all.pl` 
do 
 python Print.part2.AMSOL.py $file 
done 
 
A.1.12 PRINT.PART2.AMSOL.PY 
 
 
outfile = open("AMSOL-list.pl", 'a') 
infile = open("multiplestest.run_all.pl", 'r') 
 
def main(): 
  
 infile.readline() 
 infile.readline() 
 infile.readline() 
 infile.readline() 
 infile.readline() 
 infile.readline() 
 infile.readline() 
 infile.readline() 
 infile.readline() 
 infile.readline() 
 infile.readline() 
 infile.readline() 
 infile.readline() 
 infile.readline() 
 infile.readline() 
 infile.readline() 
 infile.readline() 
 infile.readline() 
 infile.readline() 
 infile.readline() 
 infile.readline() 
 for i in range (1, 65): 
  line = infile.readline() 
  print line 
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  outfile.write(line) 
  
main () 
 
 
A.1.13 MULTIPLESTEST.RUN_ALL.PL 
 
#!/usr/bin/perl 
# 
# 
 
$amsol_exe='./amsol7.1.exe'; 
$cp_command = 'cp -f'; 
 
 
#uncomment the next 2 lines if running in Windows 
#$amsol_exe='..\amsol7.1.exe'; 
#$cp_command = 'copy /Y'; 
 
 
 
##############################################################################
######## 
# delete any files from this list if you do not want to run any particular test runs # 
##############################################################################
######## 
 
  
$test_input_files=" 
multiples.test.mo.dat 
"; 
$test_input_files2 = "     "; 
 
$test_input_files3 = "     "; 
 
@files  = ($test_input_files  =~ /\S{1,}/g); 
@files2 = ($test_input_files2 =~ /\S{1,}/g); 
@files3 = ($test_input_files3 =~ /\S{1,}/g); 
 
 
foreach $file (@files){ 
  chop $file;chop $file; 
  chop $file;chop $file; 
  print "running $file  ..."; 
  $error_flag = system ("$amsol_exe \< $file.dat \> $file.out"); 
  if ($error_flag) {print "error running $file \n"} 
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  else{print "finished \n"} 
} 
 
foreach $file (@files2){ 
  chop $file;chop $file; 
  chop $file;chop $file; 
  print "running $file  ..."; 
  system ("$cp_command $file.xsm fort.19"); 
  $error_flag = system ("$amsol_exe \< $file.dat \> $file.out"); 
  if ($error_flag) {print "error running $file \n"} 
  else{print "finished \n"} 
} 
 
foreach $file (@files3){ 
  chop $file;chop $file; 
  chop $file;chop $file; 
  print "running $file  ..."; 
  system ("$cp_command $file.xkw fort.20"); 
  $error_flag = system ("$amsol_exe \< $file.dat \> $file.out"); 
  if ($error_flag) {print "error running $file \n"} 
  else{print "finished \n"} 
} 
   
   
A.1.14 AMSOL-LIST.PL 
 
#!/usr/bin/perl 
# 
# 
 
$amsol_exe='./amsol7.1.exe'; 
$cp_command = 'cp -f'; 
 
 
#uncomment the next 2 lines if running in Windows 
#$amsol_exe='..\amsol7.1.exe'; 
#$cp_command = 'copy /Y'; 
 
 
 
##############################################################################
######## 
# delete any files from this list if you do not want to run any particular test runs # 
##############################################################################
######## 
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$test_input_files=" 
"; 
$test_input_files2 = "     "; 
 
$test_input_files3 = "     "; 
 
@files  = ($test_input_files  =~ /\S{1,}/g); 
@files2 = ($test_input_files2 =~ /\S{1,}/g); 
@files3 = ($test_input_files3 =~ /\S{1,}/g); 
 
 
foreach $file (@files){ 
  chop $file;chop $file; 
  chop $file;chop $file; 
  print "running $file  ..."; 
  $error_flag = system ("$amsol_exe \< $file.dat \> $file.out"); 
  if ($error_flag) {print "error running $file \n"} 
  else{print "finished \n"} 
} 
 
foreach $file (@files2){ 
  chop $file;chop $file; 
  chop $file;chop $file; 
  print "running $file  ..."; 
  system ("$cp_command $file.xsm fort.19"); 
  $error_flag = system ("$amsol_exe \< $file.dat \> $file.out"); 
  if ($error_flag) {print "error running $file \n"} 
  else{print "finished \n"} 
} 
 
foreach $file (@files3){ 
  chop $file;chop $file; 
  chop $file;chop $file; 
  print "running $file  ..."; 
  system ("$cp_command $file.xkw fort.20"); 
  $error_flag = system ("$amsol_exe \< $file.dat \> $file.out"); 
  if ($error_flag) {print "error running $file \n"} 
  else{print "finished \n"} 
} 
   
   
 A.1.15 CHARGES 
 
#!/bin/sh 
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for file in `ls -1 *.mo.out` 
do 
 python charge_finder-SVS-FL.py $file 
done 
 
 
A.1.16 CHARGE FINDER 
 
DEVELOPED BY SHAWN YU 
import string  
import os 
import sys 
 
# This will only work for file names ending with .#.mo.out or the like, where 
#the file number is in the 1st from last position in the filename. 
 
inFile = sys.argv[1] 
inParts = string.split(inFile,"_") 
print inParts 
outParts = inParts[1] 
newparts = string.split(outParts, ".") 
print newparts 
lastparts = newparts[0] 
print lastparts 
print ("%s is running." %inFile) 
outName = lastparts+".chg" 
print outName  
  
input = open('%s' %inFile,'r') 
#input = open(Benz.svs.mo.out, 'r') 
outFile = open('%s' %outName,'w') 
#outFile = open(Benz.chg, 'a') 
#outFile.write("#Charges extracted from file: %s\n" %inFile) 
 
while 1: 
 inputline = input.readline() 
 if inputline == '                                   calculated with CM2 \n' : 
  inputline = input.readline() 
   inputline = input.readline() 
   inputline = input.readline() 
   while len(inputline) > 1: 
    splitline = string.split(inputline) 
    outFile.write("%s00\n" %splitline[2])  # %s is defined by %(name) 
    inputline = input.readline()  
  break 
outFile.close() 
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input.close() 
 
 
# The command while 1: is a loop the condition is inputline = input.readline().  Which creates  
# a string if it is the correct line it will continue trough the loop and this part of the  
# program skips two lines then begins to read the next line.  
 
 
A.1.17 SOLV_EXTRACTION 
 
#!/bin/sh 
#Solv_extration 
#this is the solvation extration program 
#Shana stoddard 5/30.08 
 
#!/bin/sh 
 
for file in `ls -1 *.mo.out` 
do 
 grep "DeltaG-S" $file > Solv.int,$file 
 #grep "DeltaG-S" Solv.int,* > Intermediate-Solvation.txt 
 #rm -r Test_Solv.NS.int 
done 
 
 
A.1.18 SOLVATOR 
 
#!/bin/sh 
 
for file in `ls -1 S*.mo.out` 
do 
 python Solvation-finish.py $file 
done 
 
A.1.19 SOLVATION-FINISH.PY 
 
# printfile.py 
# Prints a file to the screen 
import sys 
import os 
import string 
 
inFile = sys.argv[1] 
inParts = string.split(inFile,"_") 
#print inParts 
outParts = inParts[1] 
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newparts = string.split(outParts, ".") 
#print newparts 
lastparts = newparts[0] 
print lastparts 
print ("%s is running." %inFile) 
#outName = lastparts+".solv.txt" 
#print outName  
  
input = open('%s' %inFile,'r') 
#input = open('Intermediate-Solvation.txt','r') 
#input = open(Benz.svs.mo.out, 'r') 
outfile = open("Solvation-File2.txt", 'a')   #%outName 
#outFile = open(Benz.chg, 'a') 
#outFile.write("#Charges extracted from file: %s\n" %inFile) 
 
for i in range (50): 
 line = input.readline() 
 print line 
 Score = line[67:75]  
 print Score 
 outfile.write(lastparts+" "+ Score+'\n')  
 outfile.close() 
 
 
A.1.21 PDB.NAMECHANGE 
 
#!/bin/sh 
 
for file in `ls -1 *.pdb` 
do 
 python svs-pdb-filename-exchange.py $file 
done 
 
 
A.1.22 SVS-PDB-FILENAME-EXCHANGE.PY 
 
#READ.line.py separate lines 
#This program reads separate lines 
 
import string  
import os 
import sys 
 
# This will only work for file names ending with .#.mo.out or the like, where 
#the file number is in the 1st from last position in the filename. 
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#inFile = "result_001.pdb" 
inFile = sys.argv[1] 
inParts = string.split(inFile,"_") 
print inParts 
outParts = inParts[1] 
newparts = string.split(outParts, ".") 
print newparts 
lastparts = newparts[0] 
print lastparts 
print ("%s is running." %inFile) 
outName = lastparts+".pdb" 
print outName  
 
input = open('%s' %inFile,'r') 
#input = open(Prepare-inputfile.pdb,'r') 
outFile = open("Prepare-input-file.pdb",'a') 
 
#input = open('%s' %inFile,'r') 
#outFile = open('%s' %outName,'w') 
 
def main(): 
 
 for i in range (1, 200): 
   line = input.readline() 
   if len(line) < 75: 
    line = input.readline() 
   line = line.replace("LIG", lastparts) 
   line = line.replace("UNK", lastparts) 
   line = line.replace("AUTHOR    GENERATED BY OPEN BABEL 
2.3.1", "\n") 
   line = line.replace("HETATM", "ATOM  ") 
   line = line.replace("1.00  0.00           C  ", "                        ") 
   line = line.replace("1.00  0.00           N  ", "                        ") 
   line = line.replace("1.00  0.00           O  ", "                        ") 
   line = line.replace("1.00  0.00          Cl  ", "                        ") 
   line = line.replace("1.00  0.00          Br  ", "                        ") 
   line = line.replace("1.00  0.00           I  ", "                        ") 
   line = line.replace("1.00  0.00           F  ", "                        ") 
   line = line.replace("1.00  0.00           S  ", "                        ") 
   line = line.replace("END", "\n") 
   line = line.replace("1.00  0.00           H  ", "                        ") 
   #line = input.readline() 
   #print line   
   outFile.write(line) 
 
main () 
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APPENDIX A2: LIGBUILDER RUN FILES 
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A.2.1 EXAMPLE POCKET INPUT FILE 
 
# 
    #input file 
    # 
    RECEPTOR_FILE          
 /Users/Shana/Desktop/Tanshionones/Ligbuilder/Grandmodelversion3.14particles.pdb 
    LIGAND_FILE           
 /Users/Shana/Desktop/Tanshionones/Ligbuilder/Grand-Model-ligand.mol2 
    PARAMETER_DIRECTORY    
 /Applications/LigBuilder/LigBuilderv1.2/parameter/ 
    # 
    #Output files 
    # 
    POCKET_ATOM_FILE   
 /Users/Shana/Desktop/Tanshionones/Ligbuilder/Poc_atom_file_GM-tanshionones.txt 
    POCKET_GRID_FILE   
 /Users/Shana/Desktop/Tanshionones/Ligbuilder/Poc_atom_file_GM-tanshionones.txt     
    # 
    #Key interaction sites and pharmacophore 
    # 
    KEY_SITE_FILE    
 /Users/Shana/Desktop/Tanshionones/Ligbuilder/Key_site-File_GM-tanshionones.pdb 
    PHARMACOPHORE_TXT_FILE  
 /Users/Shana/Desktop/Tanshionones/Ligbuilder/Phar_txt_file_GM-tanshionones.txt 
    PHARMACOPHORE_PDB_FILE  
 /Users/Shana/Desktop/Tanshionones/Ligbuilder/Phar_pdb_file_GM-tanshionones.pdb 
    MINIMAL_FEATURE_DISTANCE  3.50 
    MAXIMAL_FEATURE_NUMBER   8 
    # 
    # vwl particle size 
 
 
 
 
 
A.2.2 EXAMPLE GROW INPUT FILE 
 
 # 
 # input files  
 # 
 SEED_LIGAND_FILE   
 /Users/Shana/Desktop/Tanshionones/Ligbuilder/Seeds-v2-1DT.mol2 
 POCKET_ATOM_FILE   
 /Users/Shana/Desktop/Tanshionones/Ligbuilder/Poc_atom_file_GM3.14-
tanshionones.txt   
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 POCKET_GRID_FILE   
 /Users/Shana/Desktop/Tanshionones/Ligbuilder/Poc_grid_file_GM3.14-tanshionones.txt     
 # 
 # force field directory 
 # 
 PARAMETER_DIRECTORY             
/Applications/LigBuilder/LigBuilderv1.2/parameter/ 
 # 
 # fragment libraries 
 # 
 BUILDING_BLOCK_LIBRARY  
 /Applications/LigBuilder/LigBuilderv1.2/fragment.mdb/ 
 FORBIDDEN_STRUCTURE_LIBRARY 
 /Applications/LigBuilder/LigBuilderv1.2/forbidden.mdb/ 
 TOXIC_STRUCTURE_LIBRARY  
 /Applications/LigBuilder/LigBuilderv1.2/toxicity.mdb/ 
 # 
 # structural construction parameters  
 # 
 GROWING_PROBABILITY   1.00 
 LINKING_PROBABILITY    0.50 
 MUTATION_PROBABILITY   0.50 
 # 
 # chemical viability rules  
 # 
 APPLY_CHEMICAL_RULES   YES 
 APPLY_FORBIDDEN_STRUCTURE_CHECK YES  
 APPLY_TOXIC_STRUCTURE_CHECK  YES  
 MAXIMAL_MOLECULAR_WEIGHT  350 
 MINIMAL_MOLECULAR_WEIGHT  250 
 MAXIMAL_LOGP     5.00 
 MINIMAL_LOGP     2.00 
 MAXIMAL_HB_DONOR_ATOM   5 
 MINIMAL_HB_DONOR_ATOM   2  
 MAXIMAL_HB_ACCEPTOR_ATOM  10 
 MINIMAL_HB_ACCEPTOR_ATOM  2  
 MAXIMAL_PKD      10.00 
 MINIMAL_PKD      5.00  
 # 
 # genetic algorithm parameters  
 # 
 NUMBER_OF_GENERATION   20  
 NUMBER_OF_POPULATION   3000 
 NUMBER_OF_PARENTS    200 
 ELITISM_RATIO     0.10 
 SIMILARITY_CUTOFF    0.90 
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 # 
 # output files  
 # 
 POPULATION_RECORD_FILE  
 /Users/Shana/Desktop/Tanshionones/Ligbuilder/PRF_GM-seed-v2Tan-run1.lig 
 LIGAND_COLLECTION_FILE  
 /Users/Shana/Desktop/Tanshionones/Ligbuilder/LCF_GM-seed-v2Tan-run1.lig 
 # 
 
 
A.2.3 EXAMPLE PROCES INPUT FILE 
 
 # 
 # input files  
 # 
 LIGAND_COLLECTION_FILE  
 /Users/Shana/Desktop/Tanshionones/Ligbuilder/LCF_GM-seed-v6Tan-run1.lig 
 # 
 # chemical rules 
 # 
 MAXIMAL_MOLECULAR_WEIGHT  500 
 MINIMAL_MOLECULAR_WEIGHT  300 
 MAXIMAL_LOGP     5.00 
 MINIMAL_LOGP     0.00 
 MAXIMAL_PKD      10.00 
 MINIMAL_PKD      0.00 
 # 
 # similarity threshhold  
 # 
 SIMILARITY_CUTOFF    0.90  
 # 
 # output files  
 # 
 NUMBER_OF_OUTPUT_MOLECULES  200 
 OUTPUT_DIRECTORY   
 /Users/Shana/Desktop/Tanshionones/Ligbuilder/OD_GM_seed-v6Tan.results.mdb 
 # 
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A.3.1 DNA SEQUENCE FOR PNBCE-WILD-TYPE ENZYME 
 
ATGACTCATC AAATAGTAAC GACTCAATAC GGCAAAGTAA AAGGCACAAC  
GGAAAACGGC GTACATAAGT GGAAAGGCAT CCCCTATGCC AAGCCGCCTG 
TCGGACAATG GCGTTTTAAA GCACCTGAGC CGCCTGAAGT GTGGGAAGAT  
GTGCTTGATG CCACAGCGTA CGGCTCTATT TGCCCGCAGC CGTCTGATTT  
GCTGTCACTT TCGTATACTG AGCTGCCCCG CCAGTCCGAG GATTGCTTGT 
ATGTCAATGT ATTTGCGCCT GACACCCCAA GTAAAAATCT TCCTGTCATG  
GTGTGGATTC ACGGAGGCGC TTTTTATCTA GGAGCGGGCA GTGAGCCATT 
GTATGACGGA TCAAAACTTG CGGCACAGGG AGAAGTCATT GTCGTTACAT  
TGAACTATCG GCTGGGGCCG TTTGGCTTTT TGCACTTGTC TTCATTTAAT  
GAGGCGTATT CTGATAACCT TGGGCTTTTA GACCAAGCCG CCGCGCTGAA 
ATGGGTGCGA GAGAATATTT CAGCGTTTGG CGGTGATCCC GATAACGTAA 
CAGTATTTGG AGAATCCGCC GGCGGGATGA GCATTGCCGC GCTGCTTGCT  
ATGCCTGCGG CAAAAGGCCT GTTCCAGAAA GCAATCATGG AAAGCGGCGC  
TTCTCGAACG ATGACGAAAG AACAAGCGGC GAGCACCTCG GCAGCCTTTT 
TACAGGTCCT TGGGATTAAC GAGGGCCAAC TGGATAAATT GCATACGGTT  
TCTGCGGAAG ATTTGCTAAA AGCGGCTGAT CAGCTTCGGA TTGCAGAAAA 
AGAAAATATC TTTCAGCTGT TCTTCCAGCC CGCCCTTGAT CCGAAAACGC 
TGCCTGAAGA ACCAGAAAAA GCGATCGCAG AAGGGGCTGC TTCCGGTATT  
CCGCTATTAA TTGGAACAAC CCGTGATGAA GGATATTTAT TTTTCACCCC 
GGATTCAGAC GTTCATTCTC AGGAAACGCT TGATGCAGCG CTCGAGTATT  
TACTAGGGAA GCCGCTGGCA GAGAAAGTTG CCGATTTGTA TCCGCGTTCT 
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CTGGAAAGCC AAATTCATAT GATGACTGAT TTATTATTTT GGCGCCCTGC  
CGTCGCCTAT GCATCCGCAC AGTCTCATTA CGCCCCTGTC TGGATGTACA  
GGTTCGATTG GCACCCGAAG AAGCCGCCGT ACAATAAAGC GTTTCACGCA  
TTAGAGCTTC CTTTTGTCTT TGGAAATCTG GACGGATTGG AACGAATGGC  
AAAAGCGGAG ATTACGGATG AGGTGAAACA GCTTTCTCAC ACGATACAAT  
CAGCGTGGAT CACGTTCGCC AAAACAGGAA ACCCAAGCAC CGAAGCTGTG  
AATTGGCCTG CGTATCATGA AGAAACGAGA GAGACGCTGA TTTTAGACTC 
AGAGATTACG ATCGAAAACG ATCCCGAATC TGAAAAAAGG CAGAAGCTAT  
TCCCTTCAAA AGGAGAATAA 
 
A.3.2 DNA SEQUENCE FOR PNBCE-CES1-LOOP7-MUTANT ENZYME 
 
ATGACTCATC AAATAGTAAC GACTCAATAC GGCAAAGTAA AAGGCACAAC  
GGAAAACGGC GTACATAAGT GGAAAGGCAT CCCCTATGCC AAGCCGCCTG 
TCGGACAATG GCGTTTTAAA GCACCTGAGC CGCCTGAAGT GTGGGAAGAT  
GTGCTTGATG CCACAGCGTA CGGCTCTATT TGCCCGCAGC CGTCTGATTT  
GCTGTCACTT TCGTATACTG AGCTGCCCCG CCAGTCCGAG GATTGCTTGT 
ATGTCAATGT ATTTGCGCCT GACACCCCAA GTAAAAATCT TCCTGTCATG  
GTGTGGATTC ACGGAGGCGG CCTAATGGTG GGAGCGCTTA GTGAGCCATT 
GTATGACGGA TCAAAACTTG CGGCACAGGG AGAAGTCATT GTCGTTACAT  
TGAACTATCG GCTGGGGCCG TTTGGCTTTT TGCACTTGTC TTCATTTAAT  
GAGGCGTATT CTGATAACCT TGGGCTTTTA GACCAAGCCG CCGCGCTGAA 
ATGGGTGCGA GAGAATATTT CAGCGTTTGG CGGTGATCCC GATAACGTAA 
	  178	  
CAGTATTTGG AGAATCCGCC GGCGGGATGA GCATTGCCGC GCTGCTTGCT  
ATGCCTGCGG CAAAAGGCCT GTTCCAGAAA GCAATCATGG AAAGCGGCGC  
TTCTCGAACG ATGACGAAAG AACAAGCGGC GAGCACCTCG GCAGCCTTTT 
TACAGGTCCT TGGGATTAAC GAGGGCCAAC TGGATAAATT GCATACGGTT  
TCTGCGGAAG ATTTGCTAAA AGCGGCTGAT CAGCTTCGGA TTGCAGAAAA 
AGAAAATATC TTTCAGCTGT TCTTCCAGCC CGCCCTTGAT CCGAAAACGC 
TGCCTGAAGA ACCAGAAAAA GCGATCGCAG AAGGGGCTGC TTCCGGTATT  
CCGCTATTAA TTGGAACAAC CCGTGATGAA GGATATTTAT TTTTCACCCC 
GGATTCAGAC GTTCATTCTC AGGAAACGCT TGATGCAGCG CTCGAGTATT  
TACTAGGGAA GCCGCTGGCA GAGAAAGTTG CCGATTTGTA TCCGCGTTCT 
CTGGAAAGCC AAATTCATAT GATGACTGAT TTATTATTTT GGCGCCCTGC  
CGTCGCCTAT GCATCCGCAC AGTCTCATTA CGCCCCTGTC TGGATGTACA  
GGTTCGATTG GCACCCGAAG AAGCCGCCGT ACAATAAAGC GTTTCACGCA  
TTAGAGCTTC CTTTTGTCTT TGGAAATCTG GACGGATTGG AACGAATGGC  
AAAAGCGGAG ATTACGGATG AGGTGAAACA GCTTTCTCAC ACGATACAAT  
CAGCGTGGAT CACGTTCGCC AAAACAGGAA ACCCAAGCAC CGAAGCTGTG  
AATTGGCCTG CGTATCATGA AGAAACGAGA GAGACGCTGA TTTTAGACTC 
AGAGATTACG ATCGAAAACG ATCCCGAATC TGAAAAAAGG CAGAAGCTAT  
TCCCTTCAAA AGGAGAATAA 
 
A.3.3 DNA SEQUENCE FOR PNBCE-CES2-LOOP7-MUTANT ENZYME 
 
ATGACTCATC AAATAGTAAC GACTCAATAC GGCAAAGTAA AAGGCACAAC  
	  179	  
GGAAAACGGC GTACATAAGT GGAAAGGCAT CCCCTATGCC AAGCCGCCTG 
TCGGACAATG GCGTTTTAAA GCACCTGAGC CGCCTGAAGT GTGGGAAGAT  
GTGCTTGATG CCACAGCGTA CGGCTCTATT TGCCCGCAGC CGTCTGATTT  
GCTGTCACTT TCGTATACTG AGCTGCCCCG CCAGTCCGAG GATTGCTTGT 
ATGTCAATGT ATTTGCGCCT GACACCCCAA GTAAAAATCT TCCTGTCATG  
GTGTGGATTC ACGGAGGCGC TCTAGTGTTTG GAATGCTTA GTGAGCCATT 
GTATGACGGA TCAAAACTTG CGGCACAGGG AGAAGTCATT GTCGTTACAT  
TGAACTATCG GCTGGGGCCG TTTGGCTTTT TGCACTTGTC TTCATTTAAT  
GAGGCGTATT CTGATAACCT TGGGCTTTTA GACCAAGCCG CCGCGCTGAA 
ATGGGTGCGA GAGAATATTT CAGCGTTTGG CGGTGATCCC GATAACGTAA 
CAGTATTTGG AGAATCCGCC GGCGGGATGA GCATTGCCGC GCTGCTTGCT  
ATGCCTGCGG CAAAAGGCCT GTTCCAGAAA GCAATCATGG AAAGCGGCGC  
TTCTCGAACG ATGACGAAAG AACAAGCGGC GAGCACCTCG GCAGCCTTTT 
TACAGGTCCT TGGGATTAAC GAGGGCCAAC TGGATAAATT GCATACGGTT  
TCTGCGGAAG ATTTGCTAAA AGCGGCTGAT CAGCTTCGGA TTGCAGAAAA 
AGAAAATATC TTTCAGCTGT TCTTCCAGCC CGCCCTTGAT CCGAAAACGC 
TGCCTGAAGA ACCAGAAAAA GCGATCGCAG AAGGGGCTGC TTCCGGTATT  
CCGCTATTAA TTGGAACAAC CCGTGATGAA GGATATTTAT TTTTCACCCC 
GGATTCAGAC GTTCATTCTC AGGAAACGCT TGATGCAGCG CTCGAGTATT  
TACTAGGGAA GCCGCTGGCA GAGAAAGTTG CCGATTTGTA TCCGCGTTCT 
CTGGAAAGCC AAATTCATAT GATGACTGAT TTATTATTTT GGCGCCCTGC  
CGTCGCCTAT GCATCCGCAC AGTCTCATTA CGCCCCTGTC TGGATGTACA  
GGTTCGATTG GCACCCGAAG AAGCCGCCGT ACAATAAAGC GTTTCACGCA  
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TTAGAGCTTC CTTTTGTCTT TGGAAATCTG GACGGATTGG AACGAATGGC  
AAAAGCGGAG ATTACGGATG AGGTGAAACA GCTTTCTCAC ACGATACAAT  
CAGCGTGGAT CACGTTCGCC AAAACAGGAA ACCCAAGCAC CGAAGCTGTG  
AATTGGCCTG CGTATCATGA AGAAACGAGA GAGACGCTGA TTTTAGACTC 
AGAGATTACG ATCGAAAACG ATCCCGAATC TGAAAAAAGG CAGAAGCTAT  
TCCCTTCAAA AGGAGAATAA 
 
A.3.4 PROTEIN SEQUENCE FOR PNBCE-WILD-TYPE ENZYME 
 
MTHQIVTTQY GKVKGTTENG VHKWKGIPYA KPPVGQWRFK APEPPEVWED 
VLDATAYGPI CPQPSDLLSL SYTELPRQSE DCLYVNVFAP DTPSQNLPVM 
VWIHGGAFY LGAGSEPLY DGSKLAAQGE VIVVTLNYRL GPFGFLHLSS 
FDEAYSDNLG LLDQAAALKW VRENISAFGG DPDNVTVFGE SAGGMSIAA 
LLAMPAAKGL FQKAIMESGA SRTMTKEQAA STAAAFLQVL GINESQLDRL 
HTVAAEDLLK AADQLRIAEK ENIFQLFFQP ALDPKTLPEE PEKSIAEGAA SGIPLLIGTT 
RDEGYLFFTP DSDVHSQETL DAALEYLLGK PLAEKAADLY PRSLESQIHM 
MTDLLFWRPA VAYASAQSHY APVWMYRFDW HPEKPPYNKA FHALELPFVF 
GNLDGLERMA KAEITDEVKQ LSHTIQSAWI TFAKTGNPST EAVNWPAYHE 
ETRETVILDS EITIENDPES EKRQKLFPSK GEP 
 
A.3.5 PROTEIN SEQUENCE FOR PNBCE-CES1-LOOP7-MUTANT ENZYME 
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MTHQIVTTQY GKVKGTTENG VHKWKGIPYA KPPVGQWRFK APEPPEVWED 
VLDATAYGPI CPQPSDLLSL SYTELPRQSE DCLYVNVFAP DTPSQNLPVM 
VWIHGGGLMV GAASEPLYDG SKLAAQGEVI VVTLNYRLGP FGFLHLSSFD 
EAYSDNLGLL DQAAALKWVR ENISAFGGDP DNVTVFGESA GGMSIAALLA 
MPAAKGLFQK AIMESGASRT MTKEQAASTA AAFLQVLGIN ESQLDRLHTV 
AAEDLLKAAD QLRIAEKENI FQLFFQPALD PKTLPEEPEK  SIAEGAASGI  
PLLIGTTRDE GYLFFTPDSD VHSQETLDAA LEYLLGKPLA EKAADLYPRS 
LESQIHMMTD LLFWRPAVAY ASAQSHYAPV WMYRFDWHPE KPPYNKAFHA 
LELPFVFGNL DGLERMAKAE ITDEVKQLSH TIQSAWITFA KTGNPSTEAV 
NWPAYHEETR      ETVILDSEIT       IENDPESEKR    QKLFPSKGE 
 
A.3.6 PROTEIN SEQUENCE FOR PNBCE-CES2-LOOP7-MUTANT ENZYME 
 
MTHQIVTTQY GKVKGTTENG VHKWKGIPYA KPPVGQWRFK APEPPEVWED 
VLDATAYGPI CPQPSDLLSL SYTELPRQSE DCLYVNVFAP DTPSQNLPVM 
VWIHGGALVF GMASEPLYDG SKLAAQGEVI VVTLNYRLGP FGFLHLSSFD 
EAYSDNLGLL DQAAALKWVR ENISAFGGDP DNVTVFGESA GGMSIAALLA 
MPAAKGLFQK AIMESGASRT MTKEQAASTA AAFLQVLGIN ESQLDRLHTV 
AAEDLLKAAD  QLRIAEKENI FQLFFQPALD PKTLPEEPEK SIAEGAASGI  
PLLIGTTRDE GYLFFTPDSD VHSQETLDAA LEYLLGKPLA EKAADLYPRS 
LESQIHMMTD LLFWRPAVAY ASAQSHYAPV WMYRFDWHPE KPPYNKAFHA 
LELPFVFGNL DGLERMAKAE ITDEVKQLSH TIQSAWITFA KTGNPSTEAV 
NWPAYHEETR        ETVILDSEIT        IENDPESEKR        QKLFPSKGE 
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VITA 
 
Shana V. Stoddard 
              
 Research Interests: 
My research interests include investigation of enzyme specificity for the development of specific 
inhibitors and drugs. I am particularly interested in using computational chemistry, organic chemistry, and 
biochemistry to complete these research endeavors. The impact of my research I would like to see 
translated into clinical therapies. 
              
 Education and Corresponding Research Experience: 
 
University of Mississippi; Oxford, MS: Doctor of Philosophy, Chemistry,            (Expected, 2013) 
Doctoral Dissertation Project – Molecular considerations in the design of novel alpha/beta hydrolase 
inhibitors. 
Advisor: Randy Wadkins Ph.D., Biophysical and Computational Chemistry May 2008-July 2013 
University of Mississippi, Department of Chemistry and Biochemistry 
Project Description: This project includes evaluation of the interactions important for substrate 
and inhibitor recognition in a family of enzymes called alpha/beta hydrolases with emphasis on a 
carboxylesterase subfamily. The contributions from this work will be applicable to the design of 
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novel inhibitors and drugs. This project is being accomplished through a combination of protein 
mutagenesis and kinetic analysis, quantitative structure activity relationship, de novo drug design, 
and other biochemical, computational, basic molecular and cellular biology, and organic 
chemistry protocols. 
 
Prairie View A&M University; Prairie View, TX: Post Baccalaureate studies in Chemistry (2007-2008) 
Research Project – PDK/CDK ligand interactions and mode of binding. 
Advisor: Hua-jun Fan Ph.D., Computational Chemistry Jan 2007-May 2008 
Prairie View A&M University, Prairie View, TX 
Project Description: Elucidated important ligand protein interactions present within the cyclin 
dependent kinases (CDK2 and CDK5) and 3-phosphoinositide-dependent protein kinase 1 
(PDK1) through use of docking methodology (DOCK 6.0) coupled with statistical analysis (SPSS 
software). 
 
Texas A&M University; College Station, TX: Post Baccalaureate studies in Chemistry (2005-2006) 
Research Project – Synthesis of alpha/beta unsaturated cyclohexadienes. 
Advisor: Coran Watanabe Ph.D., Organic and Bioorganic Chemistry Oct 2005-Jun 2006 
Texas A&M University, College Station, TX 
Project Description: Synthesized a series of homo- and heterodimeric cyclohexadiene analogs. 
This project was conducted using proline mediated catalysis and basic organic chemistry, and 
synthetic protocols. 
 
Prairie View A&M University; Prairie View, TX: Bachelor of Science (August 2005), 
Major: Chemistry, Biomedical Science Track 
Minor: Biology 
Research Project – Expression of sialyl lewis-X carbohydrate antigen within the female caprine 
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reproductive tract. 
Advisor: Gary Newton Ph.D., Reproductive Physiology Sep 2002-Feb 2004 
Cooperative Agricultural Research Center, Prairie View, TX 
Project Description: Investigation of the presence of L-selectin, E-selectin and sialyl lewis-x on 
caprine reproductive tract and conceptus tissues. This project was carried out using 
immunohistochemistry techniques and fluorescence microscopy. 
              
 Other Research Experience: 
 
Project – Trends in cardiovascular disease Summer 2000 
Advisor: Irving Joushua Ph.D., Physiology and Biophysics 
National Institute of Health at University of Louisville Medical School, Louisville, KY 
Project Description: This project included evaluation of the prevalence of trends in 
cardiovascular disease and stroke. 
              
Peer-Reviewed Publications: 
1. Combining Quantitative Structure Activity Relationship (QSAR) Modeling with In silico Design to 
Develop Carboxylesterase Inhibitors, Shana V. Stoddard, Philip M. Potter, Randy M. Wadkins 
Bioorganic and Medicinal Chemistry Letters (In preparation) 
2. Insights and Ideas Garnered from Marine Metabolites for Development of Acetylcholinesterase and 
Amyloid-β Aggregation Inhibitors, Shana V. Stoddard, Mark T. Hamann, Randy M. Wadkins, Journal 
of Molecular Modeling (In Preparation) 
3. In Silico Design and Evaluation of Carboxylesterase Inhibitors, Shana V. Stoddard, Xiaozhen Yu, 
Philip M. Potter, Randy M. Wadkins. Journal of Pesticide Science 35 (2010) 240-249 – invited review 
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4. Improved, Selective, Human Intestinal Carboxylesterase Inhibitors Designed to Modulate CPT-11 
Toxicity, Latorya D. Hicks, Janice L. Hyatt, Shana Stoddard, Lyudmila Tsurkan, Carol C. Edward, 
Monika Wierdl, Randy M. Wadkins, Philip M. Potter. Journal of Medicinal Chemistry 52 (2009) 3742-
3752 
              
 Technical Skills: 
 
In addition to biochemical expertise I am proficient with UNIX, Chimera, DOCK 6.0, Quasar 6.0. I have 
familiarity with SPSS software; VMD software; NMR 300, 400, and 500MHz; IR and UV spectroscopy; 
HPLC; UNIX shell and python script writing. I am skilled in program development, event organization 
and implementation. 
              
 Presentations: 
 
1. Development of Cutinase Deletion Mutant Plasmids for the Investigation of Structure Function 
Relationships in α/β Hydrolases L. Jennie Fan, Erica M. Stoddard, Shana V. Stoddard, Randy M. 
Wadkins, University of Mississippi, Oxford, MS  
2. Combining Quantitative Structure Activity Relationship (QSAR) Modeling with In silico Design to 
Develop Carboxylesterase Inhibitors (Poster Presentation) Shana V. Stoddard, Mississippi State 
EPSCoR meeting April 18th, 2013: Hattiesburg, MS. Placed 3rd 
3. Insights and Ideas Garnered from Marine Metabolites for Development of Acetylcholinesterase and 
Amyloid-β Aggregation Inhibitors, (Poster Presentation) Shana V. Stoddard, Mark T. Hamann, Randy 
M. Wadkins, National Organization for the Professional Advancement of Black Chemists and Chemical 
Engineers (NOBCChE) national meeting, September – 25th, 2012: Washington, DC. 
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4. Combining Quantitative Structure Activity Relationship (QSAR) Modeling with In silico Design to 
Develop Carboxylesterase Inhibitors (Poster Presentation) Shana V. Stoddard, Mississippi State 
EPSCoR meeting April 10th, 2012: Oxford, MS. 
5. Combining Quantitative Structure Activity Relationship (QSAR) Modeling with In silico Design to 
Develop Carboxylesterase Inhibitors (Poster Presentation) Shana V. Stoddard, Philip M. Potter, Randy 
M. Wadkins, 2nd Annual Poster Symposium and Research Day, April 5th, 2012: Oxford, MS. Conference 
Organizer 
6. In silico Generation and Evaluation of Carboxylesterase Inhibitor Scaffolds (Oral Presentation) Shana 
V. Stoddard, Mississippi Academy of Sciences Annual Meeting, February 23rd -24th, 2012: Hattiesburg, 
MS. Placed 1st 
7. Combining Quantitative Structure Activity Relationship (QSAR) Modeling with In silico Design to 
Develop Carboxylesterase Inhibitors (Oral Presentation) Shana V. Stoddard Midsouth Computational 
Biology & Bioinformatics Society, February 17th-18th, 2012: Oxford, MS. Placed 1st 
8. Structural Alignment and Normal Mode Analysis of Deletion Mutants of Cutinase to Determine 
Substructure Function in Alpha/Beta Hydrolases (Poster Presentation) Erica M. Stoddard, Austin E. 
Pernell, Shana V. Stoddard, Dawn Wilkins, Randy M. Wadkins. Midsouth Computational Biology & 
Bioinformatics Society, February 17th-18th, 2012: Oxford, MS 
9. In silico Design and Evaluation of Carboxylesterase Inhibitors, (Poster Presentation) Shana V. 
Stoddard, Philip M. Potter, Randy M. Wadkins: 4th Mississippi Biophysical Consortium, June 2nd - 3rd, 
2011: Oxford, MS. 
10. In silico Design and Evaluation of Carboxylesterase Inhibitors, (Poster Presentation) Shana V. 
Stoddard, Philip M. Potter, Randy M. Wadkins: National Organization for the Professional 
Advancement of Black Chemists and Chemical Engineers (NOBCChE) national meeting, April 18th - 
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22nd, 2011: Houston, TX. Placed 3rd 
11. In silico Design and Evaluation of Carboxylesterase Inhibitors, (Poster Presentation) Shana V. 
Stoddard, Philip M. Potter, Randy M. Wadkins: Mississippi State EPSCoR meeting April 14th, 2011: 
Starkville, MS. Placed 2nd 
12. In silico Design and Evaluation of Carboxylesterase Inhibitors, (Poster Presentation) Shana V. 
Stoddard, Philip M. Potter, Randy M. Wadkins: 1st Annual Poster Symposium and Research Day, April 
8th, 2011: Oxford, MS. Placed 1st 
13. In silico Design of Carboxylesterase Inhibitors, (Poster Presentation) Shana V. Stoddard, Philip M. 
Potter, Randy M. Wadkins: The Twenty-fourth Annual Gibbs Conference on Biothermodynamics, 
September 25th - 28th, 2010: Carbondale, IL. 
14. Graduate School at the University of Mississippi: Pursuing an Advanced Degree in the Field of 
Chemistry: (Oral Presentation) Shana V. Stoddard: April 16th, 2010: Prairie View A&M University, 
Prairie View, TX. Invited speaker 
15. In Silico Methods for Determination of Selective Inhibitors for Human Intestinal Carboxylesterase 
(hiCE), (Poster Presentation) Shana V. Stoddard, Randy M. Wadkins: Mississippi State EPSCoR 
meeting, April 15th, 2010: Jackson, MS. 
16. A New QSAR Model for the Development of Inhibitors of Human Intestinal Carboxylesterase: (Oral 
Presentation) Shana V. Stoddard, Latorya D. Hicks, Janice L. Hyatt, Philip M. Potter, Randy M. 
Wadkins: 61st Southeast Regional Meeting of the ACS (SERMACS), Bioorganic Chemistry Session I, 
October 21st – October 25th: San Juan, Puerto Rico. 
17. Improved, Selective, Human Intestinal Carboxylesterase Inhibitor Designed to Modulate CPT-11 
Toxicity, (Poster Presentation) Latorya D. Hicks, Janice L. Hyatt, Shana Stoddard, Lyudmila Tsurkan, 
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Carol C. Edward, Monika Wierdl, Randy M. Wadkins, Philip M. Potter: 61st Southeast Regional Meeting 
of the ACS (SERMACS), Bioorganic Chemistry Session I, October 21st – October 25th: San Juan, Puerto 
Rico. 
18. QSAR Study on Human Intestinal Carboxylesterase Enzyme (hiCE) using Sulfonamide Analog 
Inhibitors, (Poster Presentation) Shana Stoddard, Randy Wadkins: Mississippi State EPSCoR meeting, 
April 16th, 2009: Starkville, MS. 
19. Molecular Modeling the Interaction between the Chemical Ligands and Cyclin-Dependent Kinase, 
(Poster Presentation) Shana Stoddard, Hua-jun Fan: 236th ACS National Meeting, Medicinal Chemistry 
Division, August 20th, 2008: Philadelphia, PA. 
20. A Chemical Interpretation of the Interaction between the Ligand and CDK Binding Site, (Poster 
Presentation) Shana Stoddard, Milton Jackson, Okioa Uket, Hua-jun Fan: 4th Annual Research 
Symposium Research in the Changing Times, Sponsored by the College of Juvenile Justice and 
Psychology: April 18th, 2008: Prairie View, TX. Placed 1st 
21. Carbohydrate Antigen Expression by Caprine Oviductal Tissue, (Poster Presentation) Gary Newton, 
Shana Stoddard, Ramón Garcia, NneNna Igbo, Jamila Leake, Selamawit Woldesenbet: The Society for 
the Study of Reproduction, 38th Annual Meeting, July 24th – July 27th, 2005: Quebec City, Quebec, 
Canada. 
22. The Expression of the Sialyl Lewis-X Carbohydrate Antigen within the Female Caprine Reproductive 
Tract, (Poster Presentation) Shana Stoddard, Ramón F. Garcia, NneNna Igbo, Jamila Leake, Selamawit 
Woldesenbet, Gary Newton, Agricultural Regional Directors Symposium, March 29th – April 2nd, 2003: 
Atlanta, GA. 
23. The Expression of the Sialyl Lewis-X Carbohydrate Antigen within the Female Caprine Reproductive 
Tract, (Poster Presentation) Shana Stoddard, Ramón F. Garcia, NneNna Igbo, Jamila Leake, Selamawit 
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Woldesenbet, Gary Newton, University of Texas Medical Branch at Galveston 17th Annual 
Undergraduate Research Symposium, February 2003: Galveston, TX. Placed 2nd 
24. Alpha(1-2)Fucosyltransferase gene expression by caprine endometrial tissues obtained during the 
estrous cycle and early pregnancy, (Poster Presentation) Selamawit Woldesenbet, Ramón Garcia, S. 
Lewis, NneNna Igbo, Jamila Leake, Shana V. Stoddard, G. Rickettes, N. Ing, Gary Newton, Biology of 
Reproduction, July 2003: Cincinnati, OH. 
25. An Alternative Light Color for Lights that Need to be Seen at Low Intensities of Light: (Oral 
Presentation) Shana Stoddard: Kentucky Junior Association of Science (KJAS), Morehead State 
University, March 2001: Morehead, KY. 
26. The Minimal Amount of Light Detectable by the Human Eye: (Oral Presentation) Shana Stoddard 
Kentucky Junior Science Symposium, March 2001, Louisville, KY. Won all expense paid trip to 
National Science Camp; selected as Kentucky State alternate for National Science Fair Competition 
27. How to Organize a Scientific Research Project: (Oral Presentation) Shana Stoddard and Sarah 
Swope, Invited Speaker at Ballard High School, October 2000, Ballard High School, Louisville, KY. 
28. Trends in Cardiovascular Disease: (Oral Presentation) Shana Stoddard National Institute of Health, 
August 2000 Washington DC. 
              
 Honors, Awards, and Scholarships By Year: 
2013 
• Outstanding Graduate Student Academics, Research, and Service award.   
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Highest award given in the Ole Miss Local section of the American Chemical Society. This award is 
not given annually, and has only been given 6 times in 20 years. I am tenth recipient of the award, 
and the only 2012/2013 recipient. 
• Placed 3rd in Graduate poster competition in the computational chemistry section at the Mississippi State 
EPSCoR (Experimental Program to Stimulate Competitive Research) Meeting in Hattiesburg, MS 
• Awarded GAANN Fellowship 
 
2012 
• Best Officer Award for the 2011-2012 Graduate Student Council Term 
Position Held: Director of Graduate Affairs 
• Placed 1st in Graduate Oral Presentation competition in the Chemistry and Chemical Engineering section 
at the Mississippi Academy of Sciences meeting in Hattiesburg, MS 
• Placed 1st in Graduate Oral Presentation competition in the Graduate Student category at the Midsouth 
Computational Biology & Bioinformatics Society meeting in Oxford, MS 
 
2011 
• Placed 3rd in Graduate Biophysical Poster competition in the Biophysical Chemistry section at the 
NOBCChE (National Organization for the Professional Advancement of Black Chemists and Chemical 
Engineers) national meeting in Houston, TX 
• Placed 2nd in Graduate poster competition in the Computational chemistry section at the Mississippi 
State EPSCoR (Experimental Program to Stimulate Competitive Research) Meeting in Starkville, MS 
• Placed 1st in Graduate poster competition in the physical science section at the Graduate Student Council 
(GSC) 1st Annual Poster Symposium and Research Day, University of Mississippi 
 
2010 
• Selected as Young Researcher to attend the 60th Meeting of Nobel Laureates in Lindau Germany 
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1 of 650 selected from a three round international competition. Over 40,000+ applicants reviewed 
• Awarded the ESOF (European Open Science Forum) Fellowship to attend ESOF conference after 60th 
Meeting of Nobel Laureates 
1 of 50 selected from the 650 accepted to attend the 60th Meeting of Nobel Laureates 
 
2008 
• Placed 1st in Graduate poster competition at the 4th Annual Research Symposium Research in the 
Changing Times, sponsored by the College of Juvenile Justice and Psychology at Prairie View A&M 
University 
 
2004 
• Who’s Who Among American College Students 
• National Deans list, Prairie View A&M University 
• University Honors, Prairie View A&M University 
 
2003 
• Placed 2nd in undergraduate poster competition: University of Texas Medical Branch at Galveston; 17th 
Annual Undergraduate Research Symposium, in Galveston, TX 
• University Honors, Prairie View A&M University 
 
2002 
• Beta Beta Beta National Biological Honor Society inductee 
 
2001 
• Kentucky Science Symposium – won all expense paid trip to the National Science Camp as state 
representative 
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• Kentucky Science Symposium – elected to attend the National Science Symposium in Orlando, FL 
• Kentucky Science Symposium – elected as Kentucky State alternate for National Science Fair 
Competition 
• Unsung Hero Award; awarded by Rotary Club of Louisville 
• Papa John’s Leadership Scholarship Award 
 
2000 
• National Student Leadership Scholar 
• Kentucky Governor Scholar 
              
 Accomplishments: 
 
• Chartered three organizations, one organization chapter, and one club 
1. University of Mississippi Advocates for Students Disabilities Association (2009), 
2. Prairie View A&M University Chess club (2007), 
3. Prairie View A&M University Chemistry club (2004),  
4. Prairie View A&M University chapter of National Council of Negro Women (2002) 
5. Established and coordinated a nursing home visiting group (1999) 
 
• Coordinated Pennies for Patients Drive fundraiser for Leukemia and Lymphoma Society for NOBCChE 
(2013) 
 
• Directed grant awarding process for the University of Mississippi G01 graduate student grant (2011, 
2012) 
 
• Coordinated Graduate Student Council Research Day Poster Session at the University of Mississippi 
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(2012) 
 
• Served on the Hall of Fame selection committee to choose those students to be given the honor of 
induction into the Hall of Fame for the Class of 2011-2012 at the University of Mississippi (2011) 
 
• Developed physician shadowing program in veterinary medicine, physical therapy, and dentistry (2004) 
 
• Established and organized Annual Health Conference and College Admissions Workshop (2003) 
 
• Coordinated Registration Process for Medical School Admission Workshop and Career Fair (2002) 
 
• Coordinated College Admission Workshop for Oxford/Lafayette County (2011, 2012) 
 
• Coordinated 30+ seminars (2002-2012) 
Descriptions of selected seminars coordinated. 
1. College Admissions Workshop: Seminar presented to inform parents and students in grades 8 to 12 
about the college admission process, preparing for college during high school, and how to look for 
and obtain college scholarships. Educational Service Foundation, University of Mississippi personnel 
from the admissions office, and University of Mississippi graduate students were the speakers for this 
seminar. 
2. Post Doctoral Informational: Seminar given to assist graduate students at the University of 
Mississippi on where to look for post doctoral opportunities. Cathy Fore from Oak Ridge Universities 
(ORAU) was the invited speaker. 
3. Grant Writing Workshop: This workshop was held to assist University of Mississippi students in 
grant writing. Members from the Offices of Research and Sponsored Programs, and University of 
Mississippi professors presented the seminars 
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4. Publishing Your Work Panel Discussion: This panel discussion was held to inform University of 
Mississippi Student about the publishing process, and tips to maintain an active publishing career. 
Professors from the University of Mississippi having over 150+ publications each were panelist. 
 
• Various Elected or Appointed Positions held; 
1. Assistant Youth Director at Clear Creek Missionary Baptist Church (2012, 2013), Responsibilities 
include hosting events for the youth at Clear Creek Missionary Baptist Church. 
Highlights: Developed a summer reading program to assist Oxford/Lafayette county youth in 
improving their reading skills.  Initiated a Youth Talent Show, Youth Field day, and Youth 
Department Newsletter.  Coordinated a Youth Lock-In and Christmas program. Assisted in 
organizing Easter Program and Mother’s day program.  Re-established a Youth Tutoring 
program. 
2. Director of Graduate Affairs for Graduate Student Council (2011-2012), Responsibilities included 
overseeing the grant awarding process, organizing the GSC Research Day Poster Session, hosting 
seminars to address the needs of Graduate Students at the University of Mississippi. 
3. Served on Lecture Series Committee (2011-2013), Responsibilities include reviewing applications 
for monetary assistance from individuals or organizations at the University of Mississippi who wish 
to invite speakers to present work at UM. 
4. Hall of Fame selection committee (2011), Responsibilities included reviewing candidates for the 
University of Mississippi's Hall of Fame 
5. President of Chemistry Club (2004-2005), Responsibilities included setting a vision, for the 
organization, overseeing the events, development and distribution of departmental newsletter and 
managing the organizations operations. 
6. President of Minority Association of Pre-Health Students (2003-2004), Responsibilities included 
setting a vision, for the organization, overseeing the events, and managing the organizations 
operations. 
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7. 2nd Vice President of National Council of Negro Women PVAMU chapter (2003-2004), 
Responsibilities included overseeing all programs committees. 
8. Treasurer of Chess Club (2007-2008), Responsibilities included accounting of monies for the 
organization 
9. Secretary for Advocates for Students Disabilities Association (2009), Responsibilities included 
documenting minutes during ASDA meetings. 
10. Parliamentarian/Chaplin for Beta Kappa Chi/National Institute of Science (2002-2004), 
Responsibilities included prayer for meetings, and ensuring meetings were conducted in accordance 
to Robert's Rules of Order 
11. Community Service Chair for Minority Association of Pre-Health Students (MAPS) (2002-2003), 
Responsibilities included developing and implementing community service events for MAPS. 
12. Community Service Co-Chair for National Council of Negro Women (NCNW) PVAMU Chapter 
(2002-2003), Responsibilities included developing and implementing community service events for 
NCNW. 
13. Registration Committee Chair for Minority Association of Pre-Health Students (2002-2003), 
Responsibilities included overseeing the registration process for the Medical College Admission 
Conference and Career Fair 
14. Black History Committee Chair for Minority Association of Pre-Health Students (2001). 
Responsibilities included designing and implementing programs for Black History Month for Campus 
students at PVAMU 
              
 Teaching Experience from 2002 to 2013 
 
Classes Taught: 
Biochemistry Lab (Reorganized Laboratory, helped to implement structure in class) 
Forensic DNA Lab (Developed several DNA Laboratory experiments, student and TA lab manuals) 
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Chemistry Labs I and II for Chemistry majors 
Organic Chemistry Labs I and II 
General Chemistry Lab for Engineering majors, and Nursing majors 
Substitute lecturer for Biophysical Chemistry 
Substitute lecturer for General Chemistry 
  
Subjects Tutored: 
Medical College Admissions Test (MCAT) Chemistry, 
Dental Admissions Test (DAT) Chemistry, 
Biochemistry, 
Organic Chemistry, 
General Chemistry, 
K-12 Mathematics, 
K-12 Science, 
K-7 History, 
K-7 Language Arts, 
K-7 Reading 
              
 Current Organizational Memberships: 
 
• American Chemical Society: Graduate student member 
• Biophysical Society: Graduate student member, subgroups – biological fluorescence and membrane 
structure and assembly 
• National Organization for the Professional Advancement of Black Chemists and Chemical Engineers: 
member, University of Mississippi chapter 
• Mississippi Academy of Sciences 
	  197	  
• Midsouth Computational Biology & Bioinformatics Society 
• Alpha Kappa Alpha Sorority Incorporated 
 
              
 Community Service: 
 
• Forensic Science Exhibition for elementary and middle school youth.   
(Hosted 3 groups; Middle school (March 2013), Oxford Middle School (March 2013), and Boys 
and Girls of Oxford/University Area (April 2013) 
• Martin Luther King Day of Service (Help serve food to MLK Day activities attendants) (2012) 
• 9/11 Day of Service (Help with packaging can goods, toiletries and personal items (for the Food Pantry, 
More Than a Meal and Boxes of Love) and participated in fixing community vegetable plots 
(CommunityHarvest) – Oxford, MS, (2011) 
• Events hosted by Alpha Kappa Alpha Sorority Inc. (2003-present): Events including but not limited to 
health fairs, freshman move in, educational seminars, and serving food at cancer walks. 
•Tutor for K-12 and college students (1999-present) 
 
